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Summary 
 
The main aim of neuroscience research is the assessment of the nervous system under 
physiological and pathological conditions, with the purpose of acquiring knowledge about the 
diagnosis, prevention and treatment of neuropsychiatric disorders. A substantial portion of 
research is engaged in the discovery of biomarkers, not only to help to better understand of 
the underlying pathomechanisms, but also because they may be suitable for monitoring 
disease progression and the evaluation of therapeutic effects of already applied drugs. 
Amongst analytical methods, high performance liquid chromatography is one of the most 
popular options because it provides fast and robust determination of a wide range of 
compounds. However, these methods need substantial procedural development to be able to 
obtain valid, i.e., replicable, results. 
Amongst neurological disorders, headache is one of the most common conditions, whereas, 
neurodegenerative disorders including Alzheimer’s, Parkinson’s (PD) and Huntington's 
disease (HD) affect a smaller portion of the general population. 
The kynurenine pathway (KP) of tryptophan (TRP) metabolism is extensively studied, mostly 
because of the well-established endogenous protective properties of kynurenic acid (KYNA) 
against the excitotoxic and oxidative stress inducing effects of other KP metabolites, such as 
quinolinic acid (QUIN) and 3-hydroxy-L-kynurenine (3-OHK). It is assumed that KYNA, and 
some of its analogs with improved pharmacokinetic or pharmacodynamic properties, may 
have modifying effects on nociception. With regard to HD, there is evidence that 
glutamatergic excitotoxicity is involved in the development of the disease which may be 
influenced by endogenous substances, including certain metabolites of the KP of TRP 
metabolism. Based on these findings several metabolites of the KP were investigated in a 
well-known model of trigeminal nociception, the orofacial formalin test, and in the 3- 
nitropropionic acid toxin model of HD. As a result, we were able to provide some 
pharmacokinetic insight into the different characteristics of two KYNA analogs in the animal 
headache model, and we were the first to demonstrate some differences in the KP in the 
widely used 3-nitropropionic acid toxin model of HD. Another neurodegenerative disorder in 
our field of interest is PD, which is characterized by the loss of dopaminergic (DAergic) 
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neurons in the substantia nigra pars compacta caused by mitochondrial dysfunction, which 
results in energy deficit and oxidative stress. With regard to environmental factors, one of the 
well-established causes of this condition is the long, cumulative, low-dose exposure to 
mitochondrial toxins. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a widely used 
neurotoxin in various in vivo animal studies to investigate the pathogenesis of PD and to 
assess the therapeutic effect of potential neuroprotective agents. DA measurements provide a 
well-established way to confirm DAergic neuronal loss. Accordingly, in our study 2 MPTP 
treatment regimens were compared (acute and chronic low dose) by measuring their striatal 
DA concentrations. The results demonstrated the presence of significant neurotoxicity in the 
acute treatment regimens, while the chronic low dose regimen failed to evoke any significant 
changes in striatal DA levels. Besides QUIN and 3-OHK, there are numerous other substances 
that can facilitate the formation of reactive species (RS) which are responsible for most of the 
deleterious effects of pathological processes in the nervous system. The toxic effects of RS 
are decreased by a system of antioxidant machinery involving non-enzymatic mechanisms, 
such as vitamin E which has proven antioxidant properties. Vitamin E refers to a group of 
molecules including 4 tocotrienols and 4 tocopherols, as lipidsoluble antioxidants. Decreased 
tocopherol levels are associated with several neurological symptoms, such as cerebellar 
ataxia, peripheral neuropathy and myopathy, as the nervous system is particularly sensitive to 
oxidative damage resulting from increased energy demand and reduced antioxidant capacity. 
Severe tocopherol deficiency develops mainly as a result of malabsorption disorders, 
abetalipoproteinemia and ataxia with vitamin E deficiency (AVED). Differential diagnosis can 
sometimes be difficult in certain conditions accompanied by neurological symptoms 
(especially in AVED). Therefore the measurement of serum tocopherol levels is advised in 
cases of ataxia, myopathy or cognitive deficiency. To facilitate the diagnostic process, 
reference intervals for α-, γ-, and δ-tocopherols were determined for the adult Hungarian 
population. 
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1 Introduction 
 
According to the Global Burden of Disease Study (Patel et al. 2016), neurological disorders 
such as headache disorders (migraine, tension-type headache and medication-overuse 
headache), Alzheimer’s disease (AD) and other dementias, multiple sclerosis (MS), 
Parkinson’s disease (PD) and epilepsy are responsible for 3 percent of the worldwide burden 
of disease. Despite this seemingly small percentage, dementia, epilepsy, migraine, and stroke 
rank in the top 50 causes of disability-adjusted life years, furthermore, dementia and PD are 
among the top 15 conditions with the most substantial increase in burden in the past decade. 
Headache, one of the most common disorders of the nervous system, is a major health 
problem worldwide. The global prevalence of active headache disorders for the adult 
population is 46% for headache in general, 11% for migraine, 42% for tension-type headache 
and 3% for chronic daily headache (Stovner et al. 2007). The treatment of primary headache 
disorders is challenging, requiring both acute and preventive therapeutic strategies 
(Weatherall 2015). The efficacy of these treatments is not always satisfactory and the 
contraindications and side-effects often limit the options of the physician (Obermann et al. 
2015, Diener et al. 2015). There is, therefore, a constant need to study and develop new 
molecules. 
Although neurodegenerative disorders, including AD, PD, Huntington's disease (HD) and 
amyotrophic lateral sclerosis, affect a smaller portion of the general population, there is no 
proven causative therapy (Zádori et al. 2011b). Only symptomatic treatment is available, and 
with the exception of PD, the efficacy of these medications is quite limited with regard to 
symptom management (Klivényi and Vécsei 2010, Dézsi and Vécsei 2017). The complex and 
partially unrevealed pathomechanism of these disorders may be the underlying reason for the 
lack of causative therapy. Neurodegeneration can be described as progressive neuronal loss 
resulting in severe neuronal dysfunction. There are several identified and suspected genetic 
mutations and environmental factors in the background, but in most cases, despite the well 
delineated cellular and molecular events such as mitochondrial dysfunction and increased 
formation of reactive species, glutamate excitotoxicity, deposition of aggregated proteins, 
inflammatory response and altered gene expression, the pathogenic process is hard to 
influence (Jellinger 2001, Parihar et al. 2008). 
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The main aim of neuroscience research is the assessment of the nervous system under 
physiological and pathological conditions with the purpose of acquiring knowledge about the 
diagnosis, prevention and treatment of neuropsychiatric disorders. A substantial portion of 
research is engaged in the discovery of biomarkers in patients or in animal models of the 
assessed pathological conditions. These biomarkers may not only help in better understanding 
the underlying pathomechanisms of the investigated disorders with the possibility of finding 
novel therapeutic targets, but they may be suitable for monitoring disease progression and the 
evaluation of the therapeutic effects of already applied and potential novel drugs, as well. 
Animal and human studies suggest that glutamate receptors are present in various parts of the 
trigeminal system (Tallaksen-Greene et al. 1992, Sahara et al. 1997, Quartu et al. 2002) which 
is the system responsible for processing most of the pain originating from the head area 
(Carpenter and Sutin 1983). The stimulation of the trigeminal nerve results in elevated 
glutamate levels in the spinal trigeminal nucleus pars caudalis (TNC, (Oshinsky and Luo 
2006)). The peripheral application of glutamate to deep craniofacial tissue proved to activate 
and sensitize nociceptive afferents and neurons in the upper cervical cord (Lam et al. 2009a, 
2009b). These findings suggest that excitatory amino acid receptors (particularly N-methyl-D-
aspartate receptors (NMDAR)), which are also present in migraineurs, play an important role 
in pain processing and the sensitization process (Vikelis and Mitsikostas 2007). 
Despite the above-mentioned data, amongst NMDAR antagonists, only ketamine was 
delineated as a promising therapeutic option in patients with severe or long lasting migraine 
aura (Afridi et al. 2013). Substances which can act on α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and kainate subtypes of ionotropic glutamate receptors are 
also limited, but among them, tezampanel (Alt et al. 2006) has demonstrated promising results 
in acute migraine therapy (Sang et al. 2004). 
The kynurenine pathway (KP) of tryptophan (TRP) metabolism is extensively studied, mostly 
because of the well-established endogenous protective properties of kynurenic acid (KYNA) 
against the excitotoxic and oxidative stress inducing effects of other KP metabolites, such as 
quinolinic acid (QUIN) and 3-hydroxy-L-kynurenine (3-OHK) (Vécsei et al. 2013). KYNA is 
a non-selective antagonist of the NMDA receptor with a high affinity to its strychnine-
insensitive glycine co-agonist site and also exerts weak antagonistic effects on kainate and 
AMPA receptors (Pereira et al. 2002, Prescott et al. 2006, Szalárdy et al. 2012b). On the basis 
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of this antagonism on glutamatergic neurotransmission, it is assumed that KYNA and some of 
its analogs with improved pharmacokinetic or pharmacodynamic properties may have a 
modifying effect on nociception (Näsström et al. 1992, Párdutz et al. 2012) and thus might be 
future candidates in headache treatment. A well-known model of trigeminal nociception is the 
orofacial formalin test, where a formalin solution is administered subcutaneously into the 
upper lip of rats, causing tissue injury, inflammation and nociception (Clavelou et al. 1995, 
Raboisson and Dallel 2004). By using this model, both peripheral and central components of 
pain processing (Chichorro et al. 2017) can be assessed in preclinical studies. 
HD is an autosomal, dominantly inherited, progressive neurodegenerative disorder which 
results in cognitive, psychiatric and motor disturbances. HD is caused by an expansion of the 
cytosine-adenine-guanine (CAG) repeat in the gene coding for the N-terminal region of the 
huntingtin protein (Htt), which leads to the formation of a polyglutamine stretch. Above 39 
CAGs, there is obligatory disease development (The Huntington’s Disease Collaborative 
Research Group 1993). Although the exact mechanisms through which mutant Htt (mHtt) 
leads to the characteristic neuropathology are not fully understood, the potential roles of 
excitotoxicity and neuronal mitochondrial dysfunction are among the best-established 
concepts (Szalárdy et al. 2012a, Zádori et al. 2012). Accordingly, striatal glutamatergic 
excitotoxicity is involved in the development of HD and predominantly mediated by the 
overactivation of NMDARs, and most specifically through NR2B subunit-containing 
NMDARs at the extrasynaptic sites (Milnerwood et al. 2010). In line with this, the expression 
of mHtt has been shown to sensitize the NR2B subunit-containing NMDARs (Chen et al. 
1999). There is evidence indicating that such excitotoxic injury is mediated, at least in part, by 
endogenous substances, including certain metabolites of the KP of TRP metabolism (Zádori et 
al. 2011b). Previous studies pointed out several alterations in the KP in tissues from HD 
patients and transgenic animals (Schwarcz et al. 1988, Beal et al. 1990, 1992, Pearson and 
Reynolds 1992, Heyes et al. 1992, Jauch et al. 1995) and these results indicated decreased 
KYNA concentrations relative to the levels of toxic neuroactive kynurenines (Zádori et al. 
2011b). Further investigation of these changes in toxin or genetic animal models of HD may 
yield biomarkers with the above-mentioned properties. A decreased activity of the succinate 
dehydrogenase (SDH), complex II of the electron transport chain in post-mortem HD brains 
was one of the early findings suggestive of the role of mitochondrial dysfunction in the 
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development of HD (Stahl and Swanson 1974). Furthermore, mHtt has been shown to be able 
to bind directly to the mitochondria, altering their normal function (Choo et al. 2004). In line 
with the decreased SDH activity, mitochondrial II complex inhibitors, such as 3-
nitropropionic acid (3-NP), have been found to be useful in the investigation of HD through 
their utilization in animal toxin models (Túnez et al. 2010). Accordingly, the 3-NP model is 
frequently applied as an easy and rapid way to study certain aspects of neurodegenerative 
processes in HD (Brouillet 2014). 
Besides genetic predisposition, like in HD, certain environmental factors may also be 
responsible for the development of neurodegenerative processes. One of the main culprits in 
the pathomechanism of PD, which is characterized by the loss of dopaminergic (DAergic) 
neurons and the presence of Lewy bodies in the substantia nigra (SN) pars compacta (Forno 
1996), is mitochondrial dysfunction resulting in energy deficit and oxidative stress (Bose and 
Beal 2016). With regard to environmental factors, one of the well-established causes of this 
condition is the life-long cumulative low-dose exposure to mitochondrial toxins (Harris and 
Blain 2004). The observation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
induced Parkinsonian symptoms yielded one of the first pieces of evidence for toxin-induced 
parkinsonism (Forno et al. 1993) and since then, systemic MPTP administration has been 
widely used in various in vivo animal studies to investigate the pathogenesis of PD and to 
assess the therapeutic effect of potential neuroprotective agents (Javitch et al. 1985). 
MPTP can easily cross the blood brain barrier (BBB) and is metabolized by monoamine 
oxidase to 1-methyl-4-phenyl-pyridinium cation (Chiba et al. 1984), which is taken up by 
DAergic neurons and damages complex I in the mitochondrial electron transport chain 
(Nicklas et al. 1985). The most sensitive brain region to this toxin is the nigrostriatal system 
where neuronal loss and reduced DA levels are well-established by both histo- and 
biochemical methods in MPTP-treated animal models (Hallman et al. 1984). Histochemical 
confirmation of neuronal loss can be time consuming and is usually is only done for a few 
subjects not for the whole experimental group and there is already evidence that several 
MPTP treatment regimens cause DAerg neuronal loss associated with decreased DA 
concentrations in the striatum (Kurosaki et al. 2004, Jackson-Lewis and Przedborski 2007). 
Compared to histochemical methods, the levels of DA and its metabolites can be determined 
by high performance liquid chromatography (HPLC), and can be used on all of the animals in 
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a reasonable time. According to the above-mentioned mitochondrial dysfunction in PD, 
several causative and susceptibility genes were identified (Kalinderi et al. 2016), including 
peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1 alpha (PGC-1α). 
PGC-1α is a multifunctional transcriptional coactivator of nuclear respiratory factors 1 and 2, 
estrogen-related receptors and PPARs amongst others, and hereby regulates mitochondrial 
function and biogenesis (Knutti and Kralli 2001). According to St-Pierre et al., PGC-1α-
deficient mice are more sensitive to MPTP toxicity compared to the controls (St-Pierre et al. 
2006). Furthermore, sub-chronic administration of the toxin can result in significantly 
elevated PGC-1α expression in the striatum after 24 hours that was normalized 72 hours after 
treatment (Swanson et al. 2013). This evidence suggests an adaptive mechanism to 
neurotoxicity, but neuroprotective effects of PGC-1α were also demonstrated in pioglitazone- 
and resveratrol-treated mice against MPTP toxicity (Breidert et al. 2002, Dehmer et al. 2004). 
Despite these findings, the available data are limited with regard to the alteration of tissue-
specific PGC-1a expression in the brain following various MPTP administration regimens. 
Besides QUIN and 3-OHK there are numerous other substances that can facilitate the 
formation of reactive species (RS) which are responsible for most of the deleterious effects of 
pathological processes in the nervous system (Szalárdy et al. 2015). The synthesis and toxic 
effects of RS are decreased by a complex system of antioxidant machinery, including 
enzymatic (e.g., superoxide dismutase, catalase and glutathione (GSH) peroxidase, (Sies 
1997)) and non-enzymatic mechanisms. The latter group consists of chemical compounds, 
such as, among others, vitamin E, vitamin C, coenzyme Q10, β-carotene, GSH and flavonoids 
with proven antioxidant properties (Sies 1993). Vitamin E refers to a group of molecules 
including 4 tocotrienols and 4 tocopherols as lipid soluble antioxidants. Their molecular 
structure comprises a chromanol ring with an aliphatic side chain, unsaturated for tocotrienols 
and saturated for tocopherols. Depending on the number and position of methyl groups on the 
chromanol ring, α-, β-, γ- and δ-tocotrienols and tocopherols can be distinguished 
(Hacquebard and Carpentier 2005). 
Severe tocopherol deficiency develops mainly as a result of malabsorption disorders, 
abetalipoproteinemia and ataxia with vitamin E deficiency (AVED). AVED is caused by the 
mutation of the TTPA gene resulting in the decreased activity of the α-tocopherol transfer 
protein (αTTP, (Morley et al. 2004)). Decreased tocopherol levels are associated with several 
15 
 
neurological symptoms, such as cerebellar ataxia, peripheral neuropathy and myopathy (Ueda 
et al. 2009, Muller 2010), as the nervous system is particularly sensitive to oxidative damage 
resulting from increased energy demand and reduced antioxidant capacity (Szalárdy et al. 
2015). In addition to the above-mentioned disorders with their characteristic symptoms, some 
other neuropsychiatric conditions, such as AD (Lopes da Silva et al. 2014) and the 
exacerbation of MS (Karg et al. 1999) can also be accompanied by significantly reduced 
serum or plasma tocopherol levels. Differential diagnosis sometimes can be difficult in certain 
conditions accompanied by neurological symptoms (especially in AVED), therefore the 
measurement of serum tocopherol levels is advised in cases of ataxia, myopathy or cognitive 
deficiency (Muller 2010, Fata et al. 2014). 
During the analytical procedure to determine concentrations of various compounds from 
biological matrices, several difficulties can emerge. With regard to the metabolites of TRP, the 
main problem is that there are several compounds with neuroactive properties (e.g., KYNA, 
3-OHK and QUIN) and, so far, there is no simple way to determine their concentrations in a 
single run. In most cases, multiple runs with different methods (Gas Chromatography-Mass 
Spectrometry (MassSpec), HPLC-MassSpec, HPLC-UV/Fluorescent detection (FLD)) cannot 
be applied because of limited amounts of sample (e.g., mouse CNS samples). Another 
challenge is the measurement of novel KYNA analogs (Fülöp et al. 2009) which requires 
advanced HPLC-MassSpec method development. 
With regard to animal toxin models of neurodegenerative diseases, such as the MPTP model 
of PD, the main limiting factors are the size of the sample and the small concentration of the 
measured compounds. Neuronal loss, the decisive trait of neurodegeneration, can be evaluated 
by specific histochemical methods, but they are time consuming. However, it has been proven 
that DAergic neuronal loss correlates with the measured decrease in DA concentration in the 
striatum (Kurosaki et al. 2004). Accordingly, the determination of the levels of DA and some 
of its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) 
with HPLC and electrochemical detection may be simpler than cell counting with design-
based stereological methods following immunohistochemical labeling (Jackson-Lewis and 
Przedborski 2007). Electrochemical detectors are one of the most sensitive detector options 
for HPLC measurements and they are typically used for determining catecholamines, 
aromatic amines and phenolics. However, there are some drawbacks to these detectors 
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because they are sensitive to changes in temperature and pressure, and furthermore, the 
detector cell needs to be properly shielded from electromagnetic radiation. 
Tocopherol measurements pose a different challenge to the analytical procedure. During 
sample preparation there is liquid-liquid extraction into n-hexane, evaporation under nitrogen 
flow and reconstitution in organic solvents, all of which may contribute to overall errors in 
measurement. 
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2 Aims 
 
I., To study the possible pharmacokinetic explanation of the protective effects of two KYNA 
analogs (KA-1: N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride and KA-2: N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride) in the orofacial formalin model of headache. 
 
II., To examine the alterations in concentrations of some initial compounds in the KP of TRP 
metabolism following 3-NP administration as a toxin model of HD. 
 
III., To determine the biochemical background to assess of the presence or the lack of MPTP-
induced changes in tissue specific PGC1-α expression when grading nigrostriatal injury. 
 
IV., To establish reference intervals (RI) for serum tocopherol concentrations in relation to the 
adult Hungarian population. 
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3 Materials and methods 
 
3.1 Pharmacokinetic assessment of KYNA and KYNA amides 
During the experiments, adult male Sprague-Dawley rats weighing 200-250 g were used. The 
animals were housed under standard laboratory conditions (in an air-conditioned, humidity-
controlled and ventilated room) and were allowed free access to drinking water and regular rat 
chow on a 12 h−12 h dark-light cycle. The procedures used in this study were approved by the 
Committee of Animal Research at the University of Szeged (I-74-12/2012) and the Scientific 
Ethics Committee for Animal Research of the Protection of Animals Advisory Board 
(XXIV./352/2012.). 
At set time points (15, 30, 60, 120 and 300 min) following the intraperitoneal (i.p.) injection 
with the KYNA amides (1 mmol/kg), the rats were deeply anesthetized with i.p. injection of 
chloral hydrate (0.4 g/kg, Sigma-Aldrich). Blood samples were collected from vena cava 
caudalis and centrifuged at 13709 relative centrifugal force (RCF) for 10 min at 4°C. The 
supernatants, i.e., the serum samples, were collected and centrifuged at 13709 RCF for 10 min 
at 4°C again and the supernatants were stored at - 80°C until use. After the collection of blood 
samples, the animals were transcardially perfused with 100 ml 0.1 M phosphate-buffered 
saline (PBS) for 5 min. The CNS samples containing the medullary segment of the TNC were 
then removed and stored at - 80°C until measurements. The animals in the control group 
underwent a similar procedure. 
For the measurement of KYNA concentration, the CNS samples were cut in half, weighed and 
then sonicated for 1.5 min in an ice-cooled solution (250 μl) comprising perchloric acid 
(PCA, 2.5% w/w), 3-nitro-L-tyrosine (3-NLT, 10 or 2 µM) and distilled water in an Eppendorf 
tube. The content of the Eppendorf tube was centrifuged at 13709 RCF for 10 min at 4°C and 
the supernatant was measured. Before analysis, the serum samples were thawed and, after a 
brief vortex, the serum sample was 'shot' onto a precipitation solvent (containing PCA with 3-
NLT as internal standard, with resulting concentrations of 2.5 w/w% and 2 µM, respectively). 
The samples were subsequently centrifuged at 13709 RCF for 10 min at 4°C, and the 
supernatants were collected for measurement. 
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For the analysis of KYNA amides (KA-1 and KA-2, Figure 1), the other half of the CNS 
samples were weighed and then sonicated in ice-cold (250 μl) distilled water for 1.5 min and 
centrifuged at 13709 RCF for 10 min at 4°C. From the supernatant, 100 μl was transferred to 
an Eppendorf tube containing 750 μl HPLC gradient grade acetonitrile and 150 μl distilled 
water. After a brief vortex, the samples were centrifuged at 13709 RCF for 10 min at 4°C and 
900 μl of supernatant was evaporated in a vacuum centrifuge. After thawing and brief stirring 
with a vortex, 200 μl of serum sample was transferred to an Eppendorf tube containing 700 μl 
HPLC gradient grade acetonitrile (ACN) and 100 μl distilled water. After a brief vortex, the 
samples were centrifuged at 13709 RCF for 10 min at 4°C and 900 μl of supernatant was 
evaporated in a vacuum centrifuge. The resulting samples were stored at 4°C until use. 
 
 
 
The KYNA concentrations of the serum and CNS samples were quantified on the basis of a 
slight modification of a literature method (Hervé et al. 1996). Briefly, we used an Agilent 
1100 HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with 
fluorescence and a UV detector; the former was applied at excitation and emission 
wavelengths of 344 nm and 398 nm for the determination of KYNA and the latter was set at 
365 nm for the determination of the internal standard (3-NLT). Chromatographic separations 
were performed on an Onyx Monolithic C18 column, 100 mm x 4.6 mm I.D. (Phenomenex 
Inc., Torrance, CA, USA) after passage through a SecurityGuard pre-column C18, 4 x 3.0 mm 
I.D., 5 μm particle size (Phenomenex Inc., Torrance, CA, USA) with a mobile phase 
composition of 0.2 M zinc acetate/ACN = 95/5 (v/v), the pH of which was adjusted to 6.2 
Figure 1 The chemical structure of N-(2-
N,N-dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride 
(KA-1, a) and N-(2-N-pyrrolidinylethyl)-4-
oxo-1H-quinoline-2-carboxamide 
hydrochloride (KA-2, b) 
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with acetic acid, applying isocratic elution. The flow rate was 1.5 ml/min and the injection 
volume was 20 µl for serum, and 50 µl for CNS samples. 
For the determination of KYNA amides, a Thermo LCQFleet ion trap mass spectrometer was 
used equipped with an ESI ion source combined with a Dionex Ultimate3000 HPLC system. 
The ionization parameters were as follows: heater temperature: 500°C, sheath gas flow rate: 
60, auxiliary gas flow rate: 20, spray voltage: 4 kV, capillary temperature: 400°C. 
Chromatographic separations were performed on a Kinetex C18 column, 100 mm x 4.6 mm, 
2.6 μm particle size (Phenomenex Inc., Torrance, CA, USA ) after passage through a 
SecurityGuard pre-column C18, 4 x 3.0 mm, 5 μm particle size (Phenomenex Inc., Torrance, 
CA, USA), with a mobile phase composition of 0.05% aqueous CH3COOH/ACN = 90/10 
(v/v), applying isocratic elution. The flow rate and the injection volume were 1 ml/min and 50 
μl, respectively. 
Calibrants were prepared at 6 different concentration levels, from 1 to 100 nM, 0.5 to 5 µM 
and 0.01 to 100 µM for KYNA, 3-NLT and the KYNA amides, respectively. 3 parallel 
injections of each solution were made under the chromatographic conditions described above. 
The peak area responses were plotted against the corresponding concentration, and the linear 
regression computations were carried out by the least square method with the freely available 
R software (R Development Core Team 2008). Very good linearity (R2 ≤ 0.99) was observed 
throughout the investigated concentration ranges for KYNA, 3-NLT and the KYNA amides 
when fluorescence, UV or MassSpec detection was applied. 
The selectivity of the method was checked by comparing the chromatograms of KYNA, 
KYNA amides and the internal standard for a blank serum and CNS sample and those for a 
spiked sample. All compounds could be detected in their own selected chromatograms 
without any significant interference. 
The limit of detection (LOD) and the lower limit of quantification (LLOQ) were determined 
via the signal-to-noise ratio with a threshold of 3 and 10, respectively, according to the 
International Conference on Harmonization guidelines (ICH 1995). The LOD and LLOQ for 
KYNA in the serum samples were 1 nM and 3.75 nM, respectively, while in the CNS samples 
they were 0.4 nM and 1 nM, respectively. The LOD and LLOQ for the samples in MS 
detection were 1 nM and 15 nM, respectively. 
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Replicate HPLC analysis showed that the coefficient of variation (CV) was ≤ 2.2% for the 
peak area response and ≤ 0.1% for the retention time for KYNA and the KYNA amides. 
The relative recoveries were estimated by measuring spiked samples of KYNA and the 
KYNA amides at 2 concentrations with 3 replicates of each. No significant differences were 
observed for the lower and higher concentrations. The recoveries for the serum samples 
ranged from 103 to 108%, 81 to 94% and 79 to 80% for KYNA, KA-1 and KA-2, 
respectively. The recoveries for the CNS samples ranged from 82 to 92% and 78 to 84% for 
KYNA and KA-2, respectively. The peaks of the different compounds obtained during HPLC-
MassSpec analysis are presented in Figure 2. 
 
 
 
Figure 2 Chromatograms of the 
analyzed kynurenic acid analogs, KA-1 
(N-(2-N,N-dimethylaminoethyl)-4-oxo-
1H-quinoline-2-carboxamide 
hydrochloride; a)  and KA-2 (N-(2-N-
pyrrolidinylethyl)-4-oxo-1H-quinoline-
2-carboxamide hydrochloride; b) 
obtained with mass spectrometric 
detection from the serum of Sprague-
Dawley rats. 
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3.2 Measurement of TRP metabolites in a toxin model of HD 
We used 30 5-month-old male C57Bl/6 mice in this study. The animals were housed in cages 
under standard conditions with a 12-12-h light-dark cycle and free access to food and water. 
The experiments were carried out in accordance with the European Communities Council 
Directive (86/609/EEC) and were approved by the local animal care committee as well. The 
animals were randomly divided into two groups (n = 16 and n = 14, respectively). In the first 
group, 3-NP (Sigma-Aldrich, Saint Louis, MO, USA; dissolved in PBS, pH adjusted to 7.4) 
was administered in a subacute dosing regimen as reported previously (Török et al. 2015), 
with 2 daily i.p. injections (50 mg/kg each) for 5 consecutive days. The 2nd group served as 
the vehicle-injected control. 
On the 18th day of the experiment (12 days after the last 3-NP injection), the mice were deeply 
anesthetized with isoflurane (Forane; Abott Laboratories Hungary Ltd., Budapest, Hungary). 
After thoracotomy, 0.3–0.7 ml venous blood was obtained from the right ventricle by 
intracardial puncture, followed by perfusion with artificial cerebrospinal fluid (composition in 
mM: 122 NaCl, 3 KCl, 1 Na2SO4, 1.25 KH2PO4, 10 D-glucose*H2O, 1 MgCl2*6H2O, 2 
CaCl2*2H2O, 6 NaHCO3) for 2 min by an automatic peristaltic pump. The blood samples 
were left to coagulate for 30 min, and were then centrifuged at 13709 RCF for 10 min at 4°C. 
The supernatant sera were pipetted into Eppendorf tubes and stored at - 80°C until further 
sample handling. After perfusion, the brains were rapidly removed on ice and stored at - 80°C 
until analysis. Before analysis, the CNS samples were weighed and then sonicated in an ice-
cooled solution (250 µl) containing 2.5 w/w% PCA with 2 µM 3-NLT and 600 nM 
isoproterenol (IPR) as internal standards. The samples were next centrifuged at 13709 RCF 
for 10 min at 4°C, and the supernatants were collected. 
Before analysis, the serum samples were thawed and, after a brief vortex 200 µl of serum 
sample was 'shot' onto 200 µl of precipitation solvent (containing 5 w/w% PCA with 4 µM 3-
NLT and 2 µM IPR as internal standards). The samples were subsequently centrifuged at 
13709 RCF for 10 min at 4°C, and the supernatants were collected. 
The TRP, KYN and KYNA concentrations of the samples were quantified with the same 
equipment and method as described in paragraph 3.1 where the fluorescence detector was set 
at excitation and emission wavelengths of 254 nm and 398 nm for TRP, and the UV detector 
was set at 365 nm for the determination of KYN. 
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For determination of the concentrations of 3-OHK and its internal standard (IPR), we applied 
the Agilent 1100 HPLC system equipped with Model 105 electrochemical detector (Precision 
Instruments, Marseille, France). In brief, the working potential of the detector was set at +650 
mV, using a glassy carbon electrode and an Ag/AgCl reference electrode. The mobile phase 
containing sodium octylsulfate (2.8 mM), sodium dihydrogenphosphate (75 mM) and 
disodium ethylenediaminetetraacetate (Na2EDTA, 100 µM) was supplemented with ACN (5 
v/v%) and the pH was adjusted to 3.0 with phosphoric acid (85 w/w%). The mobile phase was 
delivered at a rate of 1 ml/min at 40°C onto the reversed-phase column (HR-80 C18, 80 x 
4.6mm, 3-μm particle size; ESA Biosciences, Chelmsford, MA, USA) after passage through a 
pre-column (Hypersil ODS, 20 x 2.1 mm, 5-μm particle size; Agilent Technologies, Santa 
Clara, CA, USA). 10 µl aliquots were injected by the auto-sampler with the cooling module 
set at 4°C.  
Method validation was conducted the same way as described in paragraph 3.1. Calibrants 
were prepared at 6 different concentration levels, from 0.1 to 50 µM, 0.05 to 5 µM, 1 to 100 
nM, 10 to 200 nM, 0.5 to 7.5 µM and 25 to 600 nM for TRP, KYN, KYNA, 3-OHK and the 
internal standards, 3-NLT and IPR, respectively. Very good linearity (R2 ≤ 0.99) was observed 
throughout the investigated concentration ranges for TRP, KYNA, KYN, 3-OHK and the 
internal standards when either fluorescence, UV or electrochemical detection was applied and 
all compounds could be detected in their own selected chromatograms without any significant 
interference. The LOD for CNS samples was 10, 40, 0.4 and 10 nM, while LLOQ was 20, 
130, 1 and 30 nM for TRP, KYN, KYNA, and 3-OHK, respectively. The LOD for the serum 
samples was 15, 100, 1 and 10 nM, while LLOQ was 35, 275, 3.75 and 30 nM for TRP, KYN, 
KYNA and 3-OHK, respectively. Replicate HPLC analysis showed that CV was ≤ 2.2% for 
the peak area response and ≤ 0.1% for the retention time for TRP, KYN and KYNA, whereas 
in the case of 3-OHK the CV was ≤ 8.6% for the peak area response and ≤ 0.3% for the 
retention time. The recoveries for the CNS samples were 86 to 91%, 98 to 100%, 82 to 92% 
and 69 to 74% for TRP, KYN, KYNA and 3-OHK, respectively. The recoveries for the serum 
samples ranged from 77 to 90%, 77 to 82%, 103 to 108% and 28 to 34% for TRP, KYN, 
KYNA and 3-OHK, respectively. The peaks of the different compounds obtained during 
chromatographic analysis are presented in Figure 3. 
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Figure 3 Chromatograms of the analyzed compounds of the kynurenine pathway of the tryptophan metabolism, 
from C57Bl/6 murine brain samples. 3-NLT 3-nitro-L-tyrosine, 3-OHK 3-hydroxykynurenine, ECD 
electrochemical detector, FLD fluorescence detector, IPR isoproterenol, KYNA kynurenic acid, KYN kynurenine, 
TRP tryptophan 
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3.3 Measurement of DA and its metabolites after MPTP treatment 
12-week-old C57Bl/6 male mice were used in this study. The animals were housed in cages 
and maintained under standard laboratory conditions with 12-12 h light-dark cycle and free 
access to food and water. The experiments were carried out in accordance with the European 
Communities Council Directive (86/609/EEC) and were approved by the local animal care 
committee as well. 
MPTP was dissolved in PBS (pH adjusted to 7.4) and was administered i.p. Animals were 
randomly divided into 6 groups (n = 7-8 in each group). The 1st and 2nd group received i.p. 
injection of 15 mg/kg body weight MPTP 5 times at 2 h intervals. The animals in the 1st group 
were deeply anesthetized with isoflurane (Forane®; Abott Laboratories Hungary Ltd., 
Budapest, Hungary) and the brains were dissected 90 min following the last MPTP injection 
(acute treatment – acute (day 1) assessment), while animals in the 2nd group were deeply 
anesthetized with isoflurane and the brains were dissected 1 week later (acute treatment - 
subacute (day 7) assessment). The mice in the 3rd group were injected i.p. with 15 mg/kg body 
weight MPTP once a day for 12 days (chronic treatment). 90 min following the last injection 
the animals were euthanized via isoflurane overdose as well. The 4th, 5th and 6th groups served 
as the respective control groups, and were injected with 0.1 M PBS according to the above-
detailed treatment regimen. During the dissection process the brains were rapidly removed on 
ice and immediately halved at the midline. Following that, both hemispheres were further cut 
to obtain the striatum, cortex and cerebellum. Thereafter, these samples were stored at - 80oC 
until the HPLC analysis. 
The striata were weighted and then homogenized in an ice-cold solution (750 µl) containing 
PCA (2.5% w/w), sodium metabisulfite (0.1 M), Na2EDTA (0.1 M), distilled water and 0.25 
mM IPR for 30 sec. The homogenate was centrifuged at 13709 RCF for 10 min at 4oC. The 
supernatant was stored at - 20oC until the analysis. DA and its metabolites, DOPAC and HVA 
were measured with an Agilent 1100 HPLC system (Agilent Technologies, Santa Clara, CA, 
USA) combined with a Model 105 electrochemical detector (Precision Instruments, Marseille, 
France) under isocratic conditions. In brief, the working potential of the detector was set at 
+750 mV, using a glassy carbon electrode and an Ag/AgCl reference electrode. The mobile 
phase containing sodium dihydrogenphosphate (75 mM), sodium octylsulfate (2.8 mM) and 
Na2EDTA (50 μM) was supplemented with ACN (10% v/v) and the pH was adjusted to 3.0 
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with phosphoric acid (85% w/w). The mobile phase was delivered at a rate of 1 ml/min at 
40°C onto the reversed-phase column (HR-80 C18, 80 x 4.6 mm, 3 µm particle size; ESA 
Biosciences, Chelmsford, MA, USA) after passage through a pre-column (SecurityGuard, 4 x 
3.0 mm I.D., 5 µm particle size, Phenomenex Inc., Torrance, CA, USA)). 10 µl aliquots were 
injected by the autosampler with the cooling module set at 4°C. With regard to method 
validation, which was conducted the same way as described in paragraph 3.1, the following 
parameters are reported briefly. Calibrants were prepared at 6 different concentration levels, 
from 2 to 200 ng/ml. Very good linearity (R2 ≤ 0.99) was observed throughout the 
investigated concentration ranges for DA, DOPAC and HVA and the internal standard (IPR) 
and all compounds could be detected in their own selected chromatograms without any 
significant interference. The LOD and LLOQ for the investigated compounds in the brain 
samples were 2 ng/ml and 10 ng/ml, respectively. With regard to precision, the CV was ≤ 
3.25% for the peak area responses and ≤ 0.05% for the retention times. The recoveries ranged 
from 109 to 110%, 108 to 109% and 99 to 102% for DA, DOPAC and HVA, respectively. The 
peaks of the different compounds obtained during chromatographic analysis are presented in 
Figure 4. 
 
 
 
Figure 4 Chromatograms of the analyzed compounds of the dopamine metabolism in C57Bl/6 murine brain 
samples with electrochemical detection. DA dopamine, DOPAC 3,4-dihydroxyphenylacetic acid, HVA 
homovanillic acid, IPR isoproterenol 
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3.4 Tocopherol measurements from human serum 
The study sample population comprised of 30 male (age range: 21-71 years, mean age: 49.50 
year) and 30 female volunteer individuals (age range: 25-76 years, mean age: 50.03 year) 
without any major chronic illness and 30 male (age range: 18-73 years, mean age: 49.43 year) 
and 30 female (age range: 24-78 years, mean age: 49.60 year) patients with other neurological 
diseases (OND; main diagnoses for males were the following: ischemic stroke: 8, PD: 5, 
epilepsy: 5, lumbar disc disorder: 3, and other: 9; main diagnoses for females were the 
following: multiple sclerosis in remission: 8, ischemic stroke: 6, epilepsy: 5, and other: 11) 
where the presence of ataxia, myopathy or cognitive dysfunction was excluding criteria. The 
distribution of the age of the subjects was Gaussian in all groups (p > 0.05, Anderson-Darling 
test) and the variances were equal (p = 0.98, Levene test). There was no significant difference 
between the groups (F = 0.01, p = 0.99, one-way ANOVA). The recent regular intake of 
antihyperlipidemic agents or any kind of drugs or food supplements containing antioxidants 
was exclusion criteria as well in all groups. All participating individuals were of Hungarian 
origin and were enrolled in the Department of Neurology at the University of Szeged. The 
study was approved by the Ethics Committee of the Faculty of Medicine, University of 
Szeged (19/2014). All study participants gave their written informed consent, in accordance 
with the Declaration of Helsinki. 
Blood was collected by venipuncture into gold-top vacutainers following fasting for 12 hours. 
The blood was immediately centrifuged at 1166 RCF for 10 min. 200 µL of the supernatant 
serum was shot into a solution containing 200 µL ascorbic acid (0.085 M) and 400 µL 
butylated hydroxytoluene (BHT, 1.14 mM) and the resulting solution was stored on - 80°C 
until measurement, while the remaining serum was aliquoted and stored on - 80°C as well. 
Before HPLC measurement, 600 µL n-hexane containing 1.14 mM BHT and rac-tocol as 
internal standard were added to the freshly thawed serum samples treated with antioxidants 
(800 µL). This mixture was mixed for 1 min and then centrifuged at 1166 RCF for 5 min at 
4°C. The hexane layer was transferred to a test vial and evaporated under nitrogen flow. The 
residue was reconstituted with 75 µL ACN and 50 µL ethanol/dioxane (1:1). The resulting 
solution was transferred into a 200 µL glass insert placed into an amber-colored vial for 
measurement. 
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Total cholesterol and triglyceride levels were determined by commercially available kits from 
Diasys (Diagnostics Systems GmbH, Holzheim, Germany) on Roche Modular P800 analyser 
(Roche, Rotkreuz, Switzerland) in the Department of Laboratory Medicine (Faculty of 
Medicine, Albert Szent‐Györgyi Clinical Center, University of Szeged, Szeged, Hungary). 
The concentrations of α-, β/γ-, δ-tocopherol were quantified with an Agilent 1200 HPLC 
system (Agilent Technologies, Santa Clara, CA, USA) equipped with an UV/VIS diode array 
detector (DAD) applying the modified method of Hess et al. (Hess et al. 1991). 
Chromatographic separations were performed on an Alltech Prevail C18 column, 150 x 4.6 
mm I.D., 5 μm particle size (Alltech Associates Inc., Deerfield, IL, USA) after passage 
through a SecurityGuard pre-column, C18, 4 x 3.0 mm I.D., 5 μm particle size (Phenomenex 
Inc., Torrance, CA, USA) with a mobile phase composition of 
ACN/tetrahydrofurane/methanol/1 w/v% ammonium acetate/distilled water 
(684:220:68:28:28) applying isocratic elution. The flow rate and the injection volume were 
2.1 mL/min and 50 µL, respectively. The detector was set at 292 (α-tocopherol) and 297 (β/γ-, 
δ-tocopherol, rac-tocol) nm. 
The separation of β- and γ-tocopherol is challenging because they only differ in the position 
of a methyl group. With the use of a C18 column these 2 compounds have almost the same 
retention time (Saha et al. 2013). β- and γ-tocopherols can only be separated with the 
application of special columns and methods (Grebenstein and Frank 2012, Górnaś et al. 
2014), the application of which may be challenging for the routine clinical practice. 
Accordingly, only γ-tocopherol was applied as standard compound for the establishment of 
the calibration curve in this study, and the concentrations at the corresponding retention time 
includes both substances and reported as β/γ-tocopherol. 
With regard to method validation, which was conducted with minor changes compared to 
paragraph 3.1, the following parameters are reported briefly. Calibrants were prepared from 
serum samples spiked with 6 different concentration levels with concentration ranges of 0 – 
40 μM, 0 – 6 μM, 0 – 6 μM and 0 – 24 μM for α-, β/γ-, δ-tocopherol and rac-tocol, 
respectively. Very good linearity (R2 ≥ 0.99) was observed throughout the concentration 
ranges for α-, β/γ-, δ-tocopherol and rac-tocol. For the determination of within-run precision, 
5 samples for 4 concentration levels were applied (i.e., 20 replicates altogether). This 
measurement was repeated 2 more times with at least 1 week intervals to obtain between-run 
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precision. With regard to within-run precision the CV of the measured concentrations were 
4.53%, 3.72% and 5.11% for α-, β/γ- and δ-tocopherols, respectively, whereas in case of 
between-run precision, they were 3.59%, 5.93% and 4.76% for α-, β/γ- and δ-tocopherol, 
respectively. The recoveries for the serum samples ranged from 86 to 105%, from 95 to 108% 
and from 116 to 124% for α-, β/γ- and δ-tocopherol, respectively. The peaks of the different 
compounds obtained during chromatographic analysis are presented in Figure 5. 
 
 
Figure 5 Chromatograms of the analyzed tocopherols from human serum with UV detection on 297 nm. rac-
tocol (1), δ‐tocopherol (2), γ‐tocopherol (3) and α-tocopherol (4) 
 
3.5 Statistics 
All statistical analyses were performed with the use of the R software (R Development Core 
Team 2002). The pharmacokinetic data were evaluated with PKSolver, a freely available 
menu-driven add-in program for Microsoft Excel (Zhang et al. 2010). 
We first checked the distribution of data populations with the Shapiro-Wilk test, and we also 
performed the Levene test for analysis of the homogeneity of variances. In the case of the 
analysis of 3-NP toxin model, due to the necessity of a large number of comparisons of data 
from the 2 groups obtained via a single measurement, two-sample t-tests via Monte-Carlo 
permutation (with 10,000 random permutations) were applied. With regard to the 
measurements for MPTP toxin model, all the data exhibited normal distribution and equal 
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variances were assumed, and therefore ANOVA was used with Bonferroni post hoc 
comparison. 
To determine RI for tocopherol measurements, we took the IFCC (International Federation of 
Clinical Chemistry and Laboratory Medicine) and CLSI (Clinical and Laboratory Standards 
Institute) guidelines (Horowitz 2016) as a basis. According to these guidelines the minimum 
required number of individuals for the determination of RI with the bootstrap method is at 
least 100 samples. First we checked the distribution of our data with the Anderson-Darling 
test and we also performed the Levene test for analysis of the homogeneity of variances. If the 
distribution proved to be Gaussian and the variances were equal, one-way ANOVA was 
applied to compare the groups, otherwise Kruskal-Wallis test was utilized. To obtain the 
necessary quantiles and their confidence intervals for the determination of the reference 
intervals, the bootstrap method (1000 iterations) was applied. The correlation between the 
concentration of the measured compounds and the age of individuals in the sample population 
was examined with the nonparametric Spearman's test. 
We rejected the null hypothesis when the corrected p values were < 0.05, and in such cases 
the differences were considered significant. Data with Gaussian or non-Gaussian distributions 
were plotted as means (± S.E.M. or ± S.D.) or medians (and interquartile range), respectively. 
 
4 Results 
 
4.1 Pharmacokinetic assessment of KYNA and KYNA amides 
The concentrations of KYNA and KYNA amides measured in rat serum and CNS samples by 
HPLC are demonstrated in Table 1. 
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Table 1 The concentration of KYNA and KYNA amides in Sprague-Dawley male rat serum and CNS samples. 
 
Serum 
Time (min) 
KA-1 treatment KA-2 treatment 
KA-1 (µM) KYNA (nM) KA-2 (µM) KYNA (nM) 
0 
(control) 
0 75.7 
(72.8−90.4) 
0 75.7 
(72.8−90.4) 
15 87.4 
(0−191.2) 
5517.9 
(3287.2−6290.1) 
2.6 
(2.2−20.9) 
287.9 
(239.1−6753.5) 
30 35.6 
(0−140.4) 
1159.3 
(523.8−2397.9) 
20.9 
(17.4−22.6) 
16709.5 
(13796.6−17519) 
60 39.6 
(0−114.4) 
464.1 
(304.9−1342.3) 
13.7 
(13.7−14) 
3375.8 
(3332.7−4604.1) 
120 19.5 
(0−87.2) 
561 
(353.2−570.4) 
3.2 
(3−4.7) 
334.6 
(232.4−422.2) 
300 3.1 
(0−61.5) 
103.6 
(99.1−128.2) 
0.5 
(0.5−0.5) 
149.3 
(110.3−150.1) 
 
CNS 
Time (min) 
KA-1 treatment KA-2 treatment 
KA-1 
(pmol/g ww) 
KYNA 
(pmol/g ww) 
KA-2 
(pmol/g ww) 
KYNA 
(pmol/g ww) 
0 
(control) 
0 5.33 
(1.00−13.17) 
0 5.33 
(1.00 - 13.17) 
15 < LOD 58.98 
(53.37−277.22) 
< LOD 17.41 
(15.02−19.31) 
30 < LOD 44.69 
(29.43−104.13) 
4.45 
(3.88−4.67) 
34.77 
(25.01−50.53) 
60 < LOD 58.61 
(25.97−103.53) 
6.44 
(5.62−7.85) 
65.70 
(41.54−110.68) 
120 < LOD 12.00 
(11.07−15.68) 
3.28 
(2.75−3.31) 
15.30 
(10.81−18.47) 
300 < LOD 13.73 
(13.16−19.79) 
1.98 
(1.50−2.90) 
22.43 
(19.63−24.62) 
 
The concentrations were measured with HPLC after pretreatment with KA-1 and KA-2. Sprague-Dawley male 
rats: n = 5 in each group; data are shown as median (interquartile range); KYNA kynurenic acid, KA-1 N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, KA-2 N-(2-N-pyrrolidinylethyl)-4-oxo-
1H-quinoline-2-carboxamide hydrochloride, LOD limit of detection. 
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The time-course profile of the KYNA amides in the rat serum revealed that, after a steep 
increase in the concentration, a subsequent steep decrease occurred in the first hour, followed 
by a prolonged further gradual decrease (Figure 6). 
 
 
Figure 6 The concentrations of KYNA and KYNA amides in serum and CNS samples of Sprague-Dawley male 
rats. Figure 6a and 6b demonstrate the concentrations of KYNA and KYNA amides in rat serum with the course 
of time after injection. Figure 6c and 6d show the concentrations of KYNA and KYNA amides in the CNS 
samples of the same animals. KA-1 concentrations were under the limit of detection in the CNS samples. 
Sprague-Dawley male rats: n = 5 in each group; data are shown as medians; KYNA kynurenic acid, KA-1 N-(2-
N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, KA-2 N-(2-N-pyrrolidinylethyl)-
4-oxo-1H-quinoline-2-carboxamide hydrochloride 
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Although the serum concentration of KA-2 did not show such a high level as that of KA-1, a 
slightly slower decrease in concentration was observed. These observations are consistent 
with the calculated serum pharmacokinetic parameters (Cmax, Tmax, area under the curve 
(AUC0-t), the half-life (t1/2), apparent total clearance (CL/Fobs) and apparent volume of 
distribution (Vz/Fobs)) of KA-1 and KA-2, demonstrated in Table 2. 
 
Serum 
 KA-1 treatment KA-2 treatment 
Pharmacokinetic 
parameters 
KA-1 KYNA KA-2 KYNA 
t1/2 (h) 1.09 0.91 0.84 0.64 
tmax (h) 0.25 0.25 0.50 0.50 
Cmax (µM) 87.44 5.44 20.87 16.63 
AUC 0 - t (µM*h) 99.22 2.61 23.35 7.89 
Vz/Fobs 
((μmol/kg)/(μmol/l)) 
15.17 - 50.02 - 
Cl/Fobs 
((μmol/kg)/(μmol/l)/h) 
9.61 - 41.81 - 
 
CNS 
 KA-1 treatment KA-2 treatment 
Pharmacokinetic 
parameters 
KA-1 KYNA KA-2 KYNA 
t1/2 (h) NA 1.67 2.61 3.45 
tmax (h) NA 0.25 1 1 
Cmax (pmol/g) NA 53.66 6.44 60.37 
AUC 0 - t (pmol/g*h) NA 86.46 16.24 97.77 
Vz/Fobs 
((pmol/kg)/(pmol/l)) 
NA - 158,88 - 
Cl/Fobs 
((pmol/kg)/(pmol/l)/h) 
NA - 42,22 - 
 
 
Table 2 Pharmacokinetic parameters 
of KYNA and KYNA amides in rat 
serum and CNS samples after 
intraperitoneal injection of KA-1 and 
KA-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The KYNA amides were applied in a 
dose of 1 mmol/kg. Sprague-Dawley 
male rats: n = 5 in each group; KYNA 
kynurenic acid, KA-1 N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide 
hydrochloride, KA-2 N-(2-N-
pyrrolidinylethyl)-4-oxo-1H-
quinoline-2-carboxamide 
hydrochloride, NA not available 
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However, the increase in serum KYNA concentration following the i.p. injection of KA-2 was 
considerably higher (an approximately 200-fold maximal increase) as compared with that of 
KA-1 (an approximately 70-fold maximal increase), also well reflected by the above-
mentioned pharmacokinetic parameters. To avoid the influence of the basal serum KYNA 
level on the calculated pharmacokinetic parameters, these basal concentrations were 
subtracted from the corresponding subsequent concentrations in the calculation of the 
pharmacokinetic parameters. The pharmacokinetic data therefore reflect only the KYNA 
amide-induced changes in KYNA concentrations. In the 5th hour, KA-1 and KA-2 were still 
present at 3.1 (0−61.5) µM and 0.5 (0.5−0.5) µM in the serum, respectively, while the KYNA 
levels had approximately returned to the baseline level, preferentially in the case of KA-1 
treatment. In the rat CNS samples the KA-1 concentration was under LOD. However, KA-2 
was present in detectable amounts in the CNS, reaching its maximum concentration (6.44 
(5.62−7.85) pmol/g ww) after an hour which subsequently gradually decreased but in the 5th 
hour it was still present at 1.98 (1.50−2.90) pmol/g ww. The CNS pharmacokinetics of KYNA 
following KA-1 and KA-2 administration showed quite similar profiles, characterized by an 
approximately maximal 10-fold increase in basal concentration within the 1st hour. Vz/Fobs 
was relatively high in KA-1 and especially in KA-2. The apparent clearance was also high in 
the case of KA-2 relative to KA-1. 
 
4.2 Measurement of TRP metabolites in the 3-NP toxin model of HD 
As shown in Table 3, no difference was found in the KYNA concentration in the serum or in 
the investigated brain regions of the toxin-treated and control mice 12 days after the last 
injection, and there was no significant difference between the TRP levels of the serum 
samples of the toxin-treated and control mice, whereas in the case of KYN, a significant 
difference was detected in the cortex (2679 ± 110 pmol/g wet weight (ww); p = 0.017, 
permutation test) relative to the control value (3110 ± 112). However, significantly decreased 
TRP levels were found in the striatum (19,530 (17,700–20,440) pmol/g ww; p = 0.0002, 
permutation test), cortex (14,360 (13,540–16,300) pmol/g ww; p = 0.003, permutation test), 
hippocampus (16,550 (14,790–17,580) pmol/g ww (ww); p = 0.006, permutation test), 
cerebellum (14,930 (14,210–16,260) pmol/g ww; p = 0.0002, permutation test) and brainstem 
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(12,740 (12,280–14,100) pmol/g ww; p = 0.0004, permutation test) of 3-NP-treated mice as 
compared with the controls (27,950 (23,820–35,700); 22,860 (17,260–28,430); 26,590 
(18,020–30,730); 24,810 (17,630–28,510); 20,960 (15,920–29,890) pmol/g ww, respectively). 
 
Table 3 The concentrations of some metabolites of the KP in different brain regions and serum of control and 3-
NP treated mice 
  Serum Str Ctx Hip Cer Stem 
T 
R 
P 
ctrl 
102.8 
(89.8 – 
115.4) 
27,950 
(23,820 – 
35,700) 
22,860 
(17,260 – 
28,430) 
26,590 
(18,020 – 
30,730) 
24,810 
(17,630 – 
28,510) 
20,960 
(15,920 – 
29,890) 
3-NP 
88.6 
(83.2 – 
94.5) 
19,530*** 
(17,700 – 
20,440) 
14,360** 
(13,540 – 
16,300) 
16,550** 
(14,790 – 
17,580) 
14,930*** 
(14,210 – 
16,260) 
12,740*** 
(12,280 – 
14,100) 
K 
Y 
N 
ctrl 
1.39 
± 0.09 
2922 
± 288 
3110 
± 112 
2914 
± 176 
3060 
± 238 
2389 
± 118 
3-NP 
1.12 
± 0.12 
3001 
± 309 
2679* 
± 110 
2723 
± 208 
2521 
± 182 
2169 
± 111 
K 
Y 
N 
A 
ctrl 
0.19 
(0.17 – 
0.21) 
5.73 
(<LOD – 
21.91) 
5.07 
(<LOD – 
7.72) 
<LOD 
(<LOD – 
7.66) 
<LOD 
(<LOD – 
4.18) 
<LOD 
3-NP 
0.10 
(0.09 – 
0.18) 
<LOD 
6.67 
(3.04 – 
7.08) 
<LOD 
(<LOD – 
7.68) 
<LOD 
(<LOD – 
7.45) 
<LOD 
3- 
O 
H 
K 
ctrl <LOD <LOD <LOD <LOD 
66.84 
(28.99 – 
97.64) 
<LOD 
(<LOD – 
25.50) 
3-NP <LOD <LOD <LOD <LOD <LOD** <LOD 
 
The concentration of TRP and some of its metabolites were measured from 5 different brain regions and serum 
of C57Bl/6 mice with HPLC. TRP levels were significantly decreased in all brain regions of 3-NP treated mice. 
In the cortex and cerebellum of toxin treated mice there was also a significant depletion in KYN and 3-OHK 
concentrations, respectively. Measurement unit was µM for serum and pmol/g wet weight for brain regions (str 
striatum; ctx cortex; hip hippocampus; cer cerebellum; stem brainstem). KYN results are expressed as mean ± 
S.E.M., the other substances are shown as median (interquartile range). KP kynurenine pathway, TRP 
tryptophan, KYN kynurenine, KYNA kynurenic acid, 3-OHK 3-hydroxykynurenine, 3-NP 3-nitropropionic acid, 
ctrl control, LOD limit of detection. * p < 0.05, ** p < 0.01, *** p < 0.001 
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The observed decreases in TRP level were generally associated with an increased KYN/TRP 
ratio, an index widely used to assess the metabolic activity of KP. Indeed, a significant 
increase in KYN/TRP ratio was observed in the striatum (0.156 ± 0.014; p = 0.008, 
permutation test), hippocampus (0.158 ± 0.008; p = 0.023, permutation test), cerebellum 
(0.166 ± 0.01; p = 0.008, permutation test) and brainstem (0.166 ± 0.008; p = 0.009, 
permutation test) as compared with the control values (0.102 ± 0.011; 0.122 ± 0.011; 0.129 ± 
0.007; 0.117 ± 0.013, respectively; Figure 7); however, the difference in the cortex did not 
reach statistical significance. 
 
Figure 7 The effects of 3-NP treatment on the KYN/TRP ratio in the serum and different brain regions of 
C57Bl/6 mice. The KYN/TRP ratio was significantly elevated in the striatum, hippocampus, cerebellum and 
brainstem of the 3-NP-treated mice. The increase in the cortex did not reach the level of statistical significance. 
No alteration was observed in the serum. Data are means ± S.E.M; 3-NP 3-nitropropionic acid, KYN 
kynurenine, TRP tryptophan, * p < 0.05, ** p < 0.01 
 
No difference in the KYN/TRP ratio was observed in the serum. With regard to 3-OHK 
levels, a significant decrease was observed in the cerebellum (to below the LOD; p = 0.005, 
permutation test) in the 3-NP-treated mice in comparison with the control value (66.84 
(28.99–97.64) pmol/g ww), but not in the other brain regions. 
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4.3 Measurement of DA and its metabolites after MPTP treatment 
The DA, DOPAC and HVA values in the respective control groups of the 3 treatment 
regimens were compared to each other, and there were no significant differences. Therefore, 
the values in these control groups were pooled for further comparisons with the MPTP-treated 
groups. The MPTP administration caused significant reductions in the striatal DA (ctrl: 8.08 ± 
0.50, MPTP: 4.36 ± 0.92, p = 0.0005, ANOVA), DOPAC (ctrl: 2.57 ± 0.21, MPTP: 0.44 ± 
0.08, p = 3.78 x 10-8, ANOVA) and HVA (ctrl: 2.18 ± 0.12, MPTP 0.67 ± 0.11, p = 5.12 x 10-
10, ANOVA) levels compared to control values 90 min following its last administration in the 
acute treatment regimen (acute-1 day; Figure 8). Moreover, a significant reduction in 
metabolite levels was also observed 1 week after the last injection in the acute treatment 
regimen (acute-7 days; Figure 8) in the DA (ctrl: 8.08 ± 0.50, MPTP: 1.34 ± 0.43, p = 4.86 x 
10-8, ANOVA), DOPAC (ctrl: 2.57 ± 0.21, MPTP: 0.76 ± 0.15, p = 7 x 10-6, ANOVA) and 
HVA (ctrl: 2.18 ± 0.12, MPTP: 0.81 ± 0.13, p = 5.08 x 10-8, ANOVA) values in the striatum of 
the MPTP-treated mice compared to the control animals. However, chronic MPTP treatment 
resulted in significant reductions of only striatal HVA (ctrl: 2.18 ± 0.12, MPTP: 1.40 ± 0.08, p 
= 0.0005, ANOVA) levels, striatal DA (ctrl: 8.08 ± 0.50, MPTP: 6.83 ± 0.48) and DOPAC 
(ctrl: 2.57 ± 0.21; MPTP: 1.99 ± 0.23) levels were not decreased significantly (Figure 8). 7 
days following the acute treatment regimen the DA levels significantly decreased compared to 
those data from samples obtained 90 min following the last MPTP injection in the acute 
treatment regimen (p = 0.039, ANOVA). 
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4.4 Tocopherol measurements from human serum 
The group-wise comparisons failed to detect any significant difference between groups 
regarding the concentrations of α-tocopherol (p = 0.48, χ2 = 2.46; Kruskal-Wallis test), β/γ-
tocopherol (p = 0.47, χ2 = 2.53; Kruskal-Wallis test) or δ-tocopherol (p = 0.82, χ2 = 0.94; 
Kruskal-Wallis test; Table 4). Accordingly, in order to establish RI with appropriate subject 
numbers, the values for each measured compounds were pooled and the minimum required 
sample size (n = 120) was achieved. 
 
 
Figure 8 Striatal DA, DOPAC and HVA 
concentrations of MPTP-treated mice in 3 
different treatment regimens. 90 min (acute-1d) 
and 7 days (acute-7d) following acute MPTP 
intoxication, DA, DOPAC and HVA levels
significantly decreased in the striatum 
compared to the controls. The chronic (12 day) 
low dose MPTP treatment did not influence the 
striatal levels of DA and DOPAC, only HVA 
levels were significantly decreased. Values are 
plotted as means ± S.E.M; * p < 0.05, ** p < 
0.01, *** p < 0.001; DA dopamine, DOPAC
3,4-dihydroxyphenylacetic acid, HVA
homovanillic acid 
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Table 4 Serum tocopherol concentrations of subjects belonging to the control and OND groups. 
 
Controls 
(women) 
Controls 
(men) 
OND patients 
(women) 
OND patients 
(men) 
Group 
comparisons 
(p) 
 
α-
tocopherol 
(μM) 
38.08 
(33.70 – 44.10) 
35.38 
(31.35 – 45.83) 
34.26 
(29.40 – 41.60) 
33.93 
(30.54 – 41.08) 
0.48 
(χ2 = 2.46) 
β/γ-
tocopherol 
(μM) 
1.83 
(1.32 – 2.23) 
1.68 
(1.39 – 2.52) 
1.57 
(1.33 – 1.82) 
1.75 
(1.52 – 2.21) 
0.47 
(χ2 = 2.53) 
δ-
tocopherol 
(μM) 
0.63 
(0.52 – 0.86) 
0.62 
(0.53 – 0.78) 
0.62 
(0.55 – 0.82) 
0.65 
(0.57 – 0.75) 
0.82 
(χ2 = 0.94) 
 
Group-wise comparisons (Kruskal-Wallis test) of the four groups failed to detect any significant difference 
between serum tocopherol levels. Data are presented as median and interquartile range. OND other neurological 
disease. 
 
Table 5 The calculated uncorrected lower (2.5%) and upper (97.5%) reference intervals for tocopherols for the 
assessed Hungarian population. 
 2.5% S.E. C.I. (95%) 97.5% S.E. C.I. (95%) 
α-tocopherol 
(μM) 
24.62 0.76 23.24 – 26.26 54.67 4.09 46.88 – 61.84 
β/γ-tocopherol 
(μM) 
0.81 0.13 0.60 – 1.11 3.69 0.45 2.71 – 4.55 
δ-tocopherol 
(μM) 
0.29 0.03 0.22 – 0.32 1.07 0.13 0.80 – 1.29 
 
n = 120, S.E. standard error; C.I. confidence interval 
 
For the determination of lower (2.5%) and upper (97.5%) RI with the corresponding 
confidence intervals and standard errors, the bootstrap method was applied and the results are 
demonstrated in Table 5. To obtain cholesterol-corrected tocopherol values as well, serum 
cholesterol concentrations were determined for each subject (median and interquartile range: 
4.99 mM (4.31 – 5.54)) and the tocopherol/cholesterol ratios were calculated. The bootstrap 
method was applied again for the lipid corrected values (Table 6). To assess the incidental 
effect of age on measured serum lipid levels, Spearman test was performed. The cholesterol 
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levels positively correlated with the age of subjects (p < 0.001, Spearman's ρ = 0.34; Figure 
10). 
 
Table 6 The calculated cholesterol corrected lower (2.5%) and upper (97.5%) reference intervals for tocopherols 
for the assessed Hungarian population. 
 2.5% S.E. C.I. (95%) 97.5% S.E. C.I. (95%) 
α-tocopherol 
(μmol/mmol) 
5.11 0.14 4.79 – 5.36 11.27 0.69 9.91 – 12.82 
β/γ-tocopherol 
(μmol/mmol) 
0.14 0.02 0.10 – 0.19 0.72 0.07 0.60 – 0.88 
δ-tocopherol 
(μmol/mmol) 
0.06 0.01 0.05 – 0.07 0.22 0.03 0.16 – 0.27 
 
n = 120, S.E. standard error; C.I. confidence interval 
 
 
 
In case of uncorrected α- and β/γ-tocopherol concentrations this correlation with age is 
present as well (α-tocopherol: p = 0.002, Spearman's ρ = 0.28, Figure 11a; β/γ-tocopherol: p = 
0.001, Spearman's ρ = 0.29, Figure 11c) whereas δ-tocopherol levels did not correlate with 
age (p = 0.98, Spearman's ρ = 0.003, Figure 11e). When tocopherol levels were normalized to 
cholesterol levels, all the correlations with age were eliminated (α-tocopherol: p = 0.99, 
Spearman's ρ = - 0.0007, Figure 11b; β/γ-tocopherol: p = 0.14, Spearman's ρ = 0.14, Figure 
11d; δ-tocopherol: p = 0.051, Spearman's ρ = - 0.18, Figure 11f). 
Figure 10 Serum cholesterol concentrations in 
function of age. There is a positive correlation 
between cholesterol levels and age (p < 0.001, 
Spearman's ρ = 0.34). 
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Figure 11 Serum tocopherol concentrations and tocopherol/cholesterol ratios plotted against the age of 
participants. The level of α-tocopherol positively correlates with age (p = 0.002, Spearman's ρ = 0.28; a), 
similarly to β/γ-tocopherol (p = 0.001, Spearman's ρ = 0.29; c), whereas δ-tocopherol levels do not correlate with 
age (p = 0.98, Spearman's ρ = 0.003; e). The cholesterol corrected values of α-tocopherol (p = 0.99, Spearman's ρ 
= - 0.0007; b) and β/γ-tocopherol (p = 0.14, Spearman's ρ = 0.14; d) do not further significantly correlate with 
age, and the correlation of δ-tocopherol levels with age also remained non-significant (p = 0.051, Spearman's ρ = 
- 0.18; f). 
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5 Discussion 
 
Bioanalytical measurements play an essential role in differential diagnostics and may have 
prognostic value as well. Accordingly, numerous preclinical and clinical studies aim to 
discover novel biomarkers to monitor various pathological processes or the therapeutic effects 
of novel drugs. Amongst analytical methods, HPLC is one of the most popular options 
because it provides fast and robust determination of a wide range of compounds. However, 
these methods require substantial development of procedures in order to obtain valid, i.e., 
replicable, results. 
For the investigation of the potential beneficial effects of KYNA amides in headache, a well-
known model of trigeminal nociception, the orofacial formalin test, was applied. 
Immunohistochemical studies have revealed that formalin induces c-FOS and nNOS 
expression in the TNC, which suggests the activation and sensitization of that region (Hunt et 
al. 1987, Párdutz et al. 2000). Our aim was to give a pharmacokinetic explanation for the 
observed beneficial effects of 2 KYNA amides (KA-1 and KA-2) in the above-mentioned 
formalin model, which involves both peripheral and central components of pain processing. 
With regard to the serum concentrations of the analogs following their i.p. administration, the 
levels of KA-2 were considerably lower than those of KA-1 from the aspects of peak 
concentration and AUC0-5h. In contrast, KA-1 could not be detected in the examined CNS 
region, and the concentration of KA-2 was likewise relatively low. On the other hand the 
serum pharmacokinetic data revealed that KA-2 decays into KYNA in larger amounts than 
KA-1, but nevertheless, in the examined CNS region, there is no major difference between 
KYNA levels following the treatments with KA-1 or KA-2. In view of these findings, the 
difference in the observed effects in behavioral and immunohistochemical studies (Veres et al. 
2017) may be explained by the differences in the serum KYNA levels. From the aspect of a 
structure-activity relationship, the difference in peripheral conversion may stem from the 
structures of the 2 analogs, e.g., in the case of KA-2 the strained pyrrolidine moiety may 
influence the faster hydrolysis of the amide bond relative to the N,N-dimethyl function (KA-
1). These findings suggest that the difference in the beneficial effects of the 2 analogs may be 
explained by the peripheral effect of elevated KYNA concentrations on formalin-induced 
pathological alterations. The molecular background would be the inhibition of NMDAR-
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mediated neurotransmission at the strychnine-insensitive glycine-binding site (Szalárdy et al. 
2012b) which is present on the peripheral process of the trigeminal nociceptors (Watanabe et 
al. 1994, Quartu et al. 2002). The observed peak serum KYNA concentration following KA-2 
treatment during the experiment (16.71 µM) may be relevant with regard to the inhibition of 
glutamatergic neurotransmission via the above-mentioned pathway (Szalárdy et al. 2012b). 
In another study, regarding the KP of TRP metabolism, we used the 3-NP toxin model of HD 
(Brouillet 2014). In contrast with genetic models (Guidetti et al. 2000, 2006, Sathyasaikumar 
et al. 2010, Mazarei et al. 2013), there are no available published data on the effects of 3-NP 
toxicity on the concentrations of TRP and KP metabolites under in vivo conditions in mice. 
One of the 2 studies on the effects of chronic 3-NP treatment in rats demonstrated a 
significant decrease in the number of kynurenine aminotransferase (KAT)-I-immunoreactive 
cells, predominantly in the striatum (Csillik et al. 2002). The other study on ex vivo rat 
cortical slices, demonstrated that 3-NP dose-dependently inhibited the production of KYNA 
and led to decreased KAT-I and KAT-II activities in the cortical tissue homogenates 
(Luchowski et al. 2002). No murine studies have been conducted previously to assess the 
effects of in vivo applied 3-NP on KP metabolism at the metabolite level per se, and there 
have been no studies of KP alterations due to 3-NP intoxication in the serum, which may 
allow the differentiation of systemic effects from those confined to the CNS. We have now 
quantitatively assessed the levels of 4 KP metabolites in the striatum, cortex, hippocampus, 
cerebellum and brainstem of mice, with a relatively high number of animals per group (n = 
14-16). 
Our findings indicated a decreased TRP level in association with an increased KYN/TRP ratio 
in most of the examined brain regions of C57Bl/6 mice treated with 3-NP, and also a reduced 
concentration of 3-OHK in the cerebellum. It is noteworthy that we did not detect any 
significant difference in serum samples, which suggests that the observed alterations are 
specific for the examined brain regions and are not affected by a systemic change and/or an 
altered permeability of the blood-brain barrier. Our results on 5-month-old 3-NP-treated 
animals resemble those from studies of 3-month-old transgenic YAC128 animals (Mazarei et 
al. 2013), which is known to be one of the best animal strains for the modeling of the 
alterations in human HD (Slow et al. 2003, Pouladi et al. 2013). The elevated KYN/TRP ratio 
is comparable with the previous finding of increased indolamine dioxigenase-1 activity in the 
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brain (but not in the serum) of YAC128 animals, an alteration reflecting that observed in 
several neurodegenerative diseases and their animal models (Vécsei et al. 2013), and which is 
suggested to contribute to the neurodegenerative process. In another study (Török et al. 2015) 
it has been confirmed with histochemical methods, that the sub-acute 3-NP treatment we used 
caused neuronal cell death in the striatum. The similarity of the findings of KP alterations in 
this 3-NP model with those observed previously in genetic models (Guidetti et al. 2000, 2006, 
Sathyasaikumar et al. 2010, Mazarei et al. 2013) leads us to presume that the KP alterations 
observed in transgenic animals might be secondary, at least partially, to a mitochondrial 
dysfunction, a well-known phenomenon in the pathogenesis of HD, and that 3-NP toxicity 
may comprise a useful and cheap tool for the screening of the efficacy of potential drug 
candidates before the application of more demanding genetic models. 
With regard to DA measurements, our aim was to confirm that the applied acute MPTP 
treatment regimen was effective in decreasing striatal DA levels, while the chronic low dose 
administration of the toxin was not. In our study, we compared the above-mentioned MPTP 
treatment regimens. MPTP is typically administered to mice according to one of 2 protocols: 
acute treatment (typically 4 injections at 2-h intervals in 1 day (Jackson-Lewis et al. 1995, 
Przedborski and Vila 2003, Anderson et al. 2006)) or subacute treatment (sometimes also 
called ‘chronic’ (Furuya et al. 2004)), in which 1 or 2 injections per day are administered for 5 
consecutive days. In our study, we tested an acute regimen similar to the others found in the 
literature (Jackson-Lewis et al. 1995) and furthermore, instead of the subacute treatment we 
applied a more prolonged low dose regimen to model drug-induced preconditioning. The 
preconditioning by MPTP is not intended to suggest a future direct therapeutic approach, but 
rather aimed at finding key players which may help to alleviate the pathological alterations. 
The situation may be similar to ischemic preconditioning where the outcome in myocardial 
infarction may depend substantially on which medications were applied with an influence on 
preconditioning (Tomai et al. 1999). Accordingly, the aim in the case of preconditioning with 
MPTP is the demonstration that this administration regimen does not cause significant 
decreases in striatal DA concentration. 
90 min after the last MPTP injection of the high-dose acute treatment (75 mg/kg/day total 
dose) the concentration of DA and its metabolites, DOPAC and HVA, were significantly 
decreased compared to the controls. 7 days after the last injection this difference could still be 
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observed. Additionally, DA levels were notably lower compared to the animals processed 
after 90 min. With regard to the chronic low dose administration of MPTP (15 mg/kg/day), it 
did not induce significant DA depletion (i.e., neurotoxic effect at biochemical level), a 
meaningful decrease in concentration was observed only in the case of HVA. 
These results demonstrated the presence of significant neurotoxicity in the case of the acute 
treatment regimen, associated with a sudden, but temporary, increase in PGC-1α expression, 
while the chronic low dose regimen failed to evoke any significant changes either in striatal 
DA concentration or in PGC-1α expression, suggesting that chronic low dose intoxication did 
not induce protective mechanisms with the involvement of PGC-1α. 
The determination of exact serum tocopherol concentrations may be substantial for the 
diagnosis and therapeutic monitoring of certain conditions usually accompanied with 
neurological symptoms, such as ataxia, myopathy or cognitive deficiency (Muller 2010, Fata 
et al. 2014). Although the symptoms of genetically-determined disorders with tocopherol 
deficiency usually manifest during childhood (Raizman et al. 2014), malabsorption disorders 
and late-onset genetically determined metabolic conditions typically appear in adulthood, 
indicating the need for tocopherol measurement in adult population as well (Ueda et al. 2009). 
However, these concentrations alone hold little diagnostic value. For proper evaluation 
physicians need a well-established RI, which can vary considerably between populations 
(Appendix I). The underlying cause of this variation may be multifactorial, mainly including 
not standardized patient selection criteria and some methodological issues. The aim of our 
tocopherol measurements was to establish RIs for the adult Hungarian population and to 
compare the method of patient selection and the analytical procedure with that of previously 
published studies. 
The investigated population in this study is homogeneously distributed with regard to age and 
covers a considerably wide age range of the adult population. The selection of a homogeneous 
study population may have a special importance, because the distribution of age can 
considerably influence reference values in light of the fact that the levels of certain 
tocopherols significantly increase with age (Figure 11; (Rifkind and Segal 1983)). 
Accordingly, when the investigated reference population includes young individuals, the 
results may be skewed to lower levels (Quesada et al. 2004, Ford et al. 2006, Paliakov et al. 
2009, Zhao et al. 2014). Moving further to another qualitative aspect of the composition of the 
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study population, in addition to the involvement of subjects without any chronic illness, the 
group of assessed individuals also comprised patients with different neurological disorders 
where tocopherol levels were not previously reported to be abnormal (the establishment of the 
so called control group of OND). This study setup may ensure the absence of significant 
alterations of tocopherol levels in neurological cases lacking the symptoms of ataxia, 
myopathy and cognitive deficiency, which may be important for future screening studies. 
Thorough statistical assessment resulted in no significant differences, thus subgroups became 
suitable for pooling, i.e., the number of individuals in the reference population could be easily 
increased to the desired level. Several previous studies lack the setup of including well-
detailed descriptions of the health condition of reference individuals, possibly introducing a 
bias into the reference values (Appendix I; (Quesada et al. 2004, Paliakov et al. 2009)). In the 
current study design, special attention was paid to dietary factors and to the intake of special 
medicines (e.g., statins) and food supplements as well, because these may considerably alter 
the levels of the assessed compounds (Colquhoun et al. 2005). The lack of this kind of 
standardization introduces another bias into the establishment of RIs (Appendix I; (Winbauer 
et al. 1999, Yuan et al. 2014)). 
Tocopherol levels are often reported as tocopherol:cholesterol ratios based on the fact that 
there is a close relationship between the concentrations of tocopherols and lipids in the blood 
(Thurnham et al. 1986). However, under special circumstances, lipid corrected tocopherol 
levels can be misleading, because it was reported that malnutrition and infectious diseases in 
children can lower the levels of circulating cholesterol and its lipoprotein carriers, which 
alteration of which can mask decreased tocopherol levels if only corrected values are reported 
(Das et al. 1996, Sauerwein et al. 1997, Squali Houssaïni et al. 2001). Contrarily, when obese 
children were investigated, their α-tocopherol levels were normal while their 
tocopherol:cholesterol ratios were significantly lower compared to the control group (Strauss 
1999). With regard to adults, in light of the fact that lipid status can vary with age (Figure 10; 
(Rifkind and Segal 1983)) the application of lipid corrected values may be necessary for the 
characterization of vitamin E status (Horwitt et al. 1972, Thurnham et al. 1986). Nevertheless, 
the report of serum tocopherol concentrations with lipid ratios may be practical for the proper 
evaluation of tocopherol status. However, only one third of the papers reported both of them 
(Appendix I). 
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During bioanalytical measurements there are several things to consider regarding the 
robustness and reproducibility of the method. An important matter is the validation of the 
applied analytical procedure, which can provide valuable information about the robustness of 
the measurement and the validity of the reported values. For scientific publications, at least a 
partial method validation is required (ICH 1995). Without method validation, the reliability of 
the presented data are questionable. With regard to the tocopherol measurements 
approximately 20% of the previous studies presenting human tocopherol concentrations are 
not validated (Appendix I). 
To compensate between the true and the measured concentrations, the use of an internal 
standard in known quantity also seems to be obligatory in bioanalytical methods, because 
during sample preparation slight changes in the concentration may occur. These changes can 
be more pronounced as the complexity of the method increases (e.g., tissue homogenization, 
liquid-liquid extraction, evaporation under N2). Of course, internal standards are required in 
other measurements as well, to enhance the quality and reproducibility of the procedures. 
Furthermore, applying these compounds for measurements from tissue samples allows 
correction for the weight of the sample so concentration can be determined precisely as g / 
wet weight tissue. With regard to sample collection, it needs to be considered that serum or 
plasma samples should be used, e.g. during tocopherol measurements the application of 
oxalate, citrate or ethylenediaminetetraacetic acid for plasma collection can reduce tocopherol 
concentration (Nierenberg and Lester 1985). 
 
6 Conclusion 
 
Our results from KP metabolite measurements in the orofacial pain model draw attention to 
the role of the glutamatergic system in the alleviation of peripheral sensitization, which can be 
utilized for future drug development. The possibility of targeting the peripheral component of 
pain processing may provide an option for pharmaceutical drug design without necessitating 
good penetration of the BBB, but other pharmacokinetic parameters, such as solubility and 
clearance, must be kept in mind. The present results and previous preclinical findings indicate 
that the KYNA amides, via their probable direct effects (KA-1 (Zádori et al. 2011a)) or as 
prodrugs (KA-2 in the current pharmacokinetic study), may be promising drug candidates in 
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neurological disorders with a high socioeconomic burden, including those involving pain and 
headache. Furthermore, we detected marked persistent increases in the KYN/TRP ratio in the 
striatum, hippocampus, cerebellum and brainstem and a slight reduction in the level of 3-
OHK in the cerebellum in mice when we applied the subacute 3-NP model of HD. Such 
alterations have not been reported earlier in 3-NP studies and are similar to those seen in 
young genetic animal models (especially in 3-month-old YAC128 transgenic mice (Mazarei et 
al. 2013)). In the era of advanced genetic models of HD, our findings demonstrate the 
continued relevance and applicability of toxin models, which may provide cost-effective and 
rapid ways of screening potential drug candidates to treat this currently intractable disease. 
Similarly to the 3-NP toxin model for HD, the MPTP toxin treatment serves as a good model 
for PD for the rapid testing of novel compounds and for the observation of various 
biochemical changes. Measuring the DA concentration in the striatum is a reliable method for 
the evaluation of possible neuroprotective effects. 
Glutamatergic excitotoxicity and mitochondrial disturbances play essential roles in the 
pathomechanism of several neurological diseases (Zádori et al. 2012) and they are almost 
always accompanied by the formation of RS (Szalárdy et al. 2015). Accordingly, we were 
interested in the characterization of the antioxidant mechanisms, more specifically the serum 
tocopherol levels. First we had to establish proper RIs for the adult Hungarian population, 
which are presented here with their corresponding cholesterol corrected values. These results 
can facilitate the diagnostic process for certain neurological conditions, such as ataxia with 
vitamin E deficiency. Moreover, we draw attention to the importance of a thoroughly 
designed protocol associated with the establishment of these RIs and the possible pitfalls of 
tocopherol measurements. 
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Footnotes to Supplementary table 1 
 
1 Abbreviations 
 
F – female 
M – male 
NA – not available 
RA – retinol acetate 
TA – tocopherol acetate 
 
2 Notes 
 
a – mean (range) 
b – mean ± standard deviation 
c – geometric mean ± standard deviation 
d – median (5-95th percentile) 
e – median (10-90th percentile) 
f – geometric mean (10-90th percentile) 
g – median (interquartile range) 
h – reference interval 
i – reference interval (95%) 
j – reference interval (90%) 
k – geometric mean 
l – median (range) 
m – median (95% confidence interval) 
* - retinyl butyrate and nonapreno-β-carotene 
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3 Methods 
 
PubMed (MEDLINE) and Web of ScienceTM were used as search engines for articles. The key 
terms for searching were: tocopherol, human, reference interval, vitamin E. Papers reporting 
only measurement data of subjects under the age of 18 years or those with a control group 
consisting less than 50 individuals were excluded. With regard to population description three 
levels were determined: descriptions without details were assigned to ‘none’; when only few 
specific criteria for patient enrollment were presented, ‘basic’ was applied; if the study 
population parameters were thoroughly delineated with special attention to vitamin E 
consumption and medications, the description was considered as ‘detailed’. There was not 
applied any differentiation between the depth of validation process, only methods without any 
reported validation were considered as unvalidated. 
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Abstract Kynurenic acid (KYNA) has well-established
protective properties against glutamatergic neurotransmis-
sion, which plays an essential role in the activation and
sensitization process during some primary headache dis-
orders. The goal of this study was to compare the effects of
two KYNA analogs, N-(2-N,N-dimethylaminoethyl)-4-
oxo-1H-quinoline-2-carboxamide hydrochloride (KA-1)
and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-car-
boxamide hydrochloride (KA-2), in the orofacial formalin
test of trigeminal pain. Following pretreatment with KA-1
or KA-2, rats were injected with subcutaneous formalin
solution in the right whisker pad. Thereafter, the rubbing
activity and c-Fos immunoreactivity changes in the spinal
trigeminal nucleus pars caudalis (TNC) were investigated.
To obtain pharmacokinetic data, KA-1, KA-2 and KYNA
concentrations were measured following KA-1 or KA-2
injection. Behavioral tests demonstrated that KA-2 induced
larger amelioration of formalin-evoked alterations as
compared with KA-1 and the assessment of c-Fos
immunoreactivity in the TNC yielded similar results.
Although KA-1 treatment resulted in approximately four
times larger area under the curve values in the serum rel-
ative to KA-2, the latter resulted in a higher KYNA ele-
vation than in the case of KA-1. With regard to TNC, the
concentration of KA-1 was under the limit of detection,
while that of KA-2 was quite small and there was no major
difference in the approximately tenfold KYNA elevations.
These findings indicate that the differences between the
beneficial effects of KA-1 and KA-2 may be explained by
the markedly higher peripheral KYNA levels following
KA-2 pretreatment. Targeting the peripheral component of
trigeminal pain processing would provide an option for
drug design which might prove beneficial in headache
conditions.
Keywords Kynurenic acid analog  Rat  Trigeminal pain 
Formalin test  Pharmacokinetics
Introduction
The kynurenine pathway (KP) of the tryptophan (TRP)
metabolism is extensively studied, mostly because of the
well-established endogenous protective properties of
kynurenic acid (KYNA) against the excitotoxic effect of
other KP metabolites, such as quinolinic acid and 3-hy-
droxy-L-kynurenine (Ve´csei et al. 2013; Za´dori et al.
2011b). Thus, KYNA has become a molecule of interest
for central nervous system (CNS) drug development for
several disorders (Schwarcz 2004). The application of
KYNA in in vivo preclinical studies would be difficult due
to its chemical and pharmacokinetic properties. There are
problems with its solubility in higher doses, it cannot pass
the blood–brain barrier in an acceptable quantity and it has
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a rapid clearance from the CNS and in the periphery,
mediated by organic anion transporters (Bahn et al. 2005;
Fukui et al. 1991). Several analogs, derivatives and pro-
drugs have been synthesized with the aim of mitigating
these disadvantages and of improving the utility of the
molecule in preclinical studies (Fu¨lo¨p et al. 2009). Among
our newly synthesized KYNA amides, two lead compounds
have been identified (Patent number #P0900281/PCT/
HU2010/00050).
With regard to in vitro electrophysiology studies, N-(2-
N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxam-
ide hydrochloride (KA-1, Fig. 1a) has been demonstrated to
be an evenmore effective inhibitor of hippocampal excitatory
synaptic transmission than KYNA (Nagy et al. 2011).
Accordingly, in an invivomodel of trigeminal activation,KA-
1 displayed better efficacy than that of its parent compound,
KYNA (Knyiha´r-Csillik et al. 2008). Following this com-
parative study, KA-1 was tested in several experimental set-
ups and proved to have beneficial effects (Gelle´rt et al.
2012, 2011; Knyiha´r-Csillik et al. 2008; Marosi et al. 2010;
Va´mos et al. 2010, 2009; Za´dori et al. 2011c). In contrast with
the electrophysiological findings with KA-1, N-(2-N-pyrro-
lidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochlo-
ride (KA-2, Fig. 1b) did not decrease, but rather slightly
increased the amplitudes of field excitatory postsynaptic
potentials (fEPSPs) (Nagy et al. 2011). However, in a recent
study, pretreatment with KA-2 was also able to attenuate the
effects of nitroglycerine (NTG) in an experimental model of
migraine (Fejes-Szabo´ et al. 2014).
The modes of action of these two compounds are still
not fully understood. The two main possibilities are the
following: (1) the intact structure is necessary for the
mechanism of action, which would mimic some effects of
the parent compound, KYNA; (2) the KYNA amides serve
as prodrugs and dissociate into KYNA, which can exert its
pharmacological effects. With regard to the clarification of
this issue, only one pharmacokinetic study is available to
date (Za´dori et al. 2011a). In that study, KYNA and KA-1
levels were measured with high-performance liquid chro-
matography (HPLC) in C57B/6 mouse serum following the
intraperitoneal administration of KA-1. The time-course
profile of KA-1 exhibited a steep increase in concentration
followed by a rapid decrease in the first hour. Although the
concentration of KYNA also increased from the basal
serum level following KA-1 administration, this increase
was considerably less than that in the case of KA-1. It may
therefore be concluded that only a small proportion of KA-
1 is metabolized to KYNA. These findings and the results
of electrophysiology studies led to the assumption that it is
less likely that KA-1 acts as a prodrug. Similar pharma-
cokinetic studies relating to KA-2 have not yet been made,
but in view of the results of the electrophysiology studies,
it seems to have a different mode of action.
The trigeminal system is responsible for most of the pain
processing originating from the area of the head (Carpenter
and Sutin 1983), and its activation therefore plays an
important role in the pathomechanism of several neuro-
logical disorders, including primary headaches and
trigeminal pain syndromes. These disorders, including
migraine cause an enormous burden to the society (Olesen
et al. 2012) underlining the need of new treatment options
with a possible different mechanism of action. On the basis
of its antagonistic influence on N-methyl-D-aspartate
(NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropi-
onic acid (AMPA) and kainate receptors (Pereira et al.
2002), it is assumed that KYNA has a modifying effect on
nociception (Na¨sstro¨m et al. 1992; Pa´rdutz et al. 2012), and
thus might possibly be a future candidate in headache
treatment.
One aim of this study was to investigate the effects of
KA-1 and KA-2 in the orofacial formalin test to quantify
the nociception in the trigeminal region of the rat (Clavelou
et al. 1995; Raboisson and Dallel 2004). A further aim was
to perform a comparative pharmacokinetic study so as to
further clarify the possible modes of action of these two
KYNA amides.
Materials and methods
Animals
During the experiments, adult male Sprague–Dawley rats
weighing 200–250 g were used. The animals were housed
under standard laboratory conditions (in an air-conditioned,
humidity-controlled and ventilated room) and were
allowed free access to drinking water and regular rat chow
on a 12 h–12 h dark–light cycle. The procedures used in
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Fig. 1 The chemical structure of N-(2-N,N-dimethylaminoethyl)-4-
oxo-1H-quinoline-2-carboxamide hydrochloride (KA-1, a) and N-(2-
N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochlo-
ride (KA-2, b)
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this study followed the guidelines of the International
Association for the Study of Pain and the directive of the
European Economic Community (86/609/ECC). They were
approved by the Committee of Animal Research at the
University of Szeged (I-74-12/2012) and the Scientific
Ethics Committee for Animal Research of the Protection of
Animals Advisory Board (XXIV./352/2012.).
Materials
The new KYNA amides (patent number #P0900281/PCT/
HU2010/00050), KA-1 and KA-2, were synthesized in the
Department of Pharmaceutical Chemistry, University of
Szeged. The reference compounds [KYNA and 3-nitro-L-
tyrosine (3-NLT)], zinc acetate dihydrate, chloral hydrate
and 3,30-diaminobenzidine were purchased from Sigma-
Aldrich (Saint Louis, MO, USA), acetonitrile, H2O2, nickel
ammonium sulfate and perchloric acid (PCA) were pur-
chased from Scharlau (Barcelona, Spain), acetic acid and
Triton X-100 were purchased from VWR International
(Radnar, PA, USA), and paraformaldehyde was purchased
from Merck (Darmstadt, Germany). The HPLC–MS grade
acetonitrile and acetic acid were obtained from VWR
International (Radnar, PA, USA).
Behavioral testing
To produce and quantify nociception in the trigeminal
region of the rat, we used the orofacial formalin test.
The animals were divided into three groups (n = 27–28
per group) and received an intraperitoneal (i.p.) injection of
phosphate-buffered saline (PBS, 0.1 M, pH 7.4) in the
Control group or an i.p. injection of KA-1 (1 mmol/kg
body weight; pH 7.4) in the KA-1 group or an i.p. injection
of KA-2 (1 mmol/kg body weight; pH 7.4) in the KA-2
group. One hour after pretreatment, the animals were
divided further into two subgroups (n = 13–15 per sub-
group), half of the rats receiving a subcutaneous (s.c.)
injection of 50 ll physiological saline without formalin
(control, KA-1 and KA-2), while the other half of the rats
were injected s.c. with 50 ll 1.5 % formalin solution
containing 0.55 % formaldehyde (control–formalin, KA-1–
formalin and KA-2–formalin), administered via a 26-gauge
needle into the right whisker pad.
The testing procedures were performed during the light
phase (between 8 a.m. and 2 p.m.) in a quiet room. The test
box was a 30 9 30 9 30 cm glass terrarium with mirrored
walls. For the offline analysis of rubbing activity directed
to the whisker pad, the behavior of the individually tested
rats was recorded with a video camera (Logitech HD
Webcam C615) situated 1 m above the terrarium. One hour
after pretreatment and following a 10-min habituation
period in the test box, the whisker pads of the rats were
injected s.c. with physiological saline or formalin and the
animals were immediately replaced in the chamber for
45-min. The rats did not receive any food or water during
the observation period. The test box was cleaned and
decontaminated after each animal. An observer blind to the
experimental procedures analyzed the recorded videos. The
45-min recording period was divided into 15 9 3-min
blocks, and we distinguished two phases following for-
malin injection [Phase 1 (time block 1, i.e., 0–3 min) and
Phase 2 (time blocks 5–15, i.e., 12–45 min)] according to
the previously published methods (Clavelou et al. 1995;
Raboisson and Dallel 2004), and the total time (number of
seconds) spent in rubbing/scraping the injected area with
the ipsilateral fore- or hindpaw was measured in each block
and defined as the nociceptive score for that block. Earlier
literature findings led us to use the grooming activity of
animals in the control subgroup as control (Clavelou et al.
1995).
Immunohistochemistry
Four hours after the formalin injection, the rats were per-
fused transcardially with 100 ml PBS, followed by 500 ml
4 % paraformaldehyde in phosphate buffer under deep
chloral hydrate (0.4 g/kg body weight) anesthesia. The
medullary segment containing the spinal trigeminal
nucleus pars caudalis (TNC) between ?1 and -5 mm from
the obex was removed, postfixed overnight for immuno-
histochemistry in the same fixative and cryoprotected
(10 % sucrose for 2 h, 20 % sucrose until the blocks sank,
and 30 % sucrose overnight). Before sectioning, each
segment was marked with a small incision on the ventral
and left (contralateral) side of the tissue block, allowing
side discrimination during the quantification process.
30-lm transverse cryostat sections were cut through the
rostrocaudal axis from the beginning of the TNC and were
serially collected in wells containing cold PBS. Each well
contained every tenth section at 0.3-mm intervals along the
rostrocaudal axis (15 levels = sections). The free-floating
sections were rinsed in PBS and immersed in 0.3 % H2O2
in PBS for 30 min to suppress endogenous peroxidase
activity. After several rinses in PBS containing 1 % Triton
X-100 (PBST), sections were incubated at room tempera-
ture overnight in PBST containing rabbit anti-rat c-Fos
polyclonal antibody (Santa Cruz Biotechnology, sc-52) at a
dilution of 1:2000. The immunohistochemical reaction was
visualized using Vectastain Elite avidin–biotin kits (Vector
Laboratories, PK6101). Briefly, the sections were incu-
bated at room temperature for 2 h in PBST containing goat
anti-rabbit biotinylated secondary antibody. After several
rinses in PBST, and incubation at room temperature for 2 h
in PBST containing avidin and biotinylated horseradish
peroxidase, the sections were stained with 3,30-
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diaminobenzidine intensified with nickel ammonium sul-
fate. The specificity of the immune reactions was checked
by omitting the primary antiserum.
The immunoreactive (IR) cells in the superficial layer of
the TNC were counted by an observer blind to the exper-
imental procedures under the 109 objective of a Nikon
Optiphot-2 (Nikon Instruments, Melville, NY, USA) light
microscope in every tenth transverse section in each ani-
mal. Before the counting, the location of each section along
the rostrocaudal axis and the location of the TNC on each
medullary section were determined by means of The Rat
Brain in Stereotaxic Coordinates Atlas (Paxinos and Wat-
son 2007). The c-Fos neurons with obvious specific nuclear
staining were taken into consideration and were counted in
the TNC both ipsilaterally and contralaterally to the for-
malin injection.
HPLC measurements
Sample preparation
At set time points (15, 30, 60, 120 and 300 min) following
the i.p. injection with the KYNA amides (1 mmol/kg), the
rats were deeply anesthetized with i.p. injection of chloral
hydrate (0.4 g/kg, Sigma-Aldrich). Blood samples were
collected from vena cava caudalis and centrifuged at 13709
RCF (relative centrifugal force) for 10 min at 4 C. The
supernatants, i.e., the serum samples, were collected and
centrifuged at 13709 RCF for 10 min at 4 C again and the
supernatants were stored at -80 C until use. After the
collection of blood samples, the animals were transcar-
dially perfused with 100 ml 0.1 M PBS for 5 min. The
CNS samples containing the medullary segment of the
TNC were then removed and stored at -80 C until mea-
surements. The animals in the Control group underwent a
similar procedure with one measurement point at 300 min.
For the measurement of KYNA concentration, the CNS
samples were cut in half, weighed and then sonicated for
1.5 min in an ice-cooled solution (250 ll) comprising PCA
(2.5 % w/w), 3-NLT (10 or 2 lM) and distilled water in an
Eppendorf tube. The content of the Eppendorf tube was
centrifuged at 13709 RCF for 10 min at 4 C and the
supernatant was measured. Before analysis, the serum
samples were thawed and, after a brief vortex, the serum
sample was ‘shot’ onto a precipitation solvent (containing
PCA with 3-NLT as internal standard, with resulting con-
centrations of 2.5 w/w% and 2 lM, respectively). The
samples were subsequently centrifuged at 13709 RCF for
10 min at 4 C, and the supernatants were collected for
measurement.
For the analysis of KYNA amides, the other half of the
CNS samples were weighed and then sonicated in ice-cold
(250 ll) distilled water for 1.5 min and centrifuged at
13709 RCF for 10 min at 4 C. From the supernatant,
100 ll was transferred to an Eppendorf tube containing
750 ll HPLC gradient grade acetonitrile and 150 ll dis-
tilled water. After a brief vortex, the samples were cen-
trifuged at 13709 RCF for 10 min at 4 C and 900 ll of
supernatant was evaporated in a vacuum centrifuge. After
thawing and brief stirring with a vortex, 200 ll of serum
sample was transferred to an Eppendorf tube containing
700 ll HPLC gradient grade acetonitrile and 100 ll dis-
tilled water. After a brief vortex, the samples were cen-
trifuged at 13709 RCF for 10 min at 4 C and 900 ll of
supernatant was evaporated in a vacuum centrifuge. The
evaporated CNS and serum samples were stored at 4 C
until use.
Chromatographic conditions
The KYNA concentrations of the CNS samples were
quantified on the basis of a slight modification of a litera-
ture method (Herve´ et al. 1996) as described in detail with
method validation in our previous article (Fejes-Szabo´
et al. 2014). For the measurement of concentration of the
above-mentioned metabolite from serum samples we
applied the same method with a slight modification. Fur-
thermore, we applied the method validation procedures to
the serum samples too. Briefly, we used an Agilent 1100
HPLC system (Agilent Technologies, Santa Clara, CA,
USA) equipped with fluorescence and a UV detector; the
former was applied for the determination of KYNA and the
latter for the determination of the internal standard (3-
NLT). Chromatographic separations were performed on an
Onyx Monolithic C18 column, 100 mm 9 4.6 mm I.D.
(Phenomenex Inc., Torrance, CA, USA) after passage
through a SecurityGuard pre-column C18, 4 9 3.0 mm
I.D., 5 lm particle size (Phenomenex Inc., Torrance, CA,
USA) with a mobile phase composition of 0.2 M zinc
acetate/ACN = 95/5 (v/v), the pH of which was adjusted
to 6.2 with acetic acid, applying isocratic elution. The flow
rate was 1.5 ml/min and the injection volume was 20 ll for
serum, and 50 ll for CNS samples. The fluorescence
detector was set at excitation and emission wavelengths of
344 and 398 nm. The UV detector was set at a wavelength
of 365 nm.
For the determination of KYNA amides, a Thermo
LCQFleet ion trap mass spectrometer was used equipped
with an ESI ion source combined with a Dionex Ultimate
3000 HPLC system. The ionization parameters were as
follows: heater temperature: 500 C, sheath gas flow rate:
60, auxiliary gas flow rate: 20, spray voltage: 4 kV, cap-
illary temperature: 400 C. Chromatographic separations
were performed on a Kinetex C18 column, 100 mm 9
4.6 mm, 2.6 lm particle size (Phenomenex Inc., Torrance,
CA, USA) after passage through a SecurityGuard pre-
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column C18, 4 9 3.0 mm, 5 lm particle size (Phenomenex
Inc., Torrance, CA, USA), with a mobile phase composi-
tion of 0.05 % aqueous CH3COOH/ACN = 90/10 (v/v),
applying isocratic elution. The flow rate and the injection
volume were 1 ml/min and 50 ll, respectively.
Calibration curve and linearity
Calibrants were prepared at six different concentration
levels, from 1 to 100 nM, 0.5 to 5 lM and 0.01 to 100 lM
for KYNA, 3-NLT and the KYNA amides, respectively.
Three parallel injections of each solution were made under
the chromatographic conditions described above. The peak
area responses were plotted against the corresponding
concentration, and the linear regression computations were
carried out by the least square method with the freely
available R software (R Development Core Team 2002).
Very good linearity was observed throughout the investi-
gated concentration ranges for KYNA, 3-NLT and the
KYNA amides when either fluorescence, UV or MS
detection was applied.
Selectivity
The selectivity of the method was checked by comparing
the chromatograms of KYNA, KYNA amides and the
internal standard for a blank serum and CNS sample and
those for a spiked sample. All compounds could be
detected in their own selected chromatograms without any
significant interference.
LOD and LLOQ
The limit of detection (LOD) and the lower limit of
quantification (LLOQ) were determined via the signal-to-
noise ratio with a threshold of 3 and 10, respectively,
according to the ICH guidelines (ICH 1995). The LOD and
LLOQ for KYNA in the serum samples were 1 and
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Fig. 2 The effects of formalin and KYNA amide treatments on
Sprague–Dawley male rats in the orofacial formalin tests. Following
formalin injection, the recording period was 45-min and this time
period was divided into 15 9 3-min time blocks. Phase 1 (time block
1) of the test is before the grayed out area, while Phase 2 (time blocks
5–15) is after the grayed out area. The two phases of formalin action
in the control ? formalin group are well demonstrated when com-
pared to the control group (*p\ 0.05; **p\ 0.01; ***p\ 0.001).
The KA-2 pretreatment significantly reduced the formalin-induced
nociceptive behavior relative to the control ? formalin group
(??p\ 0.01; ???p\ 0.001). Sprague–Dawley male rats:
n = 13–15 in each group; data are shown as mean ± SEM; KA-
1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide
hydrochloride; KA-2 N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-
2-carboxamide hydrochloride
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3.75 nM, respectively, while in the CNS samples they were
0.4 and 1 nM, respectively. The LOD and LLOQ for the
samples in MS detection were 0.001 and 0.015 lM,
respectively.
Precision
Replicate HPLC analysis showed that the relative standard
deviation was B2.2 % for the peak area response and
B0.1 % for the retention time for KYNA and the KYNA
amides.
Recovery
The relative recoveries were estimated by measuring
spiked samples of KYNA and the KYNA amides at two
concentrations with three replicates of each. No significant
differences were observed for the lower and higher con-
centrations. The recoveries for the serum samples ranged
from 103 to 108 %, 81 to 94 % and 79 to 80 % for KYNA,
KA-1 and KA-2, respectively. The recoveries for the CNS
samples ranged from 82 to 92 % and 78 to 84 % for KYNA
and KA-2, respectively.
Data evaluation
To compare the means of jaw rubbing counts (orofacial
formalin tests) in the different treatment groups (control,
control–formalin, KA-1, KA-1–formalin, KA-2, KA-2–
formalin) on rats during 15 3-min time periods (n = 13–15
animals in each group), two-way repeated measures
ANOVA were run. Treatment with six groups was used as
between-subject factor and time with 15 time points as
within-subject factor for the analysis.
When Levene’s test for homogeneity of variance was
significant in the Phase data (Phase 1 is the first 3 min,
while Phase 2 is the overall rubbing from min 12 to the end
of the examination, min 45, i.e., which is from the fifth
3-min time period to the 15th), the Welch test was run to
compare mean rubbing counts. Pairwise comparisons were
estimated by the Sidak test. The effect size (EF, f) was
calculated according to Cohen J. (Cohen 1988) with regard
to the ANOVA tests comparing the effects of compounds
on behavioral data in Phase 1 and 2.
In the case of the immunohistochemistry data, the
numbers of c-Fos-containing nuclei were assessed. Three-
way repeated measures ANOVA was used to analyze
group means across 15 adjacent measuring sites (conse-
quent slices from the medullary segment of the CNS
containing the TNC) among sides (contralateral and
ipsilateral) and between pretreatment groups (control,
KA-1 and KA-2) all with formalin injections. Measuring
sites and sides were used as within-subject factor, while
pretreatment was the between-subject factor in the general
linear model.
In the ANOVA models when Mauchly’s test of
sphericity was significant, the Greenhouse–Geisser cor-
rection was performed. In the event of the significant
interaction of factors, effects could not be reported inde-
pendently. Moreover, owing to the significant interaction,
group differences could be examined separately over the
within-subject factor based on estimated marginal means
for multiple comparisons with the Sidak adjustment.
Statistical analyses were carried out with IBM SPSS
Statistics, version 21 (IBM Corporation, Armonk, NY,
USA) software. All tests were two-sided, and p\ 0.05 was
considered to be statistically significant. The pharmacoki-
netic data were evaluated with PKSolver, a freely available
menu-driven add-in program for Microsoft Excel (Zhang
et al. 2010).
Fig. 3 Distribution of rubbing activity by groups in Phase 1 and 2 of
the orofacial formalin test. The recording period was 45-min, Phase 1
is the first 3-min, while Phase 2 is the overall rubbing activity from
min 12 to the end of the examination. Sprague–Dawley male rats:
n = 13–15 in each group; KA-1 N-(2-N,N-dimethylaminoethyl)-4-
oxo-1H-quinoline-2-carboxamide hydrochloride; KA-2 N-(2-N-pyrro-
lidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride
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Results
Behavioral assessment
The results of orofacial formalin testing are demonstrated
in Figs. 2, 3 and 4. To simplify the presentation of group
comparisons for better transparency, the groups of KA-1
and KA-2 were omitted from Figs. 2, 3 and 4. Pairwise
comparisons revealed that face rubbing activity in the
control, KA-1 and in the KA-2-treated groups was signif-
icantly lower in both Phase 1 and Phase 2 compared with
the control–formalin (ES of Phase 1, -1.88 and Phase 2,
-2.17), KA-1–formalin (ES of Phase 1, -1.75 and Phase
2, -1.56) and KA-2–formalin (ES of Phase 1, -1.64 and
Phase 2, -1.26) groups. With regard to the comparison of
the face rubbing activity in the KA-1–formalin (ES of
Phase 1, 0.11 and Phase 2, 0.51) and KA-2–formalin (ES of
Phase 1: 0.16 and Phase 2: 0.76) groups with that in the
control–formalin group, although KA-1 decreased face
rubbing activity as well (demonstrated by the correspond-
ing left-skewed histogram in Fig. 3), only KA-2 treatment
resulted in a significant reduction in the middle of Phase 2
(Figs. 2, 4).
Immunohistochemistry
The results of immunohistochemical analysis are demon-
strated in Figs. 5 and 6. The comparison of the ipsilateral
and the contralateral sides of the slices from the medullary
segment of the rat CNS containing the TNC demonstrated
that the mean number of c-Fos IR neurons was significantly
higher on the ipsilateral side than on the contralateral side
in the control–formalin, KA-1–formalin and KA-2–for-
malin groups (the two latter groups are not demonstrated to
simplify the presentation of group comparisons for better
transparency in Fig. 6). With regard to the comparison of
the ipsilateral sides of the KA-1–formalin and KA-2–for-
malin groups with the control–formalin group from the
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Fig. 4 Diagrams showing the
rubbing activity in the first
(a) and the second (b) phase in
the orofacial formalin test. In
the control ? formalin group,
the subcutaneous formalin
injection induced a significant
increase in rubbing activity in
both Phase 1 and 2
(***p\ 0.001) as compared to
the control group. In Phase 2,
pretreatment with KA-2 had a
significant effect on mitigating
the formalin-induced increase in
the time spent with rubbing
(??p\ 0.01) as compared with
the control ? formalin group.
Sprague–Dawley male rats:
n = 13–15 in each group; data
are presented as mean ± SEM;
KA-1 N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide
hydrochloride; KA-2 N-(2-N-
pyrrolidinylethyl)-4-oxo-1H-
quinoline-2-carboxamide
hydrochloride
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aspect of the mean number of c-Fos IR neurons, the
treatments, preferentially with KA-2, resulted in significant
reductions in IR cell count at certain levels of the assessed
region (the c-Fos changes followed the somatotopic rep-
resentation of the trigeminal nociceptors in the injected
whisker pad area; Strassman and Vos 1993). Besides the
observed significant differences, the effects of the treat-
ment are well demonstrated by the curves in Fig. 6.
HPLC measurements and pharmacokinetics
The concentrations of KYNA and KYNA amides measured
in rat serum and CNS samples by HPLC are demonstrated in
Table 1. The time-course profile of the KYNA amides in the
rat serum revealed that after a steep increase in the concen-
tration, a subsequent steep decrease occurred in the first hour,
followed by a prolonged further gradual decrease (Fig. 7).
Although the serum concentration of KA-2 did not show
such a high level as that of KA-1, a slightly slower decrease
in concentration was observed. These observations are
consistent with the calculated serum pharmacokinetic
parameters (Cmax, Tmax, area under the curve (AUC0–t), the
half-life (t1/2), apparent total clearance (CL/Fobs) and
apparent volume of distribution (Vz/Fobs)) of KA-1 and KA-
2, demonstrated in Table 2. However, the increase in serum
KYNA concentration following the i.p. injection of KA-2
was considerably higher (an approximately 200-fold maxi-
mal increase) as compared with that of KA-1 (an approxi-
mately 70-fold maximal increase), also well reflected by the
above-mentioned pharmacokinetic parameters. To avoid the
influence of the basal serum KYNA level on the calculated
pharmacokinetic parameters, these basal concentrations
were subtracted from the corresponding subsequent con-
centrations in the calculation of the pharmacokinetic
parameters. The pharmacokinetic data therefore reflect only
the KYNA amide-induced changes in KYNA concentra-
tions. In the fifth hour, KA-1 and KA-2 were still present at
3.1 (0–61.5) lM and 0.5 (0.5–0.5) lM in the serum,
Fig. 5 Representative histological images following c-Fos immunos-
taining in Sprague–Dawley male rats. Subcutaneous formalin injec-
tion induced an increase in the number of c-Fos IR neurons on the
ipsilateral side demonstrated on the transverse section of medulla
containing the TNC from the control ? formalin subgroup (a, b;
contralateral side is indicated with an incision on the ventral side of
the section). The pretreatments (KA-1: c; KA-2: d), reduced the
amount of IR cells in the superficial layers of TNC as compared with
control ? formalin group (b). Black arrow c-Fos IR neurons in the
superficial laminae; black frame magnified area, which can be seen in
images b–d; TNC trigeminal nucleus pars caudalis, IR immunoreac-
tive, KA-1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-car-
boxamide hydrochloride, KA-2 N-(2-N-pyrrolidinylethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride
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respectively, while the KYNA levels had approximately
returned to the baseline level, preferentially in the case of
KA-1 treatment. In the rat CNS samples, the KA-1 concen-
tration was under LOD. However, KA-2 was present in
detectable amounts in the CNS, reaching its maximum
concentration (6.44 (5.62–7.85) pmol/g ww) after an hour
which subsequently gradually decreased, but in the fifth hour
it was still present at 1.98 (1.50–2.90) pmol/g ww. The CNS
pharmacokinetics of KYNA following KA-1 and KA-2
administration showed quite similar profiles, characterized
by an approximately maximal tenfold increase in basal
concentration within the first hour. Vz/Fobs was relatively
high inKA-1 and especially inKA-2. The apparent clearance
was also high in the case of KA-2 relative to KA-1.
Discussion
Headache, one of the most common disorders of the ner-
vous system, is a major health problem worldwide. The
global prevalence for the adult population of active
headache disorder is 46 % for headache in general, 11 %
for migraine, 42 % for tension-type headache and 3 % for
chronic daily headache (Stovner et al. 2007). The treatment
of primary headache disorders is challenging requiring
both acute and preventive therapeutic strategies
(Weatherall 2015). The efficacy of these treatments is not
always satisfactory and the contraindications and side
effects often limit the options of the physician (Diener et al.
2015; Obermann et al. 2015). There is therefore a constant
need to study and develop new molecules. In addition to
the currently available drugs, e.g., NSAIDs, triptans, anti-
convulsants, verapamil, propranolol, etc. (National Institute
for Health and Care Excellence 2012), the pipeline of
pharmaceutical research in this field involves the devel-
opment of novel agents acting on the glutamatergic system
due to its essential role in the nociceptive process (Dick-
enson et al. 1997; Diener et al. 2015). Animal and human
studies have revealed that glutamate receptors are present
in various parts of the trigeminal system (Quartu et al.
2002; Sahara et al. 1997; Tallaksen-Greene et al. 1992),
and stimulation of the trigeminal nerve results in elevated
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Fig. 6 The average number of c-Fos immunoreactive cells per
section of TNC in Sprague–Dawley male rats after formalin injection
with KYNA amide pretreatments. The distance was calculated
caudally from the starting point of TNC. Subcutaneous formalin
injection resulted in a higher number of c-Fos-IR neurones on the
ipsilateral side compared with the contralateral side in the con-
trol ? formalin group (*p\ 0.05; **p\ 0.01; ***p\ 0.001). The
pretreatments (KA-1: #p\ 0.05, ##p\ 0.01; KA-2: ??p\ 0.01),
reduced the amount of IR cells in the superficial layers of TNC as
compared with the ipsilateral side in the control ? formalin group.
Sprague–Dawley male rats: n = 9–10 in each group; data are shown
as mean ± SEM; IR immunoreactive, TNC trigeminal nucleus pars
caudalis, KA-1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-
2-carboxamide hydrochloride, KA-2 N-(2-N-pyrrolidinylethyl)-4-
oxo-1H-quinoline-2-carboxamide hydrochloride
A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal…
123
glutamate levels in the TNC (Oshinsky and Luo 2006). The
peripheral application of glutamate to deep craniofacial
tissue proved to be able to activate and sensitize nocicep-
tive afferents and neurons in the upper cervical cord (Lam
et al. 2009a, b). These findings suggest that excitatory
amino acid receptors (and NMDA in particular) play an
important role in pain processing and the sensitization
process which is also present in migraineurs (Vikelis and
Mitsikostas 2007). Ketamine, an NMDA antagonist, is so
far the only promising treatment option for patients with
severe or long-lasting migraine aura (Afridi et al. 2013).
Another novel substance, tezampanel, which acts on the
AMPA and kainate subtypes of ionotropic glutamate
receptors (Alt et al. 2006), has also shown promising
results in acute migraine therapy (Sang et al. 2004).
As regards the preclinical models of headache disorders,
NTG is the most frequently used substance to trigger a
delayed migraine-like attack (Sicuteri et al. 1987). Animal
experiments have revealed that NTG can activate the
trigeminal system and stimulate the second-order trigemi-
nal neurons, which lead to increased c-Fos and neuronal
nitric oxide synthase (nNOS) expression in the affected
area (Pa´rdutz et al. 2000; Tassorelli et al. 1997). NTG is
also able to sensitize the trigeminal system in humans (Di
Clemente et al. 2009). Together, these results confirm that
NTG administration can model the central trigeminal
nociceptor sensitization demonstrated in migraine patients
(Burstein et al. 2000). With regard to the above-mentioned
therapeutic strategy with the aim of neurotransmission
modulation via the glutamatergic system, earlier studies
revealed that KA-1 is able to attenuate the effects of NTG
on the number of nNOS, calcium/calmodulin-dependent
protein kinase II type alpha (CamKIIa) and calcitonin gene
related peptide (CGRP) IR cells in the TNC, markers
related to the activation and sensitization of the nociceptors
(Va´mos et al. 2010, 2009). KA-2 was later also tested in
the NTG model and proved to be able to increase the
KYNA concentration both in the C1–C2 region and in the
serum. Pretreatment with KA-2 (0.5 and 1 mmol/kg) sig-
nificantly reduced the effects of NTG on the CGRP-,
c-Fos-, nNOS- and CaMKIIa-related changes in the C1–
C2 region (Fejes-Szabo´ et al. 2014). To date, there has
been only one study of the pharmacokinetic properties of
KYNA amides, which found that only a small proportion
of KA-1 decays into KYNA in the serum of C57B/6 mice
(Za´dori et al. 2011a).
In this study, we used another well-known model of
trigeminal nociception, the orofacial formalin test. For-
malin solution administered s.c. into the upper lip of rats
causes tissue injury, inflammation and nociception (Cla-
velou et al. 1995). Immunohistochemical studies have
revealed that formalin induces c-Fos and nNOS expression
in the TNC, similarly as in the NTG model, which suggestsT
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the activation and sensitization of the area (Hunt et al.
1987; Pa´rdutz et al. 2000). The behavioral effect of for-
malin is biphasic, with a short period of rubbing activity
immediately after injection and then a tonic prolonged
(20–22 min) second phase after a quiescent period
(Raboisson and Dallel 2004). Using the formalin model,
our aim was to compare the two compounds (KA-1 and
KA-2) in an assessment method which involves both
peripheral and central components of pain processing, with
special interest in the pharmacokinetic explanation of the
observed differences.
Our results indicated that KA-2 has more significant
beneficial effects on the formalin-induced behavioral and
immunohistochemical alterations. We carried out a
comparative pharmacokinetic study to clarify this differ-
ence between the two analogs. With regard to the serum
concentrations of the analogs following their i.p. adminis-
tration, the levels of KA-2 were considerably lower than
those of KA-1 from the aspects of peak concentration and
AUC0–5h. In contrast, KA-1 could not be detected in the
examined CNS region, and the concentration of KA-2 was
likewise relatively low. On the other hand, the serum
pharmacokinetic data revealed that KA-2 decays into
KYNA in larger amount as compared with KA-1, but
nevertheless, in the examined CNS region, there is no
major difference between KYNA levels following the
treatments with KA-1 or KA-2. Summarizing these find-
ings, the peak elevation of KYNA in the CNS
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Fig. 7 The concentrations of
KYNA and KYNA amides in
serum and CNS samples of
Sprague–Dawley male rats. a,
b Concentrations of KYNA and
KYNA amides in rat serum with
the course of time after
injection. c, d Concentrations of
KYNA and KYNA amides in
the CNS samples of the same
animals. KA-1 concentrations
were under the limit of detection
in the CNS samples. Sprague–
Dawley male rats: n = 5 in each
group; data are shown as
medians; KYNA kynurenic acid,
KA-1 N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide
hydrochloride, KA-2 N-(2-N-
pyrrolidinylethyl)-4-oxo-1H-
quinoline-2-carboxamide
hydrochloride
Table 2 Pharmacokinetic parameters of KYNA and KYNA amides in rat serum and CNS samples after intraperitoneal injection of KA-1 and
KA-2
Serum CNS
Pharmacokinetic parameters KA-1 treatment KA-2 treatment Pharmacokinetic parameters KA-1 treatment KA-2 treatment
KA-1 KYNA KA-2 KYNA KA-1 KYNA KA-2 KYNA
t1/2 (h) 1.09 0.91 0.84 0.64 t1/2 (h) NA 1.67 2.61 3.45
tmax (h) 0.25 0.25 0.50 0.50 tmax (h) NA 0.25 1 1
Cmax (lM) 87.44 5.44 20.87 16.63 Cmax (pmol/g) NA 53.66 6.44 60.37
AUC0–t (lM h) 99.22 2.61 23.35 7.89 AUC0–t (pmol/g h) NA 86.46 16.24 97.77
Vz/Fobs ((lmol/kg)/(lmol/l)) 15.17 – 50.02 – Vz/Fobs ((pmol/kg)/(pmol/l)) NA – 158,879.15 –
Cl/Fobs ((lmol/kg)/(lmol/l)/h) 9.61 – 41.81 – Cl/Fobs ((pmol/kg)/(pmol/l)/h) NA – 42,220.03 –
The KYNA amides were applied in a dose of 1 mmol/kg. Sprague–Dawley male rats: n = 5 in each group
KYNA kynurenic acid, KA-1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, KA-2 N-(2-N-pyrrolidinylethyl)-
4-oxo-1H-quinoline-2-carboxamide hydrochloride
A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal…
123
(approximately tenfold of the basal concentration) is con-
siderably lower (by one order of magnitude) than that of
peak elevation of KYNA in the serum (approximately
70–200-fold of the basal concentration) following the
administration of KA-1 and KA-2, and with respect to CNS
samples, there are no differences between KYNA levels. In
view of these findings, the difference in the observed
effects in behavioral and immunohistochemical studies
could be explained by the differences in serum KYNA
levels. From the aspect of a structure–activity relationship,
the difference in peripheral conversion may stem from the
structures of the two analogs, e.g., in the case of KA-2 the
strained pyrrolidine moiety may influence the faster
hydrolysis of the amide bond relative to the N,N-dimethyl
function (KA-1). These findings suggest that the difference
in the beneficial effects of the two analogs may be
explained by the peripheral effect of elevated KYNA
concentrations on formalin-induced pathological alter-
ations. The molecular background would be the inhibition
of NMDA receptor-mediated neurotransmission at the
strychnine-insensitive glycine-binding site (Szala´rdy et al.
2012) which is present on the peripheral process of the
trigeminal nociceptors (Quartu et al. 2002; Watanabe et al.
1994). The observed peak serum KYNA concentration
following KA-2 treatment during the experiment
(16.71 lM) would be relevant with regard to the inhibition
of glutamatergic neurotransmission via the above-men-
tioned possibility (Szala´rdy et al. 2012).
In conclusion, our results draw attention to the role of
influencing the glutamatergic system in the alleviation of
peripheral sensitization, which can be utilized during future
drug development. The possibility of targeting the
peripheral component of pain processing would provide an
option of pharmaceutical drug design without the obliga-
tion of good penetration through the BBB, but other
pharmacokinetic parameters, such as solubility and clear-
ance, must be kept in mind. The present results and pre-
vious preclinical findings indicate that the KYNA amides,
via their probable direct effects (KA-1; Za´dori et al. 2011a)
or serving as prodrugs (KA-2 in the current pharmacoki-
netic study), would be promising drug candidates in neu-
rological disorders, including those involving pain and
headache, with a high socioeconomic burden.
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Experiments on human samples and on genetic animalmodels of Huntington's disease (HD) suggest that a num-
ber of neuroactive metabolites in the kynurenine (KYN) pathway (KP) of the tryptophan (TRP) catabolism may
play a role in the development of HD. Our goal in this study was to assess the concentrations of TRP, KYN,
kynurenic acid and 3-hydroxykynurenine (3-OHK) in the serum and brain of 5-month-old C57Bl/6 mice in the
widely used 3-nitropropionic acid (3-NP) toxinmodel of HD.We additionally investigated the behavioral chang-
es through open-ﬁeld, rotarod and Y-maze tests. Our ﬁndings revealed an increased TRP catabolism via the KP as
reﬂected by elevated KYN/TRP ratios in the striatum, hippocampus, cerebellum and brainstem. As regards the
other examined metabolites of KP, we found only a signiﬁcant decrease in the 3-OHK level in the cerebellum
of the 3-NP-treated mice. The open-ﬁeld and rotarod tests demonstrated that treatment with 3-NP resulted in
a reduced motor ability, though this had almost totally disappeared a week after the last injection, similarly as
observed previously in most murine 3-NP studies. The relevance of the alterations observed in our biochemical
and behavioral analyses is discussed.We propose that the identiﬁed biochemical alterations could serve as appli-
cable therapeutic endpoints in studies of drug effects on delayed-type neurodegeneration in a relatively fast and
cost-effective toxin model of HD.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Huntington's disease (HD) is an autosomal dominantly inherited
progressive neurodegenerative disorder which results in cognitive,
psychiatric and motor disturbances. HD is caused by an expansion of
the cytosine–adenine–guanine (CAG) repeat in the gene coding for
the N-terminal region of the huntingtin protein (Htt), which leads to
the formation of a polyglutamine stretch. Above 39 CAGs, there is oblig-
atory disease development (The Huntington's Disease Collaborative
Research Group, 1993). Although the exact mechanisms through
which mutant Htt (mHtt) leads to the characteristic neuropathology
are not fully understood, the potential roles of excitotoxicity and a
neuronal mitochondrial dysfunction are among the best-established
concepts (Szalardy et al., 2012; Zádori et al., 2012).
Various evidence suggest that the involvement of striatal gluta-
matergic excitotoxicity in the development of HD is mediated predom-
inantly by the overactivation of N-methyl-D-aspartate receptors
(NMDARs), and most speciﬁcally through NR2B subunit-containing
NMDARs at the extrasynaptic sites (Milnerwood et al., 2010). In line
with this, the expression of mHtt has been shown to sensitize the
NR2B subunit-containingNMDARs (Chen et al., 1999). There is evidence
indicating that such excitotoxic injury is mediated at least in part by en-
dogenous substances, including certain metabolites of the kynurenine
pathway (KP) of the tryptophan (TRP) metabolism (Fig. 1; Zádori
et al., 2011).
This pathway involves a number of neuroactive compounds.
Among them, quinolinic acid (QUIN) is a weak NMDAR agonist (Stone
and Darlington, 2002) which demonstrated an ability to induce
excitotoxic injury, which led to QUIN toxicity being utilized as an early
toxin model of HD (Beal et al., 1986). This toxic effect of QUIN was
revealed to be augmented by another deleterious KP metabolite, 3-
hydroxykynurenine (3-OHK), which can generate oxidative stress via
the production of reactive oxygen species (ROS) (Guidetti et al., 2000).
On the other hand, kynurenic acid (KYNA) is an NMDAR antagonist at
the strychnine-insensitive glycine coagonist site (Perkins and Stone,
1982) and a weak antagonist on kainate- and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid-sensitive ionotropic glutamate re-
ceptors (Kessler et al., 1989). Furthermore, its inhibitory potential on
presynaptic α7-nicotinic acetylcholine receptors is proposed to be of
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high relevance at physiological KYNA levels, due to the suppression
of presynaptic glutamate release (Hilmas et al., 2001). On this
basis, KYNA was considered to be neuroprotective against NMDAR-
modulated glutamatergic excitotoxicity, which has since been demon-
strated by a variety of experimental evidence (Miranda et al., 1997;
Sinor et al., 2000).
Besides the theoretical considerations, evidence of the presence of
alterations in the KP of the TRP metabolism in tissues from HD patients
and transgenic animals and in human post-mortem HD brains
(Schwarcz et al., 1988; Beal et al., 1990, 1992; Heyes et al., 1992;
Pearson and Reynolds, 1992; Jauch et al., 1995; Guidetti et al., 2004,
2006) is emerging. Brieﬂy, these results indicate a relative decrease
in KYNA concentrations relative to the levels of toxic neuroactive
kynurenines (Zádori et al., 2011).
A decreased activity of the succinate dehydrogenase (SDH), complex
II of the electron transport chain in post-mortem HD brains was one of
the early ﬁndings suggestive of the role of a mitochondrial dysfunction
in the development of HD (Stahl and Swanson, 1974). Furthermore,
mHtt has been shown to be able to bind directly to the mitochondria,
altering their normal function (Choo et al., 2004). In line with the
decreased SDH activity, mitochondrial II complex inhibitors such as
3-nitropropionic acid (3-NP) ormalonate have been found to be useful
in the investigation of HD through their utilization in animal toxin
models (Túnez et al., 2010). The 3-NP model is frequently applied as
an easy and rapid way to study certain aspects of neurodegenerative
processes in HD (Brouillet, 2014). Treatment with 3-NP evokes in-
creases in the production of ROS and ·NO (La Fontaine et al., 2000)
and the activation of apoptosis-related factors including caspase-3 and
calpain (Duan et al., 2000; Bizat et al., 2003a), mechanisms through
which 3-NP evokes striatal lesions in both rodents and primates in a
rather selective manner. Several dosing regimens are applied to evoke
characteristic neuropathological and behavioral alterations in rodents
(Brouillet et al., 2005). Brieﬂy, striatal neurodegeneration in rats occurs
when the steady inhibition of SDH attains 50–60% (Alexi et al., 1998;
Brouillet et al., 1998; Blum et al., 2002; Bizat et al., 2003b). In mice,
there have been only a few studies of the dosage-related reduction in
SDH activity. Lower cumulative doses (320 mg/kg) have been shown
to induce an approximately 20% reduction of enzyme activity, which
is not associated with marked striatal lesions (Fernagut et al., 2002a).
However, higher cumulative doses (400–450 mg/kg) were widely
used to induce measurable striatal lesions (Klivenyi et al., 2000, 2006).
Accordingly, in a previous study we demonstrated a signiﬁcant
Fig. 1. Schematic depiction of the kynurenine pathway of the tryptophan metabolism.
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reduction in striatal neuronal density via the application of unbiased
semiquantitative densitometric analysis by using a subacute dosing
regimen with a cumulative dose of 500 mg/kg (Török et al., 2015).
A number of publications have reported 3-NP-evoked alterations in
motor and cognitive performance in rodents (Borlongan et al., 1995b;
El Massioui et al., 2001; Brouillet et al., 2005; Li et al., 2009). The de-
scribed alterations in motor functioning are highly reminiscent of
those characteristic of human juvenile HD, such as rigidity, bradykine-
sia, dystonia and gait disturbances (Nance and Myers, 2001). Although
it seems clear that higher cumulative doses of 3-NP cause motor and
cognitive impairments, the motor dysfunctions observed undergo a
considerable amelioration after the cessation of toxin administration
(El Massioui et al., 2001; Fernagut et al., 2002b; Li et al., 2009). Early
studies raised the possibility that the KP is altered in 3-NP models
(Csillik et al., 2002; Luchowski et al., 2002), but this has not yet been
further investigated.
The aims of the present study were a delayed assessment of the TRP
metabolism with regard to certain metabolites of the KP following
subacute 3-NP treatment, and a comparison of the time-course of the
toxin-induced behavioral alterations with the data available from the
literature.
2. Materials and methods
2.1. Animals and 3-NP treatment
We used 30 5-month-old male C57Bl/6 mice in this study. The ani-
mals were housed in cages under standard conditions with a 12–12-h
light–dark cycle and free access to food and water. The experiments
were carried out in accordancewith the European Communities Council
Directive (86/609/EEC) and were approved by the local animal care
committee. The animals were randomly divided into two groups
(n = 16 and n = 14, respectively). In the ﬁrst group, 3-NP (Sigma-
Aldrich, Saint Louis, MO, USA; dissolved in phosphate-buffered saline
(PBS), pH adjusted to 7.4) was administered in a subacute dosing
regimen as reported previously (Török et al., 2015), with twice daily in-
traperitoneal (i.p.) injections (50 mg/kg each) for 5 consecutive days.
The second group served as the vehicle-injected control.
2.2. Behavioral assessment
2.2.1. Open-ﬁeld test
Spontaneous locomotor and exploratory activities of the animals
were assessed with the open-ﬁeld paradigm. The ﬁrst analysis was per-
formed 3 days before the beginning of 3-NP administration to exclude
any spontaneous difference between the randomly distributed animals.
The second and third analyses were performed on the 3rd and the 11th
day subsequent to the last day of the toxin regimen. The tests were per-
formed at the same time of day to avoid possible changes due to diurnal
rhythm. Each mouse was placed in the center of an open-ﬁeld
motimeter box measuring 48 ∗ 48 ∗ 40 cm for 15-min tracking periods
(analyzed in three 5-min periods). The movement patterns of the ani-
mals were tracked and recorded with the Conducta 1.0 system, with
the use of infrared beams (Experimetria Ltd., Budapest, Hungary). The
ambulation distance, the time spent in immobility and the total time
spent with consecutive rearings were the parameters used to assess
the motor and exploratory characteristics of the mice. The grid and
the walls of the setup were thoroughly wiped with a cloth containing
ethanol solution 70 v/v% after each session to prevent any bias from
olfactory cues.
2.2.2. Rotarod test
The rotarod test was applied to characterize the effects of 3-NP on
motor coordination. The animals were trained on the rotarod for a 3-
session period for 5 min on 2 consecutive days prior to the ﬁrst test
day. On the ﬁrst and second days of the training sessions, a constant
speed of 5 and 10 rpm, respectively, was used. Following the training
sessions, the ﬁrst test was performed prior to the ﬁrst 3-NP injection
in order to exclude any inborn difference between the randomly distrib-
uted 2 groups. During the tracking sessions on the test days, an acceler-
ating speed proﬁle from 1 rpm to 30 rpm was set for a 5-min tracking
period. The performance of each mouse was measured three times;
resting periods of 30 min were allowed between consecutive tracking
sessions. The latency to fall values were recorded with the TSE Rotarod
Advanced system (TSE Systems International Group, Frankfurt amMain,
Germany). The average latency to fall values were used for the compar-
ative analyses. The second, third and fourth tests were performed 2 h
following the second 3-NP injection and on the 1st and 10th days fol-
lowing the last 3-NP administration, respectively. On the day before
the respective test days, a 3-session retraining at 10 rpm for 5-min
with 30-min resting periodswas carried out to enable the animals to re-
call the rotarod experience. The rods and the separating walls were
thoroughly wiped with a cloth containing ethanol solution 70 v/v%
after each session to prevent any bias from olfactory cues.
2.2.3. Y-maze test
An asymmetric Y-maze paradigm was applied to assess the short-
term spatial memory of the mice. The Y-shaped translucent maze was
placed on a black board enclosed by black walls, which prevented any
view of the external environment. Unique visual cues were placed
around the three arms of the maze. The test was performed on the 9th
day after the end of the toxin regimen. The animals were ﬁrst placed
into the labyrinth and allowed to explore the common arm and only 1
of the 2 shorter arms of the maze until each mouse had spent a total
of 2 min in the open short arm. After the session of acquisition, the
mice were returned to their home cages for 30min. In the trial of recall,
the animals were free to enter all arms, and the tracking was stopped
after a total of 2min had been spent inside the 2 short arms. The explor-
atory activity of the mice was tracked and recorded with the SMART
v2.5 system (Panlab, Barcelona, Spain). For evaluation, the recognition
indices of the time spent and the distances traveled in the novel arm
of interest were used. The recognition index was calculated via the fol-
lowing formula, where P is the examined parameter:
recognition index = Pnovel arm / (Pnovel arm + Pknown arm).
The side of the novel arm was randomly distributed in each group,
and the board and walls of the setup were thoroughly wiped with a
cloth containing ethanol solution 70 v/v% after each session to prevent
any bias from olfactory cues.
2.3. High-performance liquid chromatography (HPLC)
2.3.1. Sample preparation
The investigated reference compounds (L-TRP, L-KYN-sulfate, KYNA
and 3-OHK), the substances used as internal standards (3-nitro-L-
tyrosine (3-NLT) and isoproterenol (IPR)), zinc acetate dihydrate and
sodium octylsulfate were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Acetonitrile and perchloric acid (PCA) were purchased
from Scharlau (Barcelona, Spain), and acetic acid, phosphoric acid,
sodium dihydrogenophosphate and disodium ethylenediaminetetraac-
etate were purchased from VWR International (Radnar, PA, USA).
On the 18th day of the experiment (12 days after the last 3-NP
injection), the mice were deeply anesthetized with isoﬂurane
(Forane®; Abott Laboratories Hungary Ltd., Budapest, Hungary). After
thoracotomy, 0.3–0.7ml venous bloodwas obtained from the right ven-
tricle by intracardial puncture, followed by perfusion with artiﬁcial ce-
rebrospinal ﬂuid (composition in mM: 122 NaCl, 3 KCl, 1 Na2SO4, 1.25
KH2PO4, 10 D-glucose∗H2O, 1 MgCl2∗6H2O, 2 CaCl2∗2H2O, 6 NaHCO3)
for 2 min by an automatic peristaltic pump. The blood samples were
left to coagulate for 30 min, and were then centrifuged for 10 min at
12,000 rpm. The supernatant sera were pipetted into polypropylene
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Eppendorf tubes and stored at−80 °C until further sample handling.
After perfusion, the brains were rapidly removed on ice and stored
at −80 °C until analysis. Before analysis, the brain samples were
weighed and then sonicated in an ice-cooled solution (250 μl) contain-
ing 2.5 w/w% PCA with 2 μM 3-NLT and 600 nM IPR as internal stan-
dards. The samples were next centrifuged at 12,000 rpm for 10 min at
4 °C, and the supernatants were collected.
Before analysis, the serum samples were thawed and, after a brief
vortex 200 μl of serum sample was ‘shot’ onto 200 μl of precipitation
solvent (containing 5 w/w% PCA with 4 μM 3-NLT and 2 μM IPR
as internal standards). The samples were subsequently centrifuged
at 12,000 rpm for 10 min at 4 °C, and the supernatants were
collected.
2.3.2. Measurement of TRP, KYN and KYNA
The TRP, KYN and KYNA concentrations of the samples were quanti-
ﬁed by a slight modiﬁcation of the method of Hervé et al. (Hervé et al.,
1996), with the use of an Agilent 1100 HPLC system (Agilent Technolo-
gies, Santa Clara, CA, USA). The systemwas equippedwith a ﬂuorescent
and a UV detector, the ﬂuorescent detector was set at excitation and
emission wavelengths of 344 nm and 398 nm for the determination of
KYNA and TRP, and the UV detector was set at 365 nm for the determi-
nation of KYN and the internal standard 3-NLT. Chromatographic
separations were performed on an Onyx Monolithic C18 column,
100 mm× 4.6 mm I.D. (Phenomenex Inc., Torrance, CA, USA) after pas-
sage through aHypersil ODSpre-column, 20 × 2.1mm I.D., 5 μmparticle
size (Agilent Technologies, Santa Clara, CA, USA) with a mobile phase
composition of 0.2 M zinc acetate/ACN = 95/5 (v/v%) with the pH ad-
justed to 6.2 with glacial acetic acid, applying isocratic elution. The
ﬂow rate and the injection volume were 1.5 ml/min and 50 μl, respec-
tively. The peaks of the different compounds obtained during chromato-
graphic analysis are presented in Fig. 2.
2.3.3. Measurement of 3-OHK
For determination of the concentrations of 3-OHK and its internal
standard (IPR), we applied the Agilent 1100 HPLC system equipped
with Model 105 electrochemical detector (Precision Instruments,
Marseille, France). In brief, the working potential of the detector was
set at +650 mV, using a glassy carbon electrode and an Ag/AgCl refer-
ence electrode. The mobile phase containing sodium octylsulfate
(2.8 mM), sodium dihydrogenophosphate (75 mM) and disodium
ethylenediaminetetraacetate (100 μM) was supplemented with aceto-
nitrile (5 v/v%) and the pH was adjusted to 3.0 with phosphoric acid
(85 w/w%). The mobile phase was delivered at a rate of 1 ml/min at
40 °C onto the reversed-phase column (HR-80 C18, 80 × 4.6 mm, 3-
μm particle size; ESA Biosciences, Chelmsford, MA, USA) after passage
through a pre-column (Hypersil ODS, 20 × 2.1 mm, 5-μm particle size;
Agilent Technologies, Santa Clara, CA, USA). Ten-microliter aliquots
were injected by the auto-sampler with the cooling module set at
4 °C. The peaks of the different compounds obtained during chromato-
graphic analysis are presented in Fig. 2.
Fig. 2. Chromatograms of the analyzed compounds of the kynurenine pathway of the tryoptophanmetabolism, from C57Bl/6murine brain samples. KYNA kynurenic acid, TRP tryptophan,
KYN kynurenine, 3-NLT 3-nitro-L-tyrosine, 3-OHK 3-hydroxykynurenine, IPR isoproterenol, FLD ﬂuorescent detector, ECD electrochemical detector.
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2.4. HPLC method validation
2.4.1. Calibration curve and linearity
Calibrants were prepared at 6 different concentration levels, from
0.1 to 50 μM, 0.05 to 5 μM, 1 to 100 nM, 10 to 200 nM, 0.5 to 7.5 μM
and 25 to 600 nM for TRP, KYN, KYNA, 3-OHK and the internal stan-
dards, 3-NLT and IPR, respectively. Three parallel injections of each solu-
tion were made under the chromatographic conditions described
above. The peak area responses were plotted against the corresponding
concentration, and the linear regression computations were carried
out by the least square method with the freely available R software
(R Development Core Team, 2002). Very good linearity was observed
throughout the investigated concentration ranges for TRP, KYNA, KYN,
3-OHK and the internal standards when either ﬂuorescence, UV or elec-
trochemical detection was applied.
2.4.2. Selectivity
The selectivity of the method was checked by comparing the chro-
matograms of TRP, KYN, KYNA, 3-OHK and the internal standards for
blank serum and homogenized brain samples and those for spiked
serumand homogenized brain samples. All compounds could be detect-
ed in their own selected chromatograms without any signiﬁcant
interference.
2.4.3. LOD and LLOQ
The limit of detection (LOD) and the lower limit of quantiﬁcation
(LLOQ) were determined via the signal-to-noise ratio with a threshold
of 3 and 10, respectively, according to the ICH guidelines (ICH, 1995).
The LOD for brain samples was 10, 40, 0.4 and 10 nM, while LLOQ was
20, 130, 1 and 30 nM for TRP, KYN, KYNA, and 3-OHK, respectively.
The LOD for the serum samples was 15, 100, 1 and 10 nM, while LLOQ
was 35, 275, 3.75 and 30 nM for TRP, KYN, KYNA and 3-OHK,
respectively.
2.4.4. Precision
Replicate HPLC analysis showed that the relative standard deviation
was≤2.2% for the peak area response and≤0.1% for the retention time
for TRP, KYN and KYNA, whereas in the case of 3-OHK the relative stan-
dard deviation was≤8.6% for the peak area response and≤0.3% for the
retention time.
2.4.5. Recovery
The relative recoverieswere estimated bymeasuring spiked samples
of TRP, KYN, KYNA and 3-OHK at 2 concentrations with 3 replicates of
each. No signiﬁcant differences were observed for the lower and higher
concentrations. The recoveries for the brain samples were 86 to 91%, 98
to 100%, 82 to 92% and 69 to 74% for TRP, KYN, KYNA and 3-OHK,
respectively. The recoveries for the serum samples ranged from 77
to 90%, 77 to 82%, 103 to 108% and 28 to 34% for TRP, KYN, KYNA and
3-OHK, respectively.
2.5. Statistics
All statistical analyseswere performedwith theuse of theR software
(R Development Core Team, 2002). We ﬁrst checked the distribution of
data populationswith the Shapiro–Wilk test, andwe also performed the
Levene test for analysis of the homogeneity of variances. In the behav-
ioral analyses, all the data exhibited normal distribution and equal var-
iances were assumed, and we therefore used the independent t-test to
compare the 2 groups. As a consequence of the multiple comparisons
of the same 2 groups, the necessary corrections were carried out in p
values according to the Bonferroni method. In the case of the HPLC
analyses, due to the necessity of a large number of comparisons of
data from the 2 groups obtained via a single measurement, two-
sample t-tests viaMonte-Carlo permutation (with 10,000 random per-
mutations) were applied. We rejected the null hypothesis when the
corrected p values were b0.05, and in such cases the differences were
considered signiﬁcant. Data with Gaussian or non-Gaussian distribu-
tions were plotted as means (±S.E.M.) or medians (and interquartile
range), respectively.
3. Results
3.1. Behavioral assessment
Our results demonstrated a signiﬁcant decrease in the latency to fall
period in the 3-NP-treated animals (35.33 ± 6.97 s; p b 0.001, indepen-
dent t-test) in the rotarod test 1 day after the last toxin injection in the
subacute treatment regime as compared with the control group
(126.34 ± 8.08 s). 10 days after the last injection, this difference had
disappeared (p = 0.16, independent t-test; Fig. 3A). In the Y-maze
test, therewas no difference between the groups 9 days after the last in-
jection (p=0.37, independent t-test; Fig. 3B). In the open-ﬁeld test per-
formed 3 days after the last injection, a signiﬁcant decrease was
observed in the ambulation distance during the total 15-min tracking
period (3-NP: 3203.2 ± 249.9 cm; control: 4874.9 ± 409.6 cm; p =
0.003, independent t-test; Fig. 3C) including that in the last 5-min
period (3-NP: 950.4 ± 108.6 cm; control: 1359.5 ± 116 cm; p =
0.028, independent t-test; Fig. 3E). However, 11 days after the last
3-NP injection, the difference was signiﬁcant only as regards the
last 5-min period (3-NP: 985.2 ± 69.9 cm; control: 1417.1 ± 106 cm;
p = 0.001, independent t-test; Fig. 3C). No difference in rearing time
was detected between the groups either in the total 15-min (Fig. 3D)
or in the last 5-min (Fig. 3F) tracking period.
3.2. HPLC analysis
As shown in Table 1, no difference was found in the KYNA con-
centration in the serum or in the investigated brain regions of the
toxin-treated and control mice 12 days after the last injection, and
there was no signiﬁcant difference between the TRP levels of the
serum samples of the toxin-treated and control mice, whereas in
the case of KYN, a signiﬁcant difference was detected in the cortex
(2,679 ± 110 pmol/g wet weight (ww); p = 0.017, permutation
test) relative to the control value (3,110 ± 112 pmol/g ww).
However, signiﬁcantly decreased TRP levels were found in the stria-
tum (19,530 (17,700–20,440) pmol/g ww; p= 0.0002, permutation
test), cortex (14,360 (13,540–16,300) pmol/g ww; p = 0.003, per-
mutation test), hippocampus (16,550 (14,790–17,580) pmol/g ww;
p = 0.006, permutation test), cerebellum (14,930 (14,210–16,260)
pmol/g ww; p = 0.0002, permutation test) and brainstem (12,740
(12,280–14,100) pmol/g ww; p = 0.0004, permutation test) of 3-NP-
treated mice as compared with the controls (27,950 (23,820–35,700);
22,860 (17,260–28,430); 26,590 (18,020–30,730); 24,810 (17,630–
28,510); 20,960 (15,920–29,890) pmol/g ww, respectively). The ob-
served decreases in TRP level were generally associated with an in-
creased KYN/TRP ratio, an index widely used to assess the metabolic
activity of KP. Indeed, a signiﬁcant increase in KYN/TRP ratio was ob-
served in the striatum (0.156 ± 0.014; p = 0.008, permutation test),
hippocampus (0.158±0.008; p=0.023, permutation test), cerebellum
(0.166 ± 0.01; p = 0.008, permutation test) and brainstem (0.166 ±
0.008; p = 0.009, permutation test) as compared with the control
values (0.102 ± 0.011; 0.122 ± 0.011; 0.129 ± 0.007; 0.117 ± 0.013,
respectively; Fig. 4); however, the difference in the cortex did not
reach statistical signiﬁcance. No difference in the KYN/TRP ratio was
observed in the serum. Additionally, a signiﬁcant decrease in 3-OHK
level was observed in the cerebellum (to below the LOD; p = 0.005,
permutation test) in the 3-NP-treated mice in comparison with the
control value (66.84 (28.99–97.64) pmol/g ww), but not in the other
brain regions.
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4. Discussion
AlthoughHD is a rare condition, it serves as a prototype ofmonogen-
ically determined, but multifactorially affected neurodegenerative dis-
orders (Kim and Fung, 2014). The study of the pathogenetic process in
animal models of HD could therefore provide a valuable tool for insight
into the general neurodegenerative process, yielding a possibility of
ﬁnding promising targets for drug development.
From this respect, genetic rodent models are optimal tools for the
study of HD in view of the possiblemolecular and genetic translatability
to humans (Ramaswamy et al., 2007). However, animal genetic models
also fail to demonstrate the pathological alterations characteristic of
human HD completely. Furthermore, the relatively long duration of dis-
ease developmentmay be a disadvantage in studies in which the thera-
peutic effects of potential neuroprotective agents are assessed.
Before genetic models were established, a number of toxin-based
models were utilized to study the neurodegenerative processes in HD,
which may still be a rapid and cost-effective way of screening the
therapeutic effects of potential drug candidates prior to the costly and
demanding application of genetic models. These inhibitors of the mito-
chondrial functions are widely used to model the mitochondrial dys-
function in HD (Browne, 2008).
SDH, the enzyme of complex II in the mitochondrial electron trans-
port chain (Alston et al., 1977), is reversibly and irreversibly inhibited
by malonate and 3-NP, respectively, toxins which have proved to fur-
nish applicable phenotypic models of HD (Beal and Brouillet, 1993;
Beal et al., 1993). 3-NP is currently the toxin most widely used to
study certain neuropathological aspects of the disease.
The consecutive or continual administration of 3-NP to rodents (i.p.
or subcutaneously, respectively) leads to bilateral dystonia, rigidity, gait
disturbances and uncoordinated movements. At lower cumulative
doses of 3-NP (b60 mg/kg), motor symptoms have been described to
be manifested in mild movement disturbances, such as slowness and a
subtle wobbling gait. However, some authors have also reported
early-stage hyperactivity at lower cumulative doses (b40 mg/kg)
(Borlongan et al., 1995a). When the cumulative dose is elevated up to
80 mg/kg, the general weakness becomes more marked and dystonia
develops, the latter being particularly pronounced in the hind-limbs at
this dose, and appearing soon after toxin administration (Brouillet,
2014). A further elevation of the cumulative dose (N100mg/kg) results
in more expressed weakness and rigidity (Brouillet, 2014). However,
subsequent to the termination of the subacute toxin regimen in mice
in the widely-applied experimental setup (as used in the current
study), the detected alterations in motor functioning tend to abate
and then cease (Fernagut et al., 2002a,b; Li et al., 2009). It should be
noted, however, that the extended application of 3-NP in a considerably
higher cumulative dose resulted in persistent locomotor deﬁcits in one
study on mice (Stefanova et al., 2003). Studies involving 3-NP intoxica-
tion in rats yielded rather inconclusive results in terms of a persistent
motor dysfunction (Teunissen et al., 2001; Tasset et al., 2012).
As regards a cognitive impairment, rats treated with a cumulative
dose of 190mg/kg demonstrated a severely decreasedmemory function
in a fear-associated memory test (a passive avoidance task) and a
perceptual-learning task (an attentional set-shifting task) (El Massioui
et al., 2001). However, in a simple 2-trial Y-maze paradigm, performed
on the 15th day after termination of the administration of 3-NP to mice
(in a cumulative dose of 320 mg/kg), the intoxicated animals did not
display any 3-NP-induced memory impairment (Li et al., 2009).
The above observations in mice were conﬁrmed by our ﬁndings, i.e.
most of the behavioral changes disappeared (i.e. the latency to fall,
tested by rotarod; and the ambulation distance, tested in an open-
ﬁeld) or could not be detected (the recognition index, tested with the
Y-maze test) 11 days after the last injection. The lack of difference in
cognitive performance was not inﬂuenced by any incidental difference
in locomotor acitivity, becausewe did not observe any signiﬁcant differ-
ence in the total ambulation distancewithin the Y-maze (not shown). It
is noteworthy, however, that we observed a signiﬁcant reduction in the
ambulation distance parameter in the last 5min of the open-ﬁeld test in
the toxin-treated animals as comparedwith the controls, whichmay re-
ﬂect a slight persistent behavioral dysfunction.
As concerns to the previously observed alterations in the TRPmetab-
olism in transgenic HD animals, the 3-OHK and KYNA levels were re-
ported to be elevated in the striatum and cortex of a heterozygous
transgenic mouse (FVB/N background, 89 CAG repeats, 12–15 months
of age) model of HD (Guidetti et al., 2000). Another study involving
the R6/2 mouse model of HD revealed increased kynurenine 3-
monooxygenase activity in the striatum, cortex and cerebellum of 6–
12-week-old animals, while the 3-hydroxyanthranilic acid oxygenase,
kynurenine aminotransferase (KAT)-I and KAT-II activities (catalyzing
the conversion of KYN to KYNA) in the cortex and cerebellum were
unchanged. An elevated synthesis of 3-OHK was found in the striatum
and a decreased kynureninase activity in the striatum and cortex of 4–
12-week-old animals, but not in the cerebellum. Other investigated
compounds (KYN, KYNA and QUIN) did not display any difference
(Sathyasaikumar et al., 2010). In the R6/2 model, enhanced 3-OHK
concentrations were observed in the striatum, cortex and cerebellum
of 4–12-week-old animals, but no difference was found in younger
mice (Guidetti et al., 2006). In the HdhQ92 and HdhQ111 models, 5–17-
month-old animals demonstrated increased levels of 3-OHK in the stri-
atum, cortex and cerebellum, and of QUIN in the striatum and cortex,
whereas there were no differences in younger animals (Guidetti et al.,
2006). In the YAC128 model, the 3-OHK concentrations were increased
in the striatum, cortex and cerebellum of 5–12-month-old mice, while
the QUIN levels were elevated only in the striatum and cortex of 8–
12-month-old animals (Guidetti et al., 2006). In the same YAC128
mouse model, the striatal expression of indoleamine 2,3-dioxygenase
(IDO)-1 (probably the most important enzyme participating in the
TRP catabolism in the brain), was found to be up-regulated, whereas
IDO-2 and tryptophan 2,3-dioxygenase did not undergo any signiﬁcant
change. As concerns metabolite concentrations, the levels of TRP and 3-
OHK proved to be decreased in the striatum of 3-month-old animals.
However, no difference in TRP level was found in 12-month-old mice,
while 3-OHK and KYN were signiﬁcantly elevated in the striatum. The
KYNA and QUIN concentrations did not change in either group
(Mazarei et al., 2013). Studies on the hippocampus did not indicate sig-
niﬁcant difference in any examined model or age group (Guidetti et al.,
2006).
In contrast with genetic models, there are no available published
data on the effects of 3-NP toxicity on the concentrations of TRP and
KPmetabolites under in vivo conditions in mice. One of the two studies
of the effects of the chronic treatment of rats with 3-NP demonstrated a
signiﬁcant decrease in the amount of KAT-I-immunoreactive cells, pre-
dominantly in the striatum (Csillik et al., 2002). The other study on
ex vivo rat cortical slices, showed that 3-NP dose-dependently inhibited
the production of KYNA and led to decreased KAT-I and KAT-II activities
in the cortical tissue homogenates (Luchowski et al., 2002). No murine
studies have been conducted previously to assess the effects of in vivo
applied 3-NP on the KP metabolism at the metabolite level per se, and
there have been no studies of KP alterations due to 3-NP intoxication
in the serum, which would allow conclusions as to the possible effects
Fig. 3. The effects of 3-NP treatment on different behavioral parameters in C57Bl/6 mice. Shortly after the last 3-NP injection, the latency to fall was signiﬁcantly decreased in the rotarod
test (A), but this difference had disappeared 9 days later. The Y-maze test, performed 9 days after the last 3-NP injection, did not reveal any difference between the groups (B). In the open-
ﬁeld paradigm 3 days after the last 3-NP injection, the ambulation distance was signiﬁcantly decreased in the total 15-min examination period (C) and in the last 5-min period (E). How-
ever, 11 days after the last 3-NP injection, the differencewas signiﬁcant only in the last 5 min. No difference in rearing timewas detected (D, F). The gray area indicates the 3-NP treatment
period.3-NP mice: n = 16, control mice: n = 14; data are means± S.E.M.; 3-NP 3-nitropropionic acid, LTF latency to fall, *p b 0.05, **p b 0.01, and ***p b 0.001.
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of systemic KP alterations within the CNS. We have now quantitatively
assessed the levels of 4 KP metabolites in the striatum, cortex, hippo-
campus, cerebellum and brainstem of mice, with a relatively high num-
ber of animals per group (n = 14–16).
Our ﬁndings indicated a decreased TRP level in association with an
increased KYN/TRP ratio in most of the examined brain regions of
C57Bl/6 mice treated with 3-NP, and also a reduced concentration of
3-OHK in the cerebellum. It is noteworthy that we did not detect any
signiﬁcant difference in serum samples, which suggests that the ob-
served alterations are speciﬁc for the examined brain regions and are
not affected by a systemic change and/or an altered permeability of
the blood–brain barrier. Our results on 5-month-old 3-NP-treated ani-
mals resemble those from studies of 3-month-old transgenic YAC128
animals (Mazarei et al., 2013), which is known to be one of the best an-
imal strains for the modeling of the alterations in human HD (Slow,
2003; Pouladi et al., 2013). The increase observed in the KYN/TRP ratio
is comparable with the previous ﬁnding of increased IDO-1 activity in
the brain (but not the serum) of YAC128 animals, an alteration
reﬂecting that observed in several neurodegenerative diseases and
their animal models (Vécsei et al., 2013), and suggested to contribute
to the neurodegenerative process. The similarity of the ﬁndings of the
KP alterations in this 3-NP model with those observed previously in
genetic models (and especially the YAC128 model) leads us to presume
that the KP alterations observed in transgenic animalsmight be second-
ary to amitochondrial dysfunction as present in the pathogenesis of HD,
and that 3-NP toxicitymay comprise a useful and cheap tool withwhich
to screen the efﬁcacy of potential drug candidates before the application
of more demanding genetic models.
The rationale of our study was to ﬁnd a valuable biomarker for ther-
apeutic studies in the widely applied subacute 3-NP model of HD with
previously demonstrated neurodegenerative characteristics, at a time
point when merely minor behavioral alterations persist. Accordingly,
we have conﬁrmed that the behavioral alterations evoked by 3-NP tox-
icity aremostly intermittent, similarly as observed previously by others,
which suggests that these alterations might be only functional and do
not reﬂect the long-term effects of delayed-type neurodegeneration.
On the other hand, at this delayed time point, we detected a marked
persistent increases in the KYN/TRP ratio in the striatum, hippocampus,
cerebellumandbrainstemand a slight reduction in the level of 3-OHK in
the cerebellum. Such alterations have not been reported earlier in 3-NP
studies and are similar to those seen in young genetic animal models
(especially in 3-month-old YAC128 transgenic mice). In the era of
advanced genetic models of HD, our ﬁndings demonstrate the contin-
ued relevance and applicability of toxin models, which may provide
Table 1
The concentrations of some metabolites of the KP in different brain regions and serum of control and 3-NP treated mice.
TRP KYN KYNA 3-OHK
Ctrl 3-NP Ctrl 3-NP Ctrl 3-NP Ctrl 3-NP
Serum (μM) 102.8
(89.8–115.4)
88.6
(83.2–94.5)
1.39
±0.09
1.12
±0.12
0.19
(0.17–0.21)
0.10
(0.09–0.18)
bLOD bLOD
Striatum (pmol/g ww) 27950
(23820–35700)
19530⁎⁎⁎
(17700–20440)
2922
±288
3001
±309
5.73
(bLOD–21.91)
bLOD bLOD bLOD
Cortex (pmol/g ww) 22860
(17260–28430)
14360⁎⁎
(13540–16300)
3110
±112
2679⁎
±110
5.07
(bLOD–7.72)
6.67
(3.04–7.08)
bLOD bLOD
Hippocampus (pmol/g ww) 26590
(18020–30730)
16550⁎⁎
(14790–17580)
2914
±176
2723
±208
bLOD
(bLOD–7.66)
bLOD
(bLOD–7.68)
bLOD bLOD
Cerebellum (pmol/g ww) 24810
(17630–28510)
14930⁎⁎⁎
(14210–16260)
3060
±238
2521
±182
bLOD
(bLOD–4.18)
bLOD
(bLOD–7.45)
66.84
(28.99–97.64)
bLOD⁎⁎
Brainstem (pmol/g ww) 20960
(15920–29890)
12740⁎⁎⁎
(12280–14100)
2389
±118
2169
±111
bLOD bLOD bLOD
(bLOD–25.50)
bLOD
The concentration of TRP and some of its metabolites weremeasured from ﬁve different brain regions and serum of C57Bl/6mice with HPLC. TRP levels were signiﬁcantly decreased in all
brain regions of 3-NP treated mice. In the cortex and cerebellum of toxin treated mice there was also a signiﬁcant depletion in KYN and 3-OHK concentration, respectively. KYN results
are expressed as mean ± S.E.M.; the other substances are shown as median (interquartile range). KP kynurenine pathway, TRP tryptophan, KYN kynurenine, KYNA kynurenic acid,
3-OHK 3-hydroxykynurenine, 3-NP 3-nitropropionic acid, ctrl control, LOD limit of detection, and wwwet weight.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
Fig. 4. The effects of 3-NP treatment on the KYN/TRP ratio in the serum and different brain regions of C57Bl/6 mice. The KYN/TRP ratio was signiﬁcantly elevated in the striatum,
hippocampus, cerebellum and brainstem of the 3-NP-treated mice. The increase in the cortex did not reach the level of statistical signiﬁcance. No alteration was observed in the serum.
Data are means ± S.E.M.; 3-NP 3-nitropropionic acid, KYN kynurenine, TRP tryptophan, *p b 0.05, and **p b 0.01.
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cost-effective and rapid ways of screening potential drug candidates to
treat this currently intractable disease.
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a b s t r a c t
The peroxisome proliferator-activated receptor-c (PPARc) coactivator 1a (PGC-1a) is a key regulator of
mitochondrial biogenesis, respiration and adaptive thermogenesis. Besides the full-length protein (FL-
PGC-1a), several other functionally active PGC-1a isoforms were identified as a result of alternative splic-
ing (e.g., N-truncated PGC-1a; NT-PGC-1a) or alternative promoter usage (e.g., central nervous system-
specific PGC-1a isoforms; CNS-PGC-1a). Achieving neuroprotection via CNS-targeted pharmacological
stimulation is limited due to poor penetration of the blood brain barrier (BBB) by the proposed pharma-
ceutical agents, so preconditioning emerged as another option. The current study aimed to examine of
how the expression levels of FL-, NT-, CNS- and reference PGC-1a isoforms change in different brain
regions following various 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment regimens,
including chronic low-dose treatment for preconditioning. Ninety minutes following the acute treatment
regimen, the expression levels of FL-, NT- and CNS-PGC-1a isoforms increased significantly in the stria-
tum, cortex and cerebellum. However, this elevation diminished 7 days following the last MPTP injection
in the acute treatment regimen. The chronic low-dose administration of MPTP, which did not cause sig-
nificant toxic effects in light of the relatively unaltered dopamine levels, did not result in any significant
change of PGC-1a expression. The elevation of PGC-1a levels following acute treatment may demonstrate
a short-term compensatory mechanism against mitochondrial damage induced by the complex I inhibi-
tor MPTP. However, drug-induced preconditioning by chronic low-dose MPTP seems not to induce pro-
tective responses via the PGC-1a system.
 2017 Elsevier B.V. All rights reserved.
1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative dis-
order characterized by the loss of dopaminergic neurons, and the
presence of Lewy bodies in the substantia nigra (SN) pars compacta
(Forno, 1996). Although the precise pathomechanism of PD is not
fully understood, several molecular mechanisms of neuronal death
were described in the pathogenesis, including mitochondrial dys-
function, energy deficit and oxidative stress (Bose and Beal,
2016). It is postulated that life-long cumulative low-dose exposure
to mitochondrial toxins may contribute to the pathogenesis of cer-
tain neurodegenerative disorders (Harris and Blain, 2004). The
delineation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) induced Parkinsonian symptoms yielded one of the first
pieces of evidence that mitochondrial dysfunction is involved in
PD pathogenesis (Forno et al., 1993). Accordingly, systemic MPTP
administration has been widely used to study disease mechanisms
in various in vivo animal studies (Javitch et al., 1985).
Besides environmental factors, several causative or susceptibil-
ity genes have been identified in PD, many of them having direct
implications in mitochondrial dysfunction (Kalinderi et al., 2016).
Peroxisome proliferator-activated receptor-gamma (PPARc)
coactivator-1 alpha (PGC-1a) is one of them, which may play a role
in PD pathogenesis. PGC-1a is a multifunctional transcriptional
coactivator of nuclear respiratory factors 1 and 2 (NRF-1, -2),
estrogen-related receptors (ERRs) and PPARs amongst others, and
hereby regulates mitochondrial function and biogenesis (Knutti
and Kralli, 2001).
Analysis of human brain samples indicated that PD is associated
with the increased methylation of PGC-1a promoter and the
reduced expression of PGC-1a itself (Su et al., 2015) and its
downstream-regulated genes in the SN of PD patients (Zheng
et al., 2010). Furthermore, possible associations of PGC-1a poly-
http://dx.doi.org/10.1016/j.brainres.2017.01.032
0006-8993/ 2017 Elsevier B.V. All rights reserved.
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morphisms with PD risk, age of onset and longevity were described
as well (Clark et al., 2011). Reduced expression of PGC-1a leads to
enhanced a-synuclein oligomerization, too (Ebrahim et al., 2010),
and accordingly, overexpression of PGC-1a produced neuroprotec-
tion against a-synuclein- and rotenone-induced neurotoxicity
(Zheng et al., 2010).
Several PGC-1a isoforms were identified as a result of alterna-
tive splicing and alternative promoter usage (Martinez-Redondo
et al., 2015). The proximal promoter of PGC-1a has been reported
as an important key regulator in several neurodegenerative dis-
eases, including PD (Su et al., 2015). With regard to alternative
splicing, besides the full-length protein (FL-PGC-1a), the
N-truncated PGC-1a (NT-PGC-1a) isoform was discovered, which
is a shorter, but active isoform of PGC-1a (Zhang et al., 2009).
Recent studies identified further different tissue-specific isoforms
of PGC-1a, including central nervous system-specific isoforms
(CNS-PGC-1a (Ruas et al., 2012; Soyal et al., 2012)). The novel
CNS-specific isoforms originated from a new promoter located
587 kb upstream of exon 2 (Choi et al., 2013; Soyal et al., 2012).
A recent study demonstrated that both PGC-1a reference gene
and CNS-PGC-1a are downregulated in human PD brain and in
experimental models with a-synuclein oligomerization, and that
the pharmacological activation or genetic overexpression of
PGC-1a reference gene reduced a-synuclein oligomerization and
toxicity (Eschbach et al., 2015). In contrast, the loss of PGC-1a
enhances the vulnerability of SN pars compacta dopaminergic neu-
rons to a-synuclein toxicity (Ciron et al., 2015). These data suggest
that PGC-1a downregulation and a-synuclein oligomerization
form a vicious circle (Eschbach et al., 2015). Similarly to PD, certain
mutations in amyotrophic lateral sclerosis inhibit the expression of
CNS-specific isoforms, indicating this as a common finding in neu-
rodegeneration (Bayer et al., 2017).
St-Pierre et al. described that PGC-1a-deficient mice are more
sensitive to MPTP toxicity compared to the controls (St-Pierre
et al., 2006). Interestingly, the sub-chronic administration of MPTP
to mice resulted in the significant elevation of PGC-1a expression
in the striatum after 24 h that was normalized following 72 h
(Swanson et al., 2013). This may represent an adaptive mechanism
to neurotoxicity. Accordingly, the protective effect of PGC-1a was
demonstrated previously as well; pioglitazone- and resveratrol-
induced activation of PGC-1a was protective against MPTP toxicity
(Breidert et al., 2002; Dehmer et al., 2004). However, there is a
seeming controversy with regard to the effect of genetically-
induced overexpression of PGC-1a on MPTP neurotoxicity. On
the one hand, the transgenic overexpression of PGC-1awas proven
to be protective against MPTP (Mudo et al., 2012), on the other
hand, the adenovirus vector-mediated overexpression of PGC-1a
resulted in dopamine depletion in the SN (Ciron et al., 2012) and
consequently enhanced susceptibility to MPTP (Clark et al.,
2012). Clarification of this issue needs further studies.
Evidence suggests a beneficial role of PGC-1a stimulation in
neurodegenerative disorders. However, CNS-targeted pharmaco-
logical stimulation is limited due to the poor penetration of the
blood brain barrier (BBB) by the above-mentioned compounds, so
preconditioning emerged as another option to achieve neuropro-
tection. It was previously demonstrated that the acute administra-
tion of the selective complex II inhibitor 3-nitropropionic acid (3-
NP) increased the expression of both FL- and NT-PGC-1a isoforms
in the striatum of C57Bl/6 mice (Torok et al., 2015). As the available
data are limited with regard to the alteration of tissue-specific
PGC-1a expression in the brain following MPTP administration,
this study aimed to examine the expression levels of several
PGC-1a isoforms in different brain regions following various MPTP
treatment regimens. The hypothesis that low doses of MPTP may
produce compensatory, protective alterations in the PGC-1a sys-
tem was tested as well.
2. Results
2.1. Gene expression analysis
Ninety minutes following the last MPTP injection of the acute
treatment of MPTP, the FL-PGC-1a and NT-PGC-1a expression
significantly increased in the striatum (FL-PGC-1a: ctrl: 0.97
(0.92–1.04), MPTP: 1.47 (1.21–1.83), p = 0.0048; NT-PGC-1a: ctrl:
0.44 (0.40–0.49), MPTP: 0.70 (0.56–0.78), p = 0.019), cortex
(FL-PGC-1a: ctrl: 0.96 (0.91–1.06), MPTP: 1.23 (1.15–1.43),
p = 0.009; NT-PGC-1a: ctrl: 0.46 (0.43–0.48), MPTP: 0.69
(0.59–0.71), p = 0.0012) and cerebellum (FL-PGC-1a: ctrl: 1.50
(1.27–1.90), MPTP: 2.40 (2.07–2.76), p = 0.013; NT-PGC-1a: ctrl:
0.67 (0.48–0.86), MPTP: 1.21 (1.14–1.44), p = 0.009) (Fig. 1A, B).
Furthermore, MPTP-induced increases in CNS-PGC-1a expression
were also significantly larger in all investigated brain regions com-
pared to the controls (striatum: ctrl: 1.03 (0.88–1.11), MPTP: 1.38
(1.34–1.78), p = 0.0069; cortex: ctrl: 0.91 (0.80–0.98), MPTP: 1.41
(1.24–1.42), p = 0.0048; cerebellum: ctrl: 1.51 (1.20–1.98), MPTP:
2.77 (2.34–3.17), p = 0.019) (Fig. 1C).However, therewasnot anydif-
ference between the Ref-PGC-1a levels in the striatum (ctrl: 0.11
(0.10–0.12), MPTP: 0.11 (0.95–0.12)), cortex (ctrl: 0.11 (0.11–0.12),
MPTP: 0.09 (0.08–0.10)) and cerebellum (ctrl: 0.21 (0.20–0.29),
MPTP: 0.28 (0.24–0.29)) of MPTP-treated and control mice (Fig. 1D).
One week following the last injection in the acute treatment
regimen, there was not any significant change either in the FL-,
NT-, CNS-, or in the Ref-PGC-1a levels between the control and
the MPTP-treated animals in any brain area (Fig. 2A–D).
Furthermore, the low-dose 12-day MPTP-treatment did not
influence the expression levels of FL-PGC-1a, NT-PGC-1a,
CNS-PGC-1a and Ref-PGC-1a in any brain region (Fig. 3A–D).
2.2. HPLC measurement
Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) values in the respective control groups
of the 3 treatment regimens were compared to each other, and
there were no significant differences. Therefore the values in these
control groups were pooled for further comparisons with the
MPTP-treated groups. MPTP administration caused significant
reductions in striatal DA (ctrl: 8.08 ± 0.50, MPTP: 4.36 ± 0.92,
p = 0.0005), DOPAC (ctrl: 2.57 ± 0.21, MPTP: 0.44 ± 0.08,
p = 3.78 * 108) and HVA (ctrl: 2.18 ± 0.12, MPTP 0.67 ± 0.11,
p = 5.12 * 1010) levels compared to control values 90 min follow-
ing its last administration in the acute treatment regimen (acute-
1 day; Fig. 4). Moreover, a significant reduction in metabolite levels
was also observed one week after the last injection in the acute
treatment regimen (acute-7 days; Fig. 4) in the DA (ctrl:
8.08 ± 0.50, MPTP: 1.34 ± 0.43, p = 4.86 * 108), DOPAC (ctrl:
2.57 ± 0.21, MPTP: 0.76 ± 0.15, p = 7 * 106) and HVA (ctrl:
2.18 ± 0.12, MPTP: 0.81 ± 0.13, p = 5.08 * 108) values in the stria-
tum of the MPTP-treated mice compared to the control animals.
However, chronic MPTP treatment resulted in significant reduc-
tions of only striatal HVA (ctrl: 2.18 ± 0.12, MPTP 1.40 ± 0.08,
p = 0.0005) levels, striatal DA (ctrl: 8.08 ± 0.50, MPTP:
6.83 ± 0.48) and DOPAC (ctrl: 2.57 ± 0.21; MPTP 1.99 ± 0.23) levels
were not decreased significantly (Fig. 4). Seven days following the
acute treatment regimen DA levels significantly decreased com-
pared to those data from samples obtained 90 min following the
last MPTP injection in the acute treatment regimen (p = 0.039).
3. Discussion
PGC-1a is essential in normal mitochondrial function and its
deficiency may contribute to neurodegeneration, while its stimula-
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tion was demonstrated to be neuroprotective in certain models
(Breidert et al., 2002; Dehmer et al., 2004; Eschbach et al., 2015;
Mudo et al., 2012). Accordingly, the pharmacological induction of
PGC-1a expression may be considered as a neuroprotective
approach, but currently this possibility seems to be limited in light
of the reduced BBB penetration of the potential pharmaceutical
agents.
The aim of the current study was a thorough assessment of
the expression of PGC-1a isoforms in various brain regions
following different MPTP administration regimens, including a
**
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Fig. 1. The relative mRNA expression of PGC-1a isoforms in the striatum, cortex and the cerebellum of mice 90 min after acute MPTP intoxication. The FL-PGC-1a, NT-PGC-1a
and CNS-PGC-1a levels were significantly increased in the striatum, cortex and the cerebellum of MPTP-treated mice. (A, B, C respectively). The Ref-PGC-1a expression did
not change in any brain areas of MPTP-treated mice compared to the controls (D). Values are plotted as medians and interquartile range; *p < 0.05, **p < 0.01; MPTP MPTP-
treated; str striatum, ctx cortex, crb cerebellum.
Fig. 2. The relative mRNA expression of PGC-1a isoforms in the striatum, cortex and the cerebellum of mice 7 days after acute MPTP intoxication. The expression levels of the
PGC-1a isoforms did not change in any brain areas of MPTP-treated mice (A–D). Values are plotted as medians and interquartile range; MPTP MPTP-treated; str striatum, ctx
cortex, crb cerebellum.
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low-dose chronic one, possibly mimicking drug-induced
preconditioning.
Ninety minutes following the last MPTP injection of the high-
dose acute treatment regimen of MPTP (75 mg/kg/day total dose)
the expression level of FL-, NT- and CNS- PGC-1a isoforms
increased significantly in the striatum, cortex and cerebellum.
However, this elevation was diminished 7 days following the last
MPTP injection in the acute treatment regimen. Torok et al.
(Torok et al., 2015) demonstrated that the acute (90 min following
a single dose injection of 100 mg/kg dose), but not the subacute
(50 mg/kg twice daily for 5 days) 3-NP treatment regimen induced
the overexpression of FL- and NT- PGC-1a isoforms mainly in the
striatum (3-NP is a rather selective striatal neurotoxin (Brouillet
et al., 2005)) similar to the results of the current study. Those find-
ings were explained by a proposed reduced neuronal adaptive
capability of the striatum following the neurotoxic insult. The
above-mentioned results of the current study may also be
explained by the propagation of the neurotoxic process following
7 days of the acute treatment regimen given the extent of decrease
in striatal DA levels. The elevation of PGC-1a expression, especially
that of the CNS-specific isoform, may indicate a short-term com-
pensatory protective mechanism against mitochondrial dysfunc-
tion induced by the complex I inhibitor MPTP. It is hard to
interpret the increased expression of PGC-1a in the cerebellum,
which is not primarily affected in MPTP toxicity. However, several
lines of evidence indicate that MPTP neurotoxicity is not highly
selective to dopaminergic neurons; in specific circumstances sys-
temic MPTP administration resulted in Purkinje cell loss (Takada
et al., 1993). The involvement of the cerebellum in disease mecha-
nisms of different neurodegenerative disorders such as amy-
otrophic lateral sclerosis, Huntington’s disease (HD) and PD is
frequently seen (Rees et al., 2014; Tan et al., 2016; Wu and
Hallett, 2013). Furthermore, increasing evidence suggest that
PGC-1a expression is associated with degenerative changes in
the CNS, including cerebellum (Torok et al., 2015). It was hypothe-
sized that the elevation of PGC-1a in the cerebellum is a compen-
satory mechanism against the energy deficit which may be an
important factor underlying the relative resistance of cerebellar
neurons against neurodegenerative processes in HD and in PD.
The drug-induced preconditioning by applying low-dose neuro-
toxic agents may stimulate neuroprotective mechanisms, resulting
in the amelioration of neurodegenerative process. This approach
has already been demonstrated to be beneficial in case of 3-NP:
the low-dose of toxin treatment increased tolerance to ischemia
and hypoxia in rats and gerbils (Horiguchi et al., 2003; Riepe
et al., 1997; Wiegand et al., 1999). Although the exact mechanism
is not fully understood, the overexpression of free radical scaveng-
ing enzymes may be involved: acute 3-NP treatment activated
superoxide dismutase (SOD) and catalase (CAT) in several brain
areas (Binienda et al., 1998). Similarly, an increase in SOD activity
in the glial cells of the striatum and SN was observed following
MPTP treatment (Kurosaki et al., 2004). The preconditioning by
MPTP is not intended to suggest a future direct therapeutic
approach, but rather aimed at finding key players which may help
to alleviate the pathological alterations. The situation may be sim-
ilar to ischemic preconditioning where the outcome in myocardial
infarction may depend substantially on which medications were
applied with an influence on preconditioning (Tomai et al.,
1999). This may be especially important in light of the fact that
environmental toxins could play a role in the pathogenies of idio-
pathic PD. The chronic low-dose administration of MPTP in the cur-
rent study neither resulted in significant DA depletion (i.e.
neurotoxic effect at biochemical level), nor in any significant
change in PGC-1a expression. These data suggest that drug-
induced preconditioning by MPTP may not evoke apparent
responses in the PGC-1a system.
In conclusion the current study demonstrated that acute severe
mitochondrial dysfunction initiated protection via elevating the
expression of brain specific isoforms of the mitochondrial master
regulator PGC-1a. However, low-dose chronic administration of
Fig. 3. The relative mRNA expression of PGC-1a isoforms in the striatum, cortex and the cerebellum of mice following a 12-day treatment with low-dose MPTP. The
expression levels of the PGC-1a isoforms did not change in any brain areas of MPTP-treated mice (A–D). Values are plotted as medians and interquartile range; MPTP MPTP-
treated; str striatum, ctx cortex, crb cerebellum.
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mitochondrial toxin MPTP did not induce those protective mecha-
nisms with the involvement of PGC-1a.
4. Experimental procedures
4.1. Animals
12-Week-old C57Bl/6J male mice were used in this study. The
animal strain was originally obtained from Jackson Labs (Jackson
Laboratories, Bar Harbor, ME, USA).
The animals were housed in cages and maintained under stan-
dard laboratory conditions with 12–12 h light–dark cycle and free
access to food and water. The experiments were carried out in
accordance with the European Communities Council Directive
(86/609/EEC) and were approved by the local animal care
committee.
4.2. Treatment and sample handling
MPTP was dissolved in phosphate-buffered saline (PBS; pH
adjusted to 7.4) and was administered intraperitoneally (i.p.). Ani-
mals were randomly divided into six groups (n = 7–8 in each
group). The first and second group received i.p. injection of
15 mg/kg body weight MPTP 5 times at 2 h intervals. The animals
in the first group were deeply anesthetized with isoflurane (For-
ane; Abott Laboratories Hungary Ltd., Budapest, Hungary) and
the brains were dissected ninety minutes following the last MPTP
injection (acute treatment – acute (day 1) assessment), while ani-
mals in the second group were deeply anesthetized with isoflurane
and the brains were dissected one week later (acute treatment –
subacute (day 7) assessment). The mice in the third group were
injected i.p. with 15 mg/kg body weight MPTP once a day for
12 days (low-dose chronic treatment). Ninety minutes following
the last injection the animals were euthanized via isoflurane over-
dose as well. The fourth, fifth and sixth groups served as the
respective control groups, and were injected with 0.1 M PBS
according to the above-detailed treatment regimen. During the dis-
section process the brains were rapidly removed on ice and imme-
diately halved at the midline. Following that, both hemispheres
were further cut to obtain the striatum, cortex and cerebellum.
Thereafter, these samples were stored at 80C until the RT-PCR
and HPLC analysis.
4.3. RT-PCR analysis
The left striatum, cortex and cerebellumwere homogenized and
Trizol reagent was used to extract RNA according to the manufac-
turer’s protocol. The RNA was quantified spectrophotometrically,
and the integrity of RNA was confirmed by gel electrophoresis
using 1% agarose gel. 1 lg of total RNA was reverse-transcribed
applying random hexamer primers and reverse transcriptase
according to the RevertAid First Strand cDNA Synthesis Kit protocol
(Thermo Fisher Scientific Inc., Marietta, OH, USA). cDNAs were kept
at 20C until further use.
Real-time PCR reactions were carried out in a 20 ll final
volume.
The following, previously published primers were used: for FL-
PGC-1a, 50-TGCCATTGTTAAGACCGAG-30 (forward) and 50-TTGGG
GTCATTTGGTGAC-30 (reverse); for NT-PGC-1a, 50-GGTCACTGGAA
GATATGGC-30 (reverse); for CNS-PGC-1a and Ref-PGC-1a, 50-AAT
TGGAGCCCCATGGATGAAGG-30 and 50-TGAGTCTGTATGGAGTGA
CATCGAGTG-30 (both forward), and 50-TCAAATGAGGG
CAATCCGTC-30 (reverse), respectively (Chang et al., 2012; Soyal
et al., 2012). qRT-PCR reaction conditions were 95C for 2 min, fol-
lowed by 40 cycles of 95C for 10 s, and 60C for 30 s. Target gene
expression was normalized to the endogenous control gene 18S
rRNA (Applied Biosystems, Carlsbad, CA, USA). The relative expres-
sion was determined using the 2DDCt method (Livak and
Schmittgen, 2001).
4.4. Dopamine measurement
DA and its metabolites, DOPAC and HVA were measured by
reversed-phase chromatography from the right striatum of the
MPTP-treated and the control animals, using an Agilent 1100
high-performance liquid chromatography (HPLC) system (Agilent
Technologies, Santa Clara, CA, USA) combined with a Model 105
electrochemical detector (Precision Instruments, Marseille, France)
under isocratic conditions. The striata were weighed and then
homogenized in an ice-cold solution (750 ml) containing perchloric
acid (70% wt/wt), sodium metabisulfite (0.1 M), disodium
ethylenediaminetetraacetate (0.1 M), distilled water and 0.25 mM
isoproterenol for 30 s. The homogenate was centrifuged at
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Fig. 4. Striatal dopamine, DOPAC and HVA concentrations of MPTP-treated mice in
3 different treatment regimens. Ninety minutes (acute-1d) and 7 days (acute-7d)
after acute MPTP intoxication, DA, DOPAC and HVA levels significantly decreased in
the striatum compared to the controls. The chronic (12 day) low-dose MPTP
treatment did not influence the striatal level of DA and DOPAC, only HVA levels
were significantly decreased. Values are plotted as means ± S.E.M; ***p < 0.001; DA
dopamine, DOPAC 3,4-dihydroxyphenylacetic acid, HVA homovanillic acid.
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12,000g for 10 min at 4C. The supernatant was stored at 20C
until the analysis. The supernatants were measured with an Agi-
lent 1100 high-performance liquid chromatography (HPLC) system
(Agilent Technologies, Santa Clara, CA, USA) combined with a
Model 105 electrochemical detector (Precision Instruments, Mar-
seille, France) under isocratic conditions. In brief, the working
potential of the detector was set at +750 mV, using a glassy carbon
electrode and a Ag/AgCl reference electrode. The mobile phase con-
taining sodium dihydrogenphosphate (75 mM), sodium octylsul-
fate (2.8 mM) and disodium ethylenediaminetetraacetate (50 lM)
was supplemented with acetonitrile (10% v/v) and the pH was
adjusted to 3 with phosphoric acid (85% w/w). The mobile phase
was delivered at a rate of 1 ml/min at 40C onto the reversed-
phase column (HR-80 C18, 80  4.6 mm, 3 mm particle size; ESA
Biosciences, Chelmsford, MA, USA) after passage through a pre-
column (SecurityGuard, 4  3.0 mm I.D., 5 mm particle size, Phe-
nomenex Inc., Torrance, CA, USA)). 10 ml aliquots were injected
by the autosampler with the cooling module set at 4C. With
regard to method validation, the following parameters are reported
briefly. The LOD and LLOQ for the investigated compounds in the
brain samples were 2 ng/ml and 10 ng/ml, respectively. With
regard to precision, the relative standard deviation was 6 3.25%
for the peak area responses and 6 0.05% for the retention times.
The recoveries ranged from 109 to 110%, 108 to 109% and 99 to
102% for DA, DOPAC and HVA, respectively.
4.5. Statistics
All statistical analyses were performed with the use of the R
software (R Development Core Team). The distribution of data pop-
ulations was checked with the Shapiro–Wilk test, and Levene test
was also performed for the analysis of the homogeneity of vari-
ances. In case of gene expression analysis, due to the necessity of
a large number of comparisons of data, two-sample t-tests via
Monte-Carlo permutation (with 10,000 random permutations)
were applied for RT-PCR results. In case of HPLC analysis, all the
data exhibited normal distribution and equal variances were
assumed, and therefore ANOVA was used with Bonferroni post
hoc comparison. The null hypothesis was rejected when the cor-
rected p values were < 0.05, and in such cases the differences were
considered significant. FL- and NT-PGC-1a levels of gene expres-
sion of all brain areas were calculated relative to the levels of FL-
PGC-1a gene expression in the striatum, whereas the CNS- and
Ref-PGC-1a expression levels of all brain areas were calculated rel-
ative to the level of CNS-PGC-1a expression in the striatum. Data
with Gaussian or non-Gaussian distributions were plotted as
means (± S.E.M.) or medians (and interquartile range), respectively.
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Abstract
Evidence suggests that decreased α‐tocopherol (the most biologically active substance in the vita-
min E group) level can cause neurological symptoms, most likely ataxia. The aim of the current
study was to first provide reference intervals for serum tocopherols in the adult Hungarian pop-
ulation with appropriate sample size, recruiting healthy control subjects and neurological patients
suffering from conditions without symptoms of ataxia, myopathy or cognitive deficiency. A vali-
dated HPLC method applying a diode array detector and rac‐tocol as internal standard was uti-
lized for that purpose. Furthermore, serum cholesterol levels were determined as well for data
normalization. The calculated 2.5–97.5% reference intervals for α‐, β/γ‐ and δ‐tocopherols were
24.62–54.67, 0.81–3.69 and 0.29–1.07 μM, respectively, whereas the tocopherol/cholesterol
ratios were 5.11–11.27, 0.14–0.72 and 0.06–0.22 μmol/mmol, respectively. The establishment
of these reference intervals may improve the diagnostic accuracy of tocopherol measurements
in certain neurological conditions with decreased tocopherol levels. Moreover, the current study
draws special attention to the possible pitfalls in the complex process of the determination of ref-
erence intervals as well, including the selection of study population, the application of internal
standard and method validation and the calculation of tocopherol/cholesterol ratios.
KEYWORDS
cholesterol, HPLC, human samples, reference interval, tocopherol
1 | INTRODUCTION
Most of the deleterious effects of pathological processes in the
human organism are mediated by the formation of reactive species
(RS; Szalárdy, Zádori, Klivényi, Toldi, & Vécsei, 2015). The synthesis
and toxic effects of RS are ameliorated by a complex system of anti-
oxidant machinery, including enzymatic (e.g. superoxide dismutase,
catalase and glutathione peroxidase; Sies, 1997) and nonenzymatic
mechanisms (Figure 1).
The latter group consists of numerous chemical compounds, such
as vitamin E, vitamin C, coenzyme Q10, β‐carotene, glutathione and
flavonoids with proved antioxidant properties (Sies, 1993). In addition
to the capability of these agents to react with RS, their sufficient tissue
concentrations and their suitability for regeneration are desirable prop-
erties as well for efficient antioxidant protection (Rose & Bode, 1993).
The vitamin E group includes four tocotrienols and four tocopherols as
lipid soluble antioxidants. Their molecular structure comprises a
chromanol ringwith an aliphatic side chain, unsaturated for tocotrienols
and saturated for tocopherols. Depending on the number and position
of methyl groups on the chromanol ring, α‐, β‐, γ‐ and δ‐tocotrienols
and tocopherols can be distinguished (Hacquebard & Carpentier,
2005). The bioavailability of tocotrienols is inefficient and physiological
serum concentrations are low (O'Byrne et al., 2000), suggesting that
under normal circumstances their role as antioxidants is negligible.
However, increasing α‐tocotrienol concentration by its external supple-
mentation can ameliorate the symptoms caused by α‐tocopherol defi-
ciency (Sen, Khanna, & Roy, 2007). α‐Tocopherol has the highest
concentration and biological activity from the vitamin E group, while
the other tocopherols have a less expressed role in antioxidant protec-
tion (Hacquebard & Carpentier, 2005). Tocopherols are taken up by the
enterocytes from the intestines and they are incorporated into the
secreted chylomicrons and transported to the liver (Cooper, 1997). In
the liver, the cytosolic α‐tocopherol transport protein (α‐TTP)
Abbreviations used: α‐TTP, α‐tocopherol transport protein; ACN, acetonitrile;
BHT, butylated hydroxy toluene; OND, other neurological disease; RI,
reference interval; RS, reactive species; THF, tetrahydofurane
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recognizes and binds α‐tocopherol with good selectivity, and themajor-
ity of the other forms of tocopherols are rapidly excreted in the bile. α‐
TTP is responsible for the secretion of α‐tocopherol into plasma and
very‐low‐density lipoprotein particles (Arita, Nomura, Arai, & Inoue,
1997). Very‐low‐density lipoprotein is catabolized on the periphery
by lipoprotein lipase, localized at the endothelium, and the formed
high‐density lipoprotein and low‐density lipoprotein particles become
responsible for the distribution of α‐tocopherol to extrahepatic tissues
(Mardones &Rigotti, 2004).With regard to the other forms of vitamin E,
there is no discrimination between them and α‐tocopherol during
absorption from the intestines; however, in the liver there is a preferen-
tial secretion of α‐tocopherol into the blood, as well as a preferential
metabolism of the other forms (Traber, 2013). Accordingly, cholesterol
levels and metabolism may considerably influence the bioavailability
of tocopherols (Schmölz, Birringer, Lorkowski, & Wallert, 2016).
The major causes of severe tocopherol deficiency are malabsorp-
tion disorders with decreased intestinal lipid uptake (e.g. cholestasis,
cystic fibrosis, short bowel syndrome), abetalipoproteinemia and ataxia
with vitamin E deficiency where the underlying pathological alteration
is the decreased activity of α‐TTP caused by mutations in the TTPA
gene (Morley et al., 2004).
Decreased vitamin‐E levels are associated with several neurolog-
ical symptoms, such as cerebellar ataxia, peripheral neuropathy and
myopathy (Muller, 2010; Ueda et al., 2009), as the nervous system
is particularly sensitive to oxidative damage resulting from reduced
antioxidant capacity (Zádori, Klivényi, Plangár, Toldi, & Vécsei,
2011; Zádori et al., 2012). Accordingly, in addition to the above‐
mentioned disorders with their characteristic symptoms, some other
neuropsychiatric conditions, such as Alzheimer's disease (Lopes da
Silva et al., 2014) and the exacerbation of multiple sclerosis (Karg
et al., 1999) can also be accompanied by significantly reduced serum
or plasma tocopherol levels. Therefore, the measurement of serum
tocopherol levels is advised to be part of the differential diagnostic
process in certain neuropsychiatric conditions. The establishment of
unbiased reference values for the targeted population is essential
for that purpose.
The aim of the current study was to develop an unbiased
method for tocopherol (α‐, β/γ‐ and δ‐tocopherol) measurements
in human serum samples and to hereby establish reference intervals
(RI) via the participation of 120 individuals for the adult Hungarian
population based on the pooling of the values of control subjects
without any chronic disease and neurological patients suffering
from conditions without symptoms of ataxia, myopathy or cognitive
deficiency (the so‐called control group of other neurological
diseases; OND).
2 | MATERIALS AND METHODS
2.1 | Materials
The investigated reference compounds {α‐, γ‐, δ‐tocopherol; (2R)‐
2,5,7,8‐tetramethyl‐2‐[(4R,8R)‐(4,8,12‐trimethyltridecyl)]‐6‐chromanol,
(2R)‐2,7,8‐trimethyl‐2‐[(4R,8R)‐4,8,12‐trimethyltridecyl]‐6‐chromanol,
(2R)‐2,8‐dimethyl‐2‐[(4R,8R)‐4,8,12‐trimethyltridecyl]‐6‐chroma-
nol, respectively}, ammonium acetate, ascorbic acid {(5R)‐[(1S)‐1,2‐
dihydroxyethyl]‐3,4‐dihydroxyfuran‐2(5H)‐one}, butylated hydroxy
toluene (BHT), dioxane and methanol were purchased from Sigma‐
Aldrich (Saint Louis, MO, USA), rac‐tocol [2‐methyl‐2‐(4,8,12‐
trimethyltridecyl)‐6‐chromanol, as internal standard] was purchased
from Matreya LLC. (Pleasant Gap, PA, USA), and acetonitrile (ACN),
absolute ethanol, n‐hexane and tetrahydofurane (THF) were purchased
from VWR International (Radnar, PA, USA).
2.2 | Enrollment criteria and sample preparation
The study sample population comprised 30 male (age range 21–
71 years, mean age 49.50 year) and 30 female volunteer individuals
(age range 25–76 years, mean age 50.03 year) without any major
chronic illness and 30 male (age range 18–73 years, mean age
49.43 year) and 30 female (age range 24–78 years, mean age
49.60 year) patients with OND (main diagnoses for males were the fol-
lowing: ischemic stroke, 8; Parkinson's disease, 5; epilepsy, 5; lumbar
disk disorder, 3; and other, 9; main diagnoses for females were the fol-
lowing: multiple sclerosis in remission, 8; ischemic stroke, 6; epilepsy,
5; and other, 11) where the presence of ataxia, myopathy or cognitive
dysfunction were excluding criteria. The distribution of the age of the
subjects was Gaussian in all groups (p > 0.05, Anderson–Darling test)
and the variances were equal (p = 0.98, Levene test). There was no sig-
nificant difference between the groups (F = 0.01, p = 0.99, one‐way
ANOVA). The recent regular intake of antihyperlipidemic agents or
any kind of drugs or food supplements containing antioxidants were
exclusion criteria as well in all groups. All participating individuals were
of Hungarian origin and were enrolled in the Department of Neurology
at the University of Szeged. The study was approved by the Ethics
Committee of the Faculty of Medicine, University of Szeged (19/
2014). All study participants gave their written informed consent, in
accordance with the Declaration of Helsinki.
Blood was collected by venipuncture into gold‐top vacutainers fol-
lowing fasting for 12 h. The blood was immediately centrifuged at
3500 rpm for 10min. A 200 μL aliquot of the supernatant serum was
shot into a solution containing 200 μL ascorbic acid (0.085M) and
FIGURE 1 The schematic depiction of
nonenzymatic mechanisms in antioxidant
protection. NADPH, reduced nicotinamide
adenine dinucleotide phosphate; RS, reactive
species
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400 μL BHT (1.14mM) and the resulting solution was stored at −80°C
until measurement, while the remaining serum was aliquoted and
stored at −80°C as well.
Before high‐performance liquid chromatography (HPLC) measure-
ment, 600 μL n‐hexane containing 1.14mM BHT and rac‐tocol as inter-
nal standard was added to the freshly thawed serum samples treated
with antioxidants (800 μL). This mixture was mixed for 1min, then cen-
trifuged at 3500 rpm for 5min at 4°C. The hexane layer was trans-
ferred to a test vial and evaporated under nitrogene flow. The
residue was reconstituted with 75 μL ACN and 50 μL EtOH–dioxane
(1:1). The resulting solution was transferred into a 200 μL glass insert
placed into an amber‐colored vial for measurement.
2.3 | Serum cholesterol and triglyceride
measurement
Total cholesterol and triglyceride levels were determined by commer-
cially available kits from Diasys (Diagnostics Systems GmbH, Holzheim,
Germany) on Roche Modular P800 analyser (Roche, Rotkreuz,
Switzerland).
2.4 | Chromatographic conditions
The concentrations of α‐, β/γ‐, δ‐tocopherol were quantified with an
Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA,
USA) equipped with an UV/VIS diode array detector applying the mod-
ified method of Hess, Keller, Oberlin, Bonfanti, and Schuep (1991).
Chromatographic separations were performed on an Alltech Prevail
C18 column, 150 × 4.6mm i.d., 5 μm particle size (Alltech Associates
Inc., Deerfield, IL, USA) after passage through a SecurityGuard pre‐
column, 4 × 3.0mm i.d., 5 μm particle size (Phenomenex Inc., Torrance,
CA, USA) with a mobile phase composition of ACN–THF–MeOH–1%
w/v ammonium acetate–distilled water (684:220:68:28:28) applying
isocratic elution. The flow rate and the injection volume were
2.1mL/min and 50 μL, respectively. The detector was set at 292
(α‐tocopherol) and 297 (β/γ‐, δ‐tocopherol, rac‐tocol) nm.
Separating β‐ and γ‐tocopherol is challenging because they only
differ in the position of a methyl group. With the use of a C18 column
these two compounds have almost the same retention times (Saha,
Walia, Kundu, & Pathak, 2013). The β‐ and γ‐tocopherols can only be
separated with the application of special columns and methods
(Gornas et al., 2014; Grebenstein & Frank, 2012), the application of
which may be challenging for routine clinical practice. Accordingly,
only γ‐tocopherol was applied as a standard compound for the estab-
lishment of the calibration curve in this study, and the concentration
at the corresponding retention time includes both substances and is
reported as β/γ‐tocopherol.
2.5 | HPLC method validation for serum samples
2.5.1 | Calibration curve and linearity
Calibrants were prepared in six different concentration levels and
spiked serum samples were used with concentration ranges of 0–40,
0–6, 0–6 and 0–24 μM for α‐, β/γ‐, δ‐tocopherol and rac‐tocol, respec-
tively. The peak area responses were plotted against the
corresponding concentration, and linear regression computations were
carried out by the least square method with the freely available R soft-
ware (R Development Core Team, 2002). Very good linearity
(R2 ≥ 0.99) was observed throughout the concentration ranges for α‐,
β/γ‐, δ‐tocopherol and rac‐tocol.
2.5.2 | Selectivity
The selectivity of the method was checked by comparing the chro-
matograms of α‐, β/γ‐, δ‐tocopherol and rac‐tocol for a blank serum
sample and those for a spiked sample. All compounds could be
detected in their own selected chromatograms without any significant
interference, as can be seen in Figure 2.
2.5.3 | Precision
For the determination of within‐run precision five samples for four
concentration levels were applied (i.e., 20 replicates altogether). This
study was repeated two more times with at least one week intervals
to obtain between‐run precision. With regard to within‐run precision
the coefficients of variation of the measured concentrations were
4.53, 3.72 and 5.11% for α‐, β/γ‐ and δ‐tocopherols, respectively,
whereas in case of between‐run precision, they were 3.59, 5.93 and
4.76% for α‐, β/γ‐ and δ‐tocopherol, respectively.
2.5.4 | Recovery
The relative recoveries were estimated by measuring spiked samples of
α‐, β/γ‐ and δ‐tocopherol at two different concentrations with three
replicates of each. No significant differences were observed for the
lower and higher concentrations. The recoveries for the serum samples
ranged from 86 to 105%, from 95 to 108% and from 116 to 124% for
α‐, β/γ‐ and δ‐tocopherol, respectively.
FIGURE 2 The representative chromatograms of tocopherol
measurement. The gray line represents a blank serum sample which
was spiked with a mixture containing rac‐tocol (1), α‐tocopherol (2), γ‐
tocopherol (4) and δ‐tocopherol (3) (black line). The peak spiked with γ‐
tocopherol may contain β‐tocopherol from the blank serum as well
VERES ET AL. 3 of 8
2.6 | Statistics
All statistical calculations were performed with the use of the freely
available R software (R Development Core Team, 2002) according to
the International Federation of Clinical Chemistry and Laboratory
Medicine and Clinical and Laboratory Standards Institute guidelines
(Horowitz, 2016). Based on these guidelines, the minimum required
number of individuals for the determination of RI with the bootstrap
method is at least 100. First we checked the distribution of our data
with the Anderson–Darling test and we also performed the Levene test
for analysis of the homogeneity of variances. If the distribution proved
to be Gaussian and the variances were equal, one‐way ANOVA was
applied to compare the groups, otherwise the Kruskal–Wallis test was
utilized. To obtain the necessary quantiles and their confidence inter-
vals for the determination of the reference intervals, the bootstrap
method (1000 iterations) was applied. The correlation between the con-
centration of themeasured compounds and the age of individuals in the
sample population was examined with the nonparametric Spearman's
test.We rejected the null hypothesis when the corrected p‐values were
≤0.05, and in such cases the differences were considered significant.
Data with Gaussian or non‐Gaussian distributions were plotted as
means (SD) or medians (and interquartile range), respectively.
3 | RESULTS
The group‐wise comparisons failed to detect any significant difference
between groups regarding the concentrations of α‐tocopherol
(p = 0.48, χ2 = 2.46; Kruskal–Wallis test), β/γ‐tocopherol (p = 0.47,
χ2 = 2.53; Kruskal–Wallis test) or δ‐tocopherol (p = 0.82, χ2 = 0.94;
Kruskal–Wallis test; Table 1).
Accordingly, in order to establish RI with appropriate subject
numbers, the values for each measured compounds were pooled
and the minimum required sample size (n = 120) was achieved. For
the determination of lower (2.5%) and upper (97.5%) RI with the
corresponding confidence intervals and standard errors, the boot-
strap method was applied and the results are demonstrated in
Table 2.
To obtain cholesterol‐corrected tocopherol values as well,
serum cholesterol concentrations were determined for each subject
[median and interquartile range 4.99mM (4.31–5.54)] and the
tocopherol/cholesterol ratios were calculated. The bootstrap
method was applied again for the lipid corrected values (Table 3).
To assess the incidental effect of age on measured serum lipid
levels, the Spearman test was performed. The cholesterol levels
positively correlated with the age of subjects (p < 0.001, Spearman's
ρ = 0.34; Figure 3).
In the case of uncorrected α‐ and β/γ‐tocopherol concentra-
tions, this correlation with age is present as well (α‐tocopherol:
p = 0.002, Spearman's ρ = 0.28, Figure 4A; β/γ‐tocopherol:
p = 0.001, Spearman's ρ = 0.29, Figure 4C) whereas δ‐tocopherol
levels did not correlate with age (p = 0.98, Spearman's ρ = 0.003,
Figure 4E). When tocopherol levels were normalized to cholesterol
levels, all the correlations with age were eliminated (α‐tocopherol:
p = 0.99, Spearman's ρ = −0.0007, Figure 4B; β/γ‐tocopherol:
p = 0.14, Spearman's ρ = 0.14, Figure 4D; δ‐tocopherol: p = 0.051,
Spearman's ρ = − 0.18, Figure 4F).
TABLE 1 Serum tocopherol concentrations of subjects belonging to the control and OND groups
Controls (women) Controls (men) OND patients (women) OND patients (men) Group comparisons (p)
α‐Tocopherol (μM) 38.08 (33.70–44.10) 35.38 (31.35–45.83) 34.26 (29.40–41.60) 33.93 (30.54–41.08) 0.48 (χ2 = 2.46)
β/γ‐Tocopherol (μM) 1.83 (1.32–2.23) 1.68 (1.39–2.52) 1.57 (1.33–1.82) 1.75 (1.52–2.21) 0.47 (χ2 = 2.53)
δ‐Tocopherol (μM) 0.63 (0.52–0.86) 0.62 (0.53–0.78) 0.62 (0.55–0.82) 0.65 (0.57–0.75) 0.82 (χ2 = 0.94)
Group‐wise comparisons (Kruskal–Wallis test) of the four groups failed to detect any significant difference between serum tocopherol levels. Data are pre-
sented as median and interquartile range. OND, Other neurological disease.
TABLE 2 The calculated uncorrected lower (2.5%) and upper (97.5%) reference intervals for tocopherols for the assessed Hungarian population
(n = 120)
2.5% SE CI (95%) 97.5% SE CI (95%)
α‐Tocopherol (μM) 24.62 0.76 23.24–26.26 54.67 4.09 46.88–61.84
β/γ‐Tocopherol (μM) 0.81 0.13 0.60–1.11 3.69 0.45 2.71–4.55
δ‐Tocopherol (μM) 0.29 0.03 0.22–0.32 1.07 0.13 0.80–1.29
SE, Standard error; CI, confidence interval.
TABLE 3 The calculated cholesterol corrected lower (2.5%) and upper (97.5%) reference intervals for tocopherols for the assessed Hungarian
population (n = 120)
2.5% SE CI (95%) 97.5% SE CI (95%)
α‐Tocopherol (μmol/mmol) 5.11 0.14 4.79–5.36 11.27 0.69 9.91–12.82
β/γ‐Tocopherol (μmol/mmol) 0.14 0.02 0.10–0.19 0.72 0.07 0.60–0.88
δ‐Tocopherol (μmol/mmol) 0.06 0.01 0.05–0.07 0.22 0.03 0.16–0.27
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4 | DISCUSSION
The determination of exact serum tocopherol concentrations may be
substantial for the diagnosis and therapeutic monitoring of certain con-
ditions usually accompanied by neurological symptoms, such as ataxia,
myopathy or cognitive deficiency (La Fata, Weber, & Mohajeri, 2014;
Muller, 2010). Although the symptoms of genetically determined disor-
ders with tocopherol deficiency usually manifest during childhood
(Raizman et al., 2014), malabsorption disorders and late‐onset geneti-
cally determined metabolic conditions preferentially appear in adult-
hood, indicating the need for tocopherol measurement in adult
population as well (Ueda et al., 2009). However, these concentrations
alone hold little diagnostic value, for proper evaluation physicians need
a well‐established RI, which can considerably vary between popula-
tions (Table S1 in the Supporting Information). The underlying cause
of this variation may be multifactorial, mainly including nonstandard-
ized patient selection criteria and some methodological issues. The
FIGURE 4 Serum tocopherol concentrations and tocopherol/cholesterol ratios plotted against the age of participants. The level of α‐tocopherol
positively correlates with age (p = 0.002, Spearman's ρ = 0.28; A), similarly to β/γ‐tocopherol (p = 0.001, Spearman's ρ = 0.29; C), whereas δ‐
tocopherol levels do not correlate with age (p = 0.98, Spearman's ρ = 0.003; E). The cholesterol corrected values of α‐tocopherol (p = 0.99,
Spearman's ρ = −0.0007; B) and β/γ‐tocopherol (p = 0.14, Spearman's ρ = 0.14; D) do not further significantly correlate with age, and the correlation
of δ‐tocopherol levels with age also remained nonsignificant (p = 0.051, Spearman's ρ = −0.18; F)
FIGURE 3 Serum cholesterol concentrations in function of age. There
is a positive correlation between cholesterol levels and age (p < 0.001,
Spearman's ρ = 0.34)
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aim of the current study was to establish RIs for the Hungarian popu-
lation and to compare the method of patient selection and the analyt-
ical procedure with those of previously published studies.
The investigated population in this study is homogeneously dis-
tributed with regard to age and covers a considerably wide age range
for the adult population. The selection of a homogeneous study popu-
lation may have a special importance, because age distribution can
considerably influence reference values in light of the fact that the
levels of certain tocopherols significantly increase with age (Figure 4;
Rifkind & Segal, 1983). Accordingly when the investigated reference
population includes young individuals, the results may be skewed to
lower levels (Ford, Schleicher, Mokdad, Ajani, & Liu, 2006; Paliakov
et al., 2009; Quesada, Mata‐Granados, & Luque De Castro, 2004;
Zhao, Monahan, McNulty, Gibney, & Gibney, 2014). Moving on to
another qualitative aspect of the composition of the study population,
in addition to the involvement of subjects without any chronic illness,
the group of assessed individuals also comprised patients with differ-
ent neurological disorders where tocopherol levels were not previously
reported to be abnormal (the establishment of the so‐called control
group of OND). This study setup may ensure the absence of significant
alterations of tocopherol levels in neurological cases lacking the symp-
toms of ataxia, myopathy and cognitive deficiency, which may be
important for future screening studies. Following thorough statistical
assessment resulting in the lack of significant differences, these sub-
groups become suitable for pooling, i.e. the number of individuals in
the reference population can be increased easily to the desired level.
Several previous studies lack this study setup including well‐detailed
description of the health condition of reference individuals, possibly
introducing a bias into the reference values (Table S1; Paliakov et al.,
2009; Quesada et al., 2004). In the current study design, special atten-
tion was paid to dietary factors and to the intake of special medicines
(e.g. statins) and food supplements as well, because these may consid-
erably alter the levels of the assessed compounds (Colquhoun et al.,
2005). The lack of this kind of standardization introduces another bias
into the establishment of RIs (Table S1; Winbauer, Pingree, & Nuttall,
1999; Yuan et al., 2014).
With regard to the analytical procedure of the determination of
tocopherol concentrations from biological matrices, several difficul-
ties can emerge as well. While the use of serum or heparinized
plasma for measurement does not affect α‐tocopherol level
(Table S1), the application of oxalate, citrate or ethylenediaminetet-
raacetic acid significantly reduces its concentration (Nierenberg &
Lester, 1985). The most problematic step in the measurement pro-
cess may be the sample preparation, which includes liquid–liquid
extraction into n‐hexane, evaporation under nitrogen flow and
reconstitution in organic solvents. The emerging problems during
these steps and during sample injection can considerably contribute
to the overall error of the measurement. Internal standards in known
quantity can be utilized to compensate for the bias between the
measured and true concentrations. In the current study, rac‐tocol
was applied as internal standard, but several other compounds can
be utilized (Table S1).
Another important matter may be the validation of the applied
analytical procedure, which can provide valuable information about
the robustness of the measurement and the validity of the reported
values. For scientific publications at least a partial method validation
is required (ICH, 1995). Without method validation the reliability of
the presented data is questionable. Approximately 80% of the previous
studies presenting human tocopherol concentrations applied a valida-
tion procedure (Table S1).
Tocopherol levels are often reported as tocopherol–cholesterol
ratios based on the fact that there is a close relationship between
the concentrations of tocopherols and lipids in the blood (Thurnham,
Davies, Crump, Situnayake, & Davis, 1986). However, under special
circumstances lipid‐corrected tocopherol levels can be misleading,
because it was reported that malnutrition and infectious diseases in
children can lower the levels of circulating cholesterol and its lipopro-
tein carriers, which alteration can mask decreased tocopherol levels if
only corrected values are reported (Das, Thurnham, & Das, 1996;
Sauerwein et al., 1997; Squali Houssaïni et al., 2001). Contrarily, when
obese children were investigated, their α‐tocopherol levels were nor-
mal while their tocopherol–cholesterol ratios were significantly lower
compared with the control group (Strauss, 1999). With regard to
adults, in light of the fact that lipid status can vary with aging
(Figure 3; Rifkind & Segal, 1983), the application of lipid‐corrected
values may be necessary for the characterization of vitamin E status
(Horwitt, Harvey, Dahm, & Searcy, 1972; Thurnham et al., 1986).
Nevertheless, the report of serum tocopherol concentrations with lipid
ratios may be practical for the proper evaluation of tocopherol status.
However, only one‐third of the papers reported both of them
(Table S1 in the Supporting Information).
In conclusion, the current study presents RIs for the first time for
serum tocopherol concentrations and their corresponding cholesterol
corrected values with regard to the adult Hungarian population. These
results can facilitate the diagnostic process for certain neurological
conditions, such as ataxia with vitamin E deficiency. Moreover, this
paper draws attention to the importance of thorough design associ-
ated with the establishment of these RIs and the possible pitfalls in
tocopherol measurements.
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